

Return of Organization Exempt From Income Tax

OMB No. 1545-0047

Form **990**

Department of the Treasury
Internal Revenue Service

Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except private foundations)
Do not enter social security numbers on this form as it may be made public.
Go to www.irs.gov/Form990 for instructions and the latest information.

2024

Open to Public
Inspection

A For the **2024** calendar year, or tax year beginning **APR 1, 2024** and ending **MAR 31, 2025**

B Check if applicable:	C Name of organization BRIGHTFOCUS FOUNDATION Doing business as Number and street (or P.O. box if mail is not delivered to street address) Room/suite 22512 GATEWAY CENTER DRIVE City or town, state or province, country, and ZIP or foreign postal code CLARKSBURG, MD 20871	D Employer identification number 23-7337229
Address change Name change Initial return Final return/terminated Amended return Application pending	F Name and address of principal officer: STACY PAGOS HALLER SAME AS C ABOVE	E Telephone number (301) 948-3244 G Gross receipts \$ 89,178,037. H(a) Is this a group return for subordinates? Yes <input checked="" type="checkbox"/> No H(b) Are all subordinates included? Yes No If "No," attach a list. See instructions H(c) Group exemption number
I Tax-exempt status: <input checked="" type="checkbox"/> 501(c)(3) 501(c) () (insert no.) 4947(a)(1) or 527		
J Website: WWW.BRIGHTFOCUS.ORG		
K Form of organization: <input checked="" type="checkbox"/> Corporation Trust Association Other		L Year of formation: 1973 M State of legal domicile: DC

Part I Summary

1	Briefly describe the organization's mission or most significant activities: BRIGHTFOCUS FOUNDATION (BRIGHTFOCUS) SEEKS A WORLD FREE FROM DISEASES OF MIND AND SIGHT.		
2	Check this box if the organization discontinued its operations or disposed of more than 25% of its net assets.		
3	Number of voting members of the governing body (Part VI, line 1a)	3	14
4	Number of independent voting members of the governing body (Part VI, line 1b)	4	14
5	Total number of individuals employed in calendar year 2024 (Part V, line 2a)	5	59
6	Total number of volunteers (estimate if necessary)	6	85
7a	Total unrelated business revenue from Part VIII, column (C), line 12	7a	0.
7b	Net unrelated business taxable income from Form 990-T, Part I, line 11	7b	0.
8	Contributions and grants (Part VIII, line 1h)	Prior Year	Current Year
9	Program service revenue (Part VIII, line 2g)	43,373,203.	52,879,488.
10	Investment income (Part VIII, column (A), lines 3, 4, and 7d)	0.	0.
11	Other revenue (Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)	4,702,264.	9,840,578.
12	Total revenue - add lines 8 through 11 (must equal Part VIII, column (A), line 12)	587,403.	703,858.
13	Grants and similar amounts paid (Part IX, column (A), lines 1-3)	48,662,870.	63,423,924.
14	Benefits paid to or for members (Part IX, column (A), line 4)	10,704,093.	16,943,701.
15	Salaries, other compensation, employee benefits (Part IX, column (A), lines 5-10)	0.	0.
16a	Professional fundraising fees (Part IX, column (A), line 11e)	6,876,671.	6,479,211.
b	Total fundraising expenses (Part IX, column (D), line 25)	952,781.	1,027,076.
17	Other expenses (Part IX, column (A), lines 11a-11d, 11f-24e)	13,859,870.	
18	Total expenses. Add lines 13-17 (must equal Part IX, column (A), line 25)	27,683,861.	28,845,021.
19	Revenue less expenses. Subtract line 18 from line 12	46,217,406.	53,295,009.
20	Total assets (Part X, line 16)	2,445,464.	10,128,915.
21	Total liabilities (Part X, line 26)	Beginning of Current Year	End of Year
22	Net assets or fund balances. Subtract line 21 from line 20	63,464,652.	65,129,292.
		37,245,915.	28,168,825.
		26,218,737.	36,960,467.

Part II Signature Block

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

Sign Here	<div style="text-align: center;"> STACY PAGOS HALLER, PRESIDENT/CEO Type or print name and title </div>	October 22, 2025 Date
Paid Preparer Use Only	Preparer's name FRANK SMITH Preparer's signature FRANK SMITH Date 10/22/25 Check if self-employed <input type="checkbox"/> PTIN P00639053 Firm's name CBIZ ADVISORS, LLC Firm's EIN 88-1478669 Firm's address 1899 L STREET, NW #850 Phone no. 202-227-4000 WASHINGTON, DC 20036	

May the IRS discuss this return with the preparer shown above? See instructions ☒ Yes ☐ No

Part III Statement of Program Service AccomplishmentsCheck if Schedule O contains a response or note to any line in this Part III ☒**1** Briefly describe the organization's mission:

BRIGHTFOCUS FOUNDATION FUNDS EXCEPTIONAL RESEARCH WORLDWIDE TO DEFEAT ALZHEIMER'S DISEASE, MACULAR DEGENERATION, AND GLAUCOMA AND PROVIDES EXPERT INFORMATION ON THESE HEARTBREAKING DISEASES. PLEASE REFER TO SCHEDULE O FOR A COMPLETE OVERVIEW OF OUR MISSION.

2 Did the organization undertake any significant program services during the year which were not listed on the prior Form 990 or 990-EZ? ☐ Yes ☒ No

If "Yes," describe these new services on Schedule O.

3 Did the organization cease conducting, or make significant changes in how it conducts, any program services? ☐ Yes ☒ No

If "Yes," describe these changes on Schedule O.

4 Describe the organization's program service accomplishments for each of its three largest program services, as measured by expenses.

Section 501(c)(3) and 501(c)(4) organizations are required to report the amount of grants and allocations to others, the total expenses, and revenue, if any, for each program service reported.

4a (Code:) (Expenses \$ 21,402,299. including grants of \$ 10,412,240.) (Revenue \$)
ALZHEIMER'S DISEASE RESEARCH (ADR)

PLEASE REFER TO SCHEDULE O FOR A COMPLETE DESCRIPTION OF THE ACCOMPLISHMENTS FOR ALZHEIMER'S DISEASE RESEARCH.

4b (Code:) (Expenses \$ 10,955,751. including grants of \$ 5,329,984.) (Revenue \$)
MACULAR DEGENERATION RESEARCH (MDR)

PLEASE REFER TO SCHEDULE O FOR A COMPLETE DESCRIPTION OF THE ACCOMPLISHMENTS FOR MACULAR DEGENERATION RESEARCH.

4c (Code:) (Expenses \$ 2,469,629. including grants of \$ 1,201,477.) (Revenue \$)
NATIONAL GLAUCOMA RESEARCH (NGR)

PLEASE REFER TO SCHEDULE O FOR A COMPLETE DESCRIPTION OF THE ACCOMPLISHMENTS FOR NATIONAL GLAUCOMA RESEARCH.

4d Other program services (Describe on Schedule O.)

(Expenses \$ including grants of \$) (Revenue \$)

4e Total program service expenses 34,827,679.

Part IV Checklist of Required Schedules

	Yes	No
1 Is the organization described in section 501(c)(3) or 4947(a)(1) (other than a private foundation)? <i>If "Yes," complete Schedule A</i>	1 X	
2 Is the organization required to complete <i>Schedule B, Schedule of Contributors</i> ? See instructions	2 X	
3 Did the organization engage in direct or indirect political campaign activities on behalf of or in opposition to candidates for public office? <i>If "Yes," complete Schedule C, Part I</i>	3	X
4 Section 501(c)(3) organizations. Did the organization engage in lobbying activities, or have a section 501(h) election in effect during the tax year? <i>If "Yes," complete Schedule C, Part II</i>	4 X	
5 Is the organization a section 501(c)(4), 501(c)(5), or 501(c)(6) organization that receives membership dues, assessments, or similar amounts as defined in Rev. Proc. 98-19? <i>If "Yes," complete Schedule C, Part III</i>	5	X
6 Did the organization maintain any donor advised funds or any similar funds or accounts for which donors have the right to provide advice on the distribution or investment of amounts in such funds or accounts? <i>If "Yes," complete Schedule D, Part I</i>	6	X
7 Did the organization receive or hold a conservation easement, including easements to preserve open space, the environment, historic land areas, or historic structures? <i>If "Yes," complete Schedule D, Part II</i>	7	X
8 Did the organization maintain collections of works of art, historical treasures, or other similar assets? <i>If "Yes," complete Schedule D, Part III</i>	8	X
9 Did the organization report an amount in Part X, line 21, for escrow or custodial account liability; serve as a custodian for amounts not listed in Part X; or provide credit counseling, debt management, credit repair, or debt negotiation services? <i>If "Yes," complete Schedule D, Part IV</i>	9	X
10 Did the organization, directly or through a related organization, hold assets in donor-restricted endowments or in quasi-endowments? <i>If "Yes," complete Schedule D, Part V</i>	10 X	
11 If the organization's answer to any of the following questions is "Yes," then complete Schedule D, Parts VI, VII, VIII, IX, or X, as applicable.		
a Did the organization report an amount for land, buildings, and equipment in Part X, line 10? <i>If "Yes," complete Schedule D, Part VI</i>	11a X	
b Did the organization report an amount for investments - other securities in Part X, line 12, that is 5% or more of its total assets reported in Part X, line 16? <i>If "Yes," complete Schedule D, Part VII</i>	11b X	
c Did the organization report an amount for investments - program related in Part X, line 13, that is 5% or more of its total assets reported in Part X, line 16? <i>If "Yes," complete Schedule D, Part VIII</i>	11c	X
d Did the organization report an amount for other assets in Part X, line 15, that is 5% or more of its total assets reported in Part X, line 16? <i>If "Yes," complete Schedule D, Part IX</i>	11d	X
e Did the organization report an amount for other liabilities in Part X, line 25? <i>If "Yes," complete Schedule D, Part X</i>	11e X	
f Did the organization's separate or consolidated financial statements for the tax year include a footnote that addresses the organization's liability for uncertain tax positions under FIN 48 (ASC 740)? <i>If "Yes," complete Schedule D, Part X</i>	11f X	
12a Did the organization obtain separate, independent audited financial statements for the tax year? <i>If "Yes," complete Schedule D, Parts XI and XII</i>	12a	X
b Was the organization included in consolidated, independent audited financial statements for the tax year? <i>If "Yes," and if the organization answered "No" to line 12a, then completing Schedule D, Parts XI and XII is optional</i>	12b X	
13 Is the organization a school described in section 170(b)(1)(A)(ii)? <i>If "Yes," complete Schedule E</i>	13	X
14a Did the organization maintain an office, employees, or agents outside of the United States?	14a	X
b Did the organization have aggregate revenues or expenses of more than \$10,000 from grantmaking, fundraising, business, investment, and program service activities outside the United States, or aggregate foreign investments valued at \$100,000 or more? <i>If "Yes," complete Schedule F, Parts I and IV</i>	14b X	
15 Did the organization report on Part IX, column (A), line 3, more than \$5,000 of grants or other assistance to or for any foreign organization? <i>If "Yes," complete Schedule F, Parts II and IV</i>	15 X	
16 Did the organization report on Part IX, column (A), line 3, more than \$5,000 of aggregate grants or other assistance to or for foreign individuals? <i>If "Yes," complete Schedule F, Parts III and IV</i>	16	X
17 Did the organization report a total of more than \$15,000 of expenses for professional fundraising services on Part IX, column (A), lines 6 and 11e? <i>If "Yes," complete Schedule G, Part I. See instructions</i>	17 X	
18 Did the organization report more than \$15,000 total of fundraising event gross income and contributions on Part VIII, lines 1c and 8a? <i>If "Yes," complete Schedule G, Part II</i>	18 X	
19 Did the organization report more than \$15,000 of gross income from gaming activities on Part VIII, line 9a? <i>If "Yes," complete Schedule G, Part III</i>	19	X
20a Did the organization operate one or more hospital facilities? <i>If "Yes," complete Schedule H</i>	20a	X
b If "Yes" to line 20a, did the organization attach a copy of its audited financial statements to this return?	20b	
21 Did the organization report more than \$5,000 of grants or other assistance to any domestic organization or domestic government on Part IX, column (A), line 1? <i>If "Yes," complete Schedule I, Parts I and II</i>	21 X	

Part IV Checklist of Required Schedules (continued)

	Yes	No
22 Did the organization report more than \$5,000 of grants or other assistance to or for domestic individuals on Part IX, column (A), line 2? <i>If "Yes," complete Schedule I, Parts I and III</i>	22	X
23 Did the organization answer "Yes" to Part VII, Section A, line 3, 4, or 5, about compensation of the organization's current and former officers, directors, trustees, key employees, and highest compensated employees? <i>If "Yes," complete Schedule J</i>	23	X
24a Did the organization have a tax-exempt bond issue with an outstanding principal amount of more than \$100,000 as of the last day of the year, that was issued after December 31, 2002? <i>If "Yes," answer lines 24b through 24d and complete Schedule K. If "No," go to line 25a</i>	24a	X
b Did the organization invest any proceeds of tax-exempt bonds beyond a temporary period exception?	24b	
c Did the organization maintain an escrow account other than a refunding escrow at any time during the year to defease any tax-exempt bonds?	24c	
d Did the organization act as an "on behalf of" issuer for bonds outstanding at any time during the year?	24d	
25a Section 501(c)(3), 501(c)(4), and 501(c)(29) organizations. Did the organization engage in an excess benefit transaction with a disqualified person during the year? <i>If "Yes," complete Schedule L, Part I</i>	25a	X
b Is the organization aware that it engaged in an excess benefit transaction with a disqualified person in a prior year, and that the transaction has not been reported on any of the organization's prior Forms 990 or 990-EZ? <i>If "Yes," complete Schedule L, Part I</i>	25b	X
26 Did the organization report any amount on Part X, line 5 or 22, for receivables from or payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons? <i>If "Yes," complete Schedule L, Part II</i>	26	X
27 Did the organization provide a grant or other assistance to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor or employee thereof, a grant selection committee member, or to a 35% controlled entity (including an employee thereof) or family member of any of these persons? <i>If "Yes," complete Schedule L, Part III</i>	27	X
28 Was the organization a party to a business transaction with one of the following parties? (See the Schedule L, Part IV, instructions for applicable filing thresholds, conditions, and exceptions):		
a A current or former officer, director, trustee, key employee, creator or founder, or substantial contributor? <i>If "Yes," complete Schedule L, Part IV</i>	28a	X
b A family member of any individual described in line 28a? <i>If "Yes," complete Schedule L, Part IV</i>	28b	X
c A 35% controlled entity of one or more individuals and/or organizations described in line 28a or 28b? <i>If "Yes," complete Schedule L, Part IV</i>	28c	X
29 Did the organization receive more than \$25,000 in noncash contributions? <i>If "Yes," complete Schedule M</i>	29	X
30 Did the organization receive contributions of art, historical treasures, or other similar assets, or qualified conservation contributions? <i>If "Yes," complete Schedule M</i>	30	X
31 Did the organization liquidate, terminate, or dissolve and cease operations? <i>If "Yes," complete Schedule N, Part I</i>	31	X
32 Did the organization sell, exchange, dispose of, or transfer more than 25% of its net assets? <i>If "Yes," complete Schedule N, Part II</i>	32	X
33 Did the organization own 100% of an entity disregarded as separate from the organization under Regulations sections 301.7701-2 and 301.7701-3? <i>If "Yes," complete Schedule R, Part I</i>	33	X
34 Was the organization related to any tax-exempt or taxable entity? <i>If "Yes," complete Schedule R, Part II, III, or IV, and Part V, line 1</i>	34	X
35a Did the organization have a controlled entity within the meaning of section 512(b)(13)?	35a	X
b If "Yes" to line 35a, did the organization receive any payment from or engage in any transaction with a controlled entity within the meaning of section 512(b)(13)? <i>If "Yes," complete Schedule R, Part V, line 2</i>	35b	
36 Section 501(c)(3) organizations. Did the organization make any transfers to an exempt non-charitable related organization? <i>If "Yes," complete Schedule R, Part V, line 2</i>	36	X
37 Did the organization conduct more than 5% of its activities through an entity that is not a related organization and that is treated as a partnership for federal income tax purposes? <i>If "Yes," complete Schedule R, Part VI</i>	37	X
38 Did the organization complete Schedule O and provide explanations on Schedule O for Part VI, lines 11b and 19?	38	X

Note: All Form 990 filers are required to complete Schedule O

Part V Statements Regarding Other IRS Filings and Tax ComplianceCheck if Schedule O contains a response or note to any line in this Part V ☐

	Yes	No
1a Enter the number reported in box 3 of Form 1096. Enter -0- if not applicable	1a	88
b Enter the number of Forms W-2G included on line 1a. Enter -0- if not applicable	1b	0
c Did the organization comply with backup withholding rules for reportable payments to vendors and reportable gaming (gambling) winnings to prize winners?	1c	X

Part V Statements Regarding Other IRS Filings and Tax Compliance (continued)

	Yes	No
2a Enter the number of employees reported on Form W-3, Transmittal of Wage and Tax Statements, filed for the calendar year ending with or within the year covered by this return	2a	59
b If at least one is reported on line 2a, did the organization file all required federal employment tax returns?	2b	X
3a Did the organization have unrelated business gross income of \$1,000 or more during the year?	3a	X
b If "Yes," has it filed a Form 990-T for this year? If "No" to line 3b, provide an explanation on Schedule O	3b	
4a At any time during the calendar year, did the organization have an interest in, or a signature or other authority over, a financial account in a foreign country (such as a bank account, securities account, or other financial account)?	4a	X
b If "Yes," enter the name of the foreign country See instructions for filing requirements for FinCEN Form 114, Report of Foreign Bank and Financial Accounts (FBAR).		
5a Was the organization a party to a prohibited tax shelter transaction at any time during the tax year?	5a	X
b Did any taxable party notify the organization that it was or is a party to a prohibited tax shelter transaction?	5b	X
c If "Yes" to line 5a or 5b, did the organization file Form 8886-T?	5c	
6a Does the organization have annual gross receipts that are normally greater than \$100,000, and did the organization solicit any contributions that were not tax deductible as charitable contributions?	6a	X
b If "Yes," did the organization include with every solicitation an express statement that such contributions or gifts were not tax deductible?	6b	
7 Organizations that may receive deductible contributions under section 170(c).		
a Did the organization receive a payment in excess of \$75 made partly as a contribution and partly for goods and services provided to the payor?	7a	X
b If "Yes," did the organization notify the donor of the value of the goods or services provided?	7b	X
c Did the organization sell, exchange, or otherwise dispose of tangible personal property for which it was required to file Form 8282?	7c	X
d If "Yes," indicate the number of Forms 8282 filed during the year	7d	
e Did the organization receive any funds, directly or indirectly, to pay premiums on a personal benefit contract?	7e	X
f Did the organization, during the year, pay premiums, directly or indirectly, on a personal benefit contract?	7f	X
g If the organization received a contribution of qualified intellectual property, did the organization file Form 8899 as required?	7g	
h If the organization received a contribution of cars, boats, airplanes, or other vehicles, did the organization file a Form 1098-C?	7h	
8 Sponsoring organizations maintaining donor advised funds. Did a donor advised fund maintained by the sponsoring organization have excess business holdings at any time during the year?	8	
9 Sponsoring organizations maintaining donor advised funds.		
a Did the sponsoring organization make any taxable distributions under section 4966?	9a	
b Did the sponsoring organization make a distribution to a donor, donor advisor, or related person?	9b	
10 Section 501(c)(7) organizations. Enter:		
a Initiation fees and capital contributions included on Part VIII, line 12	10a	
b Gross receipts, included on Form 990, Part VIII, line 12, for public use of club facilities	10b	
11 Section 501(c)(12) organizations. Enter:		
a Gross income from members or shareholders	11a	
b Gross income from other sources. (Do not net amounts due or paid to other sources against amounts due or received from them.)	11b	
12a Section 4947(a)(1) non-exempt charitable trusts. Is the organization filing Form 990 in lieu of Form 1041?	12a	
b If "Yes," enter the amount of tax-exempt interest received or accrued during the year	12b	
13 Section 501(c)(29) qualified nonprofit health insurance issuers.		
a Is the organization licensed to issue qualified health plans in more than one state? Note: See the instructions for additional information the organization must report on Schedule O.	13a	
b Enter the amount of reserves the organization is required to maintain by the states in which the organization is licensed to issue qualified health plans	13b	
c Enter the amount of reserves on hand	13c	
14a Did the organization receive any payments for indoor tanning services during the tax year?	14a	X
b If "Yes," has it filed a Form 720 to report these payments? If "No," provide an explanation on Schedule O	14b	
15 Is the organization subject to the section 4960 tax on payment(s) of more than \$1,000,000 in remuneration or excess parachute payment(s) during the year? If "Yes," see the instructions and file Form 4720, Schedule N.	15	X
16 Is the organization an educational institution subject to the section 4968 excise tax on net investment income? If "Yes," complete Form 4720, Schedule O.	16	X
17 Section 501(c)(21) organizations. Did the trust, or any disqualified or other person engage in any activities that would result in the imposition of an excise tax under section 4951, 4952 or 4953? If "Yes," complete Form 6069.	17	

Part VI Governance, Management, and Disclosure. For each "Yes" response to lines 2 through 7b below, and for a "No" response to line 8a, 8b, or 10b below, describe the circumstances, processes, or changes on Schedule O. See instructions.

Check if Schedule O contains a response or note to any line in this Part VI

☒**Section A. Governing Body and Management**

	1a	1b	Yes	No
1a Enter the number of voting members of the governing body at the end of the tax year	14			
If there are material differences in voting rights among members of the governing body, or if the governing body delegated broad authority to an executive committee or similar committee, explain on Schedule O.				
b Enter the number of voting members included on line 1a, above, who are independent		14		
2 Did any officer, director, trustee, or key employee have a family relationship or a business relationship with any other officer, director, trustee, or key employee?				X
3 Did the organization delegate control over management duties customarily performed by or under the direct supervision of officers, directors, trustees, or key employees to a management company or other person?				X
4 Did the organization make any significant changes to its governing documents since the prior Form 990 was filed?				X
5 Did the organization become aware during the year of a significant diversion of the organization's assets?				X
6 Did the organization have members or stockholders?				X
7a Did the organization have members, stockholders, or other persons who had the power to elect or appoint one or more members of the governing body?				X
b Are any governance decisions of the organization reserved to (or subject to approval by) members, stockholders, or persons other than the governing body?				X
8 Did the organization contemporaneously document the meetings held or written actions undertaken during the year by the following:				
a The governing body?			X	
b Each committee with authority to act on behalf of the governing body?			X	
9 Is there any officer, director, trustee, or key employee listed in Part VII, Section A, who cannot be reached at the organization's mailing address? If "Yes," provide the names and addresses on Schedule O				X

Section B. Policies (This Section B requests information about policies not required by the Internal Revenue Code.)

	Yes	No
10a Did the organization have local chapters, branches, or affiliates?		X
b If "Yes," did the organization have written policies and procedures governing the activities of such chapters, affiliates, and branches to ensure their operations are consistent with the organization's exempt purposes?		
11a Has the organization provided a complete copy of this Form 990 to all members of its governing body before filing the form?	X	
b Describe on Schedule O the process, if any, used by the organization to review this Form 990.		
12a Did the organization have a written conflict of interest policy? If "No," go to line 13	X	
b Were officers, directors, or trustees, and key employees required to disclose annually interests that could give rise to conflicts?	X	
c Did the organization regularly and consistently monitor and enforce compliance with the policy? If "Yes," describe on Schedule O how this was done	X	
13 Did the organization have a written whistleblower policy?	X	
14 Did the organization have a written document retention and destruction policy?	X	
15 Did the process for determining compensation of the following persons include a review and approval by independent persons, comparability data, and contemporaneous substantiation of the deliberation and decision?		
a The organization's CEO, Executive Director, or top management official	X	
b Other officers or key employees of the organization	X	
If "Yes" to line 15a or 15b, describe the process on Schedule O. See instructions.		
16a Did the organization invest in, contribute assets to, or participate in a joint venture or similar arrangement with a taxable entity during the year?		X
b If "Yes," did the organization follow a written policy or procedure requiring the organization to evaluate its participation in joint venture arrangements under applicable federal tax law, and take steps to safeguard the organization's exempt status with respect to such arrangements?		

Section C. Disclosure

17 List the states with which a copy of this Form 990 is required to be filed AK, AL, AR, CA, CT, FL, GA, HI, IL, KS, KY, ME

18 Section 6104 requires an organization to make its Forms 1023 (1024 or 1024-A, if applicable), 990, and 990-T (section 501(c)(3)s only) available for public inspection. Indicate how you made these available. Check all that apply.
☒ Own website ☒ Another's website ☒ Upon request ☐ Other (explain on Schedule O)

19 Describe on Schedule O whether (and if so, how) the organization made its governing documents, conflict of interest policy, and financial statements available to the public during the tax year.

20 State the name, address, and telephone number of the person who possesses the organization's books and records
JONATHAN WALSH - 301-556-9385
22512 GATEWAY CENTER DRIVE, CLARKSBURG, MD 20871

Part VII Compensation of Officers, Directors, Trustees, Key Employees, Highest Compensated Employees, and Independent ContractorsCheck if Schedule O contains a response or note to any line in this Part VII ☐**Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees****1a** Complete this table for all persons required to be listed. Report compensation for the calendar year ending with or within the organization's tax year.

- List all of the organization's **current** officers, directors, trustees (whether individuals or organizations), regardless of amount of compensation. Enter -0- in columns (D), (E), and (F) if no compensation was paid.

- List all of the organization's **current** key employees, if any. See the instructions for definition of "key employee."

- List the organization's five **current** highest compensated employees (other than an officer, director, trustee, or key employee) who received reportable compensation (box 5 of Form W-2, box 6 of Form 1099-MISC, and/or box 1 of Form 1099-NEC) of more than \$100,000 from the organization and any related organizations.

- List all of the organization's **former** officers, key employees, and highest compensated employees who received more than \$100,000 of reportable compensation from the organization and any related organizations.

- List all of the organization's **former directors or trustees** that received, in the capacity as a former director or trustee of the organization, more than \$10,000 of reportable compensation from the organization and any related organizations.

See the instructions for the order in which to list the persons above.

☐ Check this box if neither the organization nor any related organization compensated any current officer, director, or trustee.

(A) Name and title	(B) Average hours per week (list any hours for related organizations below line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)						(D) Reportable compensation from the organization (W-2/1099-MISC/1099-NEC)	(E) Reportable compensation from related organizations (W-2/1099-MISC/1099-NEC)	(F) Estimated amount of other compensation from the organization and related organizations
		Individual trustee or director	Institutional trustee	Officer	Key employee	Highest compensated employee	Former			
(1) STACY PAGOS HALLER PRESIDENT/CEO	45.00			X				424,828.	0.	46,677.
(2) NANCY KEACH SR. VP, STRATEGIC PARTNERSHIPS	45.00				X			270,157.	0.	51,713.
(3) R. BRIAN ELDERTON SR. VP, DEVELOPMENT	45.00				X			261,323.	0.	40,046.
(4) JONATHAN WALSH SVP, FINANCE & ADMINISTRATION	45.00				X			226,786.	0.	4,251.
(5) DIANE BOVENKAMP, PHD VP, SCIENTIFIC AFFAIRS	45.00				X			196,242.	0.	24,358.
(6) SHARYN ROSSI - PHD, DIR. OF SCIENT. PROGRAMS, NEUROSCIENCE	40.00					X		125,732.	0.	42,143.
(7) LISA MORGAN SENIOR DIRECTOR, ANNUAL GIVING	40.00					X		135,115.	0.	22,867.
(8) PREETI SUBRAMANIAN - PHD, DIR. OF SCIENT. PROGRAMS, VISION SCIENCE	40.00					X		139,931.	0.	16,400.
(9) JEFFREY HONAKER SR. MGR. OPS AND BUILDING	40.00					X		115,469.	0.	33,854.
(10) KACI BAEZ - VP, INTEGRATED MKTNG & COMM. UNTIL 06/24	45.00					X		110,647.	0.	8,838.
(11) PATRICIA M. STEWART CHAIR	10.00	X		X				0.	0.	0.
(12) SCOTT KAISER, MD SECRETARY UNTIL 06/24, VICE CHAIR	6.00	X		X				0.	0.	0.
(13) THOMAS F. FREDDO, OD, PHD DIRECTOR UNTIL 06/24, SECRETARY	6.00	X		X				0.	0.	0.
(14) SHAWNA GOTTLIEB TREASURER	6.00	X		X				0.	0.	0.
(15) CECILIA ARRADAZA VICE CHAIR UNTIL 06/24, DIRECTOR	6.00	X		X				0.	0.	0.
(16) PAUL CAMPBELL DIRECTOR	5.00	X						0.	0.	0.
(17) HERBERT L. DRAYTON III DIRECTOR	5.00	X						0.	0.	0.

Part VII Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees (continued)

(A) Name and title	(B) Average hours per week (list any hours for related organizations below line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)						(D) Reportable compensation from the organization (W-2/1099-MISC/1099-NEC)	(E) Reportable compensation from related organizations (W-2/1099-MISC/1099-NEC)	(F) Estimated amount of other compensation from the organization and related organizations
		Individual trustee or director	Institutional trustee	Officer	Key employee	Highest compensated employee	Former			
(18) DANA GRIFFIN DIRECTOR	5.00	X						0.	0.	0.
(19) TONYA MATTHEWS, PHD DIRECTOR	5.00	X						0.	0.	0.
(20) ANN SECLOW DIRECTOR	5.00	X						0.	0.	0.
(21) JAN M. STOUFFER, PHD DIRECTOR	6.00	X						0.	0.	0.
(22) ADAM MYERS DIRECTOR AS OF 04/24	5.00	X						0.	0.	0.
(23) JOHN PENN DIRECTOR AS OF 03/25	5.00	X						0.	0.	0.
(24) DALE YOUNG DIRECTOR AS OF 03/25	5.00	X						0.	0.	0.
1b Subtotal								2,006,230.	0.	291,147.
c Total from continuation sheets to Part VII, Section A								0.	0.	0.
d Total (add lines 1b and 1c)								2,006,230.	0.	291,147.

2 Total number of individuals (including but not limited to those listed above) who received more than \$100,000 of reportable compensation from the organization

12

- 3** Did the organization list any **former** officer, director, trustee, key employee, or highest compensated employee on line 1a? *If "Yes," complete Schedule J for such individual*
- 4** For any individual listed on line 1a, is the sum of reportable compensation and other compensation from the organization and related organizations greater than \$150,000? *If "Yes," complete Schedule J for such individual*
- 5** Did any person listed on line 1a receive or accrue compensation from any unrelated organization or individual for services rendered to the organization? *If "Yes," complete Schedule J for such person*

	Yes	No
3		X
4	X	
5		X

Section B. Independent Contractors

1 Complete this table for your five highest compensated independent contractors that received more than \$100,000 of compensation from the organization. Report compensation for the calendar year ending with or within the organization's tax year.

(A) Name and business address	(B) Description of services	(C) Compensation
RKD GROUP, 35 PARKWOOD DRIVE, SUITE 160, HOPKINTON, MA 01748	PUBLIC AWARENESS CONSULTING & MATERIA	12,374,028.
ADSTRA LLC, 750 COLLEGE ROAD EAST, STE 201, PRINCETON, NJ 08540	MAIL LIST RENTAL	1,758,266.
DATA MANAGEMENT, INC. 160 STONE STREET, STONEVILLE, NC 27048	DATABASE MANAGEMENT	310,839.
ROYAL SONESTA CHICAGO DOWNTOWN 71 E WACKER DRIVE, CHICAGO, IL 60601	HOTEL CONFERENCE	219,320.
THE ROBERT JOSEPH GROUP 6901 ROCKLEDGE DRIVE, BETHESDA, MD 20817	FINANCE AND ACCOUNTING	213,430.

2 Total number of independent contractors (including but not limited to those listed above) who received more than \$100,000 of compensation from the organization

12

Part VIII Statement of RevenueCheck if Schedule O contains a response or note to any line in this Part VIII ☐

				(A) Total revenue	(B) Related or exempt function revenue	(C) Unrelated business revenue	(D) Revenue excluded from tax under sections 512 - 514
Contributions, Gifts, Grants and Other Similar Amounts	1 a Federated campaigns	1a	124,297.				
	b Membership dues	1b					
	c Fundraising events	1c	222,435.				
	d Related organizations	1d					
	e Government grants (contributions)	1e					
	f All other contributions, gifts, grants, and similar amounts not included above ...	1f	52532756.				
	g Noncash contributions included in lines 1a-1f	1g	\$ 394,954.				
	h Total. Add lines 1a-1f						
Program Service Revenue	2 a			Business Code			
	b						
	c						
	d						
	e						
	f All other program service revenue						
	g Total. Add lines 2a-2f						
	Other Revenue	3 Investment income (including dividends, interest, and other similar amounts)			1,052,357.		
4 Income from investment of tax-exempt bond proceeds							
5 Royalties			370,381.			370,381.	
6 a Gross rents		6a	(i) Real				
			(ii) Personal				
b Less: rental expenses ...		6b	565,015.				
c Rental income or (loss)		6c	179,056.				
d Net rental income or (loss)			385,959.				385,959.
7 a Gross amount from sales of assets other than inventory		7a	(i) Securities				
			(ii) Other				
b Less: cost or other basis and sales expenses		7b	22404949	11871081			
c Gain or (loss)		7c	21893998	3593811.			
d Net gain or (loss)			510,951.	8277270.			
e Net gain or (loss)		8,788,221.				8788221.	
8 a Gross income from fundraising events (not including \$ 222,435. of contributions reported on line 1c). See Part IV, line 18	8a						
b Less: direct expenses	8b	30,640.					
c Net income or (loss) from fundraising events		87,248.					
d Net income or (loss) from fundraising events		-56,608.				-56,608.	
9 a Gross income from gaming activities. See Part IV, line 19	9a						
b Less: direct expenses	9b						
c Net income or (loss) from gaming activities							
10 a Gross sales of inventory, less returns and allowances	10a						
b Less: cost of goods sold	10b						
c Net income or (loss) from sales of inventory							
Miscellaneous Revenue	11 a OTHER INCOME			Business Code			
	b			900099	4,126.		4,126.
	c						
	d All other revenue						
	e Total. Add lines 11a-11d				4,126.		
	12 Total revenue. See instructions				63423924.	0.	0.10544436.

Part IX Statement of Functional Expenses

Section 501(c)(3) and 501(c)(4) organizations must complete all columns. All other organizations must complete column (A).

Check if Schedule O contains a response or note to any line in this Part IX ☐

Do not include amounts reported on lines 6b, 7b, 8b, 9b, and 10b of Part VIII.	(A) Total expenses	(B) Program service expenses	(C) Management and general expenses	(D) Fundraising expenses
1 Grants and other assistance to domestic organizations and domestic governments. See Part IV, line 21	13,267,808.	13,267,808.		
2 Grants and other assistance to domestic individuals. See Part IV, line 22				
3 Grants and other assistance to foreign organizations, foreign governments, and foreign individuals. See Part IV, lines 15 and 16	3,675,893.	3,675,893.		
4 Benefits paid to or for members				
5 Compensation of current officers, directors, trustees, and key employees	1,652,825.	975,321.	365,576.	311,928.
6 Compensation not included above to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B)				
7 Other salaries and wages	3,413,792.	1,685,554.	1,263,641.	464,597.
8 Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions)	327,893.	172,202.	105,437.	50,254.
9 Other employee benefits	735,356.	386,193.	236,460.	112,703.
10 Payroll taxes	349,345.	183,468.	112,335.	53,542.
11 Fees for services (nonemployees):				
a Management				
b Legal	71,456.	38,524.	25,216.	7,716.
c Accounting	118,544.	63,911.	41,833.	12,800.
d Lobbying				
e Professional fundraising services. See Part IV, line 17	1,027,076.			1,027,076.
f Investment management fees	241,293.		241,293.	
g Other. (If line 11g amount exceeds 10% of line 25, column (A), amount, list line 11g expenses on Sch O.)	1,441,677.	1,266,242.	147,747.	27,688.
12 Advertising and promotion	2,434,520.	1,230,126.		1,204,394.
13 Office expenses	1,270,619.	658,427.	135,325.	476,867.
14 Information technology	602,095.	326,769.	171,648.	103,678.
15 Royalties				
16 Occupancy	368,766.	214,621.	114,177.	39,968.
17 Travel	258,884.	221,715.	19,208.	17,961.
18 Payments of travel or entertainment expenses for any federal, state, or local public officials				
19 Conferences, conventions, and meetings	876,230.	820,584.	24,020.	31,626.
20 Interest	383,185.		383,185.	
21 Payments to affiliates				
22 Depreciation, depletion, and amortization	596,953.	332,227.	181,264.	83,462.
23 Insurance	54,674.	25,895.	14,298.	14,481.
24 Other expenses. Itemize expenses not covered above. (List miscellaneous expenses on line 24e. If line 24e amount exceeds 10% of line 25, column (A), amount, list line 24e expenses on Schedule O.)				
a PUB. AWARENESS POSTAGE	9,119,632.	4,191,654.	528,303.	4,399,675.
b PUB. AWARENESS PRINTING	6,362,574.	2,938,902.	276,015.	3,147,657.
c PUB. AWARENESS COMP.	2,744,419.	1,277,945.	127,580.	1,338,894.
d LIST RENTAL	1,899,500.	873,698.	92,899.	932,903.
e All other expenses				
25 Total functional expenses. Add lines 1 through 24e	53,295,009.	34,827,679.	4,607,460.	13,859,870.
26 Joint costs. Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation. Check here <input checked="" type="checkbox"/> if following SOP 98-2 (ASC 958-720)	19,360,619.	8,338,957.	982,887.	10,038,775.

Part X Balance SheetCheck if Schedule O contains a response or note to any line in this Part X ☐

		(A) Beginning of year		(B) End of year
Assets	1 Cash - non-interest-bearing	829,628.	1	3,278,680.
	2 Savings and temporary cash investments	8,516,562.	2	6,619,066.
	3 Pledges and grants receivable, net	6,199,054.	3	9,183,959.
	4 Accounts receivable, net	23,832.	4	25,908.
	5 Loans and other receivables from any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons		5	
	6 Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), and persons described in section 4958(c)(3)(B)		6	
	7 Notes and loans receivable, net		7	
	8 Inventories for sale or use	28,325.	8	36,763.
	9 Prepaid expenses and deferred charges	998,282.	9	1,557,144.
	10a Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D	10a 9,283,683.		
	b Less: accumulated depreciation	10b 5,312,032.	10c	3,971,651.
	11 Investments - publicly traded securities	31,237,150.	11	32,437,847.
	12 Investments - other securities. See Part IV, line 11	7,784,535.	12	8,018,274.
	13 Investments - program-related. See Part IV, line 11		13	
	14 Intangible assets		14	
	15 Other assets. See Part IV, line 11		15	
16 Total assets. Add lines 1 through 15 (must equal line 33)	63,464,652.	16	65,129,292.	
Liabilities	17 Accounts payable and accrued expenses	2,580,327.	17	1,551,998.
	18 Grants payable	24,991,458.	18	25,940,333.
	19 Deferred revenue		19	
	20 Tax-exempt bond liabilities		20	
	21 Escrow or custodial account liability. Complete Part IV of Schedule D		21	
	22 Loans and other payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons		22	
	23 Secured mortgages and notes payable to unrelated third parties	9,000,000.	23	0.
	24 Unsecured notes and loans payable to unrelated third parties		24	
	25 Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17-24). Complete Part X of Schedule D	674,130.	25	676,494.
	26 Total liabilities. Add lines 17 through 25	37,245,915.	26	28,168,825.
Net Assets or Fund Balances	Organizations that follow FASB ASC 958, check here <input checked="" type="checkbox"/> and complete lines 27, 28, 32, and 33.			
	27 Net assets without donor restrictions	12,270,789.	27	25,140,265.
	28 Net assets with donor restrictions	13,947,948.	28	11,820,202.
	Organizations that do not follow FASB ASC 958, check here <input type="checkbox"/> and complete lines 29 through 33.			
	29 Capital stock or trust principal, or current funds		29	
	30 Paid-in or capital surplus, or land, building, or equipment fund		30	
	31 Retained earnings, endowment, accumulated income, or other funds		31	
	32 Total net assets or fund balances	26,218,737.	32	36,960,467.
	33 Total liabilities and net assets/fund balances	63,464,652.	33	65,129,292.

Form 990 (2024)

Part XI Reconciliation of Net AssetsCheck if Schedule O contains a response or note to any line in this Part XI ☒

1	Total revenue (must equal Part VIII, column (A), line 12)	1	63,423,924.
2	Total expenses (must equal Part IX, column (A), line 25)	2	53,295,009.
3	Revenue less expenses. Subtract line 2 from line 1	3	10,128,915.
4	Net assets or fund balances at beginning of year (must equal Part X, line 32, column (A))	4	26,218,737.
5	Net unrealized gains (losses) on investments	5	502,498.
6	Donated services and use of facilities	6	
7	Investment expenses	7	
8	Prior period adjustments	8	
9	Other changes in net assets or fund balances (explain on Schedule O)	9	110,317.
10	Net assets or fund balances at end of year. Combine lines 3 through 9 (must equal Part X, line 32, column (B))	10	36,960,467.

Part XII Financial Statements and ReportingCheck if Schedule O contains a response or note to any line in this Part XII ☒

	Yes	No
1 Accounting method used to prepare the Form 990: <input type="checkbox"/> Cash <input checked="" type="checkbox"/> Accrual <input type="checkbox"/> Other _____ If the organization changed its method of accounting from a prior year or checked "Other," explain on Schedule O.		
2a Were the organization's financial statements compiled or reviewed by an independent accountant? _____ If "Yes," check a box below to indicate whether the financial statements for the year were compiled or reviewed on a separate basis, consolidated basis, or both: <input type="checkbox"/> Separate basis <input type="checkbox"/> Consolidated basis <input type="checkbox"/> Both consolidated and separate basis		<input checked="" type="checkbox"/>
b Were the organization's financial statements audited by an independent accountant? _____ If "Yes," check a box below to indicate whether the financial statements for the year were audited on a separate basis, consolidated basis, or both: <input type="checkbox"/> Separate basis <input checked="" type="checkbox"/> Consolidated basis <input type="checkbox"/> Both consolidated and separate basis	<input checked="" type="checkbox"/>	
c If "Yes" to line 2a or 2b, does the organization have a committee that assumes responsibility for oversight of the audit, review, or compilation of its financial statements and selection of an independent accountant? _____ If the organization changed either its oversight process or selection process during the tax year, explain on Schedule O.	<input checked="" type="checkbox"/>	
3a As a result of a federal award, was the organization required to undergo an audit or audits as set forth in the Uniform Guidance, 2 C.F.R. Part 200, Subpart F? _____		<input checked="" type="checkbox"/>
b If "Yes," did the organization undergo the required audit or audits? If the organization did not undergo the required audit or audits, explain why on Schedule O and describe any steps taken to undergo such audits _____		

Form 990 (2024)

Department of the Treasury
Internal Revenue Service

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2024

Open to Public Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I	Reason for Public Charity Status. (All organizations must complete this part.) See instructions.
---------------	---

The organization is not a private foundation because it is: (For lines 1 through 12, check only one box.)

- ☐ 1 A church, convention of churches, or association of churches described in **section 170(b)(1)(A)(i).**
- ☐ 2 A school described in **section 170(b)(1)(A)(ii).** (Attach Schedule E (Form 990).)
- ☐ 3 A hospital or a cooperative hospital service organization described in **section 170(b)(1)(A)(iii).**
- ☐ 4 A medical research organization operated in conjunction with a hospital described in **section 170(b)(1)(A)(iii).** Enter the hospital's name, city, and state: _____
- ☐ 5 An organization operated for the benefit of a college or university owned or operated by a governmental unit described in **section 170(b)(1)(A)(iv).** (Complete Part II.)
- ☐ 6 A federal, state, or local government or governmental unit described in **section 170(b)(1)(A)(v).**
- ☒ 7 An organization that normally receives a substantial part of its support from a governmental unit or from the general public described in **section 170(b)(1)(A)(vi).** (Complete Part II.)
- ☐ 8 A community trust described in **section 170(b)(1)(A)(vi).** (Complete Part II.)
- ☐ 9 An agricultural research organization described in **section 170(b)(1)(A)(ix)** operated in conjunction with a land-grant college or university or a non-land-grant college of agriculture (see instructions). Enter the name, city, and state of the college or university: _____
- ☐ 10 An organization that normally receives (1) more than 33 1/3% of its support from contributions, membership fees, and gross receipts from activities related to its exempt functions, subject to certain exceptions; and (2) no more than 33 1/3% of its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses acquired by the organization after June 30, 1975. See **section 509(a)(2).** (Complete Part III.)
- ☐ 11 An organization organized and operated exclusively to test for public safety. See **section 509(a)(4).**
- ☐ 12 An organization organized and operated exclusively for the benefit of, to perform the functions of, or to carry out the purposes of one or more publicly supported organizations described in **section 509(a)(1)** or **section 509(a)(2).** See **section 509(a)(3).** Check the box on lines 12a through 12d that describes the type of supporting organization and complete lines 12e, 12f, and 12g.
 - ☐ a **Type I.** A supporting organization operated, supervised, or controlled by its supported organization(s), typically by giving the supported organization(s) the power to regularly appoint or elect a majority of the directors or trustees of the supporting organization. **You must complete Part IV, Sections A and B.**
 - ☐ b **Type II.** A supporting organization supervised or controlled in connection with its supported organization(s), by having control or management of the supporting organization vested in the same persons that control or manage the supported organization(s). **You must complete Part IV, Sections A and C.**
 - ☐ c **Type III functionally integrated.** A supporting organization operated in connection with, and functionally integrated with, its supported organization(s) (see instructions). **You must complete Part IV, Sections A, D, and E.**
 - ☐ d **Type III non-functionally integrated.** A supporting organization operated in connection with its supported organization(s) that is not functionally integrated. The organization generally must satisfy a distribution requirement and an attentiveness requirement (see instructions). **You must complete Part IV, Sections A and D, and Part V.**
 - ☐ e Check this box if the organization received a written determination from the IRS that it is a Type I, Type II, Type III functionally integrated, or Type III non-functionally integrated supporting organization.

f Enter the number of supported organizations

g Provide the following information about the supported organization(s).

g Provide the following information about the supported organization(s).						
(i) Name of supported organization	(ii) EIN	(iii) Type of organization (described on lines 1-10 above (see instructions))	(iv) Is the organization listed in your governing document?		(v) Amount of monetary support (see instructions)	(vi) Amount of other support (see instructions)
			Yes	No		
Total						

Part II Support Schedule for Organizations Described in Sections 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)

(Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization fails to qualify under the tests listed below, please complete Part III.)

Section A. Public Support

Calendar year (or fiscal year beginning in)	(a) 2020	(b) 2021	(c) 2022	(d) 2023	(e) 2024	(f) Total
1 Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.")	48502473.	46522410.	43451535.	43373203.	52879488.	234729109
2 Tax revenues levied for the organization's benefit and either paid to or expended on its behalf						
3 The value of services or facilities furnished by a governmental unit to the organization without charge						
4 Total. Add lines 1 through 3	48502473.	46522410.	43451535.	43373203.	52879488.	234729109
5 The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f)						91,938.
6 Public support. Subtract line 5 from line 4.						234637171

Section B. Total Support

Calendar year (or fiscal year beginning in)	(a) 2020	(b) 2021	(c) 2022	(d) 2023	(e) 2024	(f) Total
7 Amounts from line 4	48502473.	46522410.	43451535.	43373203.	52879488.	234729109
8 Gross income from interest, dividends, payments received on securities loans, rents, royalties, and income from similar sources	1887633.	2074361.	1972869.	1910285.	1987753.	9832901.
9 Net income from unrelated business activities, whether or not the business is regularly carried on						
10 Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.)		7,500.		70.	4,126.	11,696.
11 Total support. Add lines 7 through 10						244573706
12 Gross receipts from related activities, etc. (see instructions)					12	
13 First 5 years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and stop here						<input type="checkbox"/>

Section C. Computation of Public Support Percentage

14 Public support percentage for 2024 (line 6, column (f), divided by line 11, column (f))	14	95.94	%
15 Public support percentage from 2023 Schedule A, Part II, line 14	15	95.40	%
16a 33 1/3% support test - 2024. If the organization did not check the box on line 13, and line 14 is 33 1/3% or more, check this box and stop here. The organization qualifies as a publicly supported organization			<input checked="" type="checkbox"/>
b 33 1/3% support test - 2023. If the organization did not check a box on line 13 or 16a, and line 15 is 33 1/3% or more, check this box and stop here. The organization qualifies as a publicly supported organization			<input type="checkbox"/>
17a 10% -facts-and-circumstances test - 2024. If the organization did not check a box on line 13, 16a, or 16b, and line 14 is 10% or more, and if the organization meets the facts-and-circumstances test, check this box and stop here. Explain in Part VI how the organization meets the facts-and-circumstances test. The organization qualifies as a publicly supported organization			<input type="checkbox"/>
b 10% -facts-and-circumstances test - 2023. If the organization did not check a box on line 13, 16a, 16b, or 17a, and line 15 is 10% or more, and if the organization meets the facts-and-circumstances test, check this box and stop here. Explain in Part VI how the organization meets the facts-and-circumstances test. The organization qualifies as a publicly supported organization			<input type="checkbox"/>
18 Private foundation. If the organization did not check a box on line 13, 16a, 16b, 17a, or 17b, check this box and see instructions			<input type="checkbox"/>

Schedule A (Form 990) 2024

Part III Support Schedule for Organizations Described in Section 509(a)(2)

(Complete only if you checked the box on line 10 of Part I or if the organization failed to qualify under Part II. If the organization fails to qualify under the tests listed below, please complete Part II.)

Section A. Public Support

Calendar year (or fiscal year beginning in)	(a) 2020	(b) 2021	(c) 2022	(d) 2023	(e) 2024	(f) Total
1 Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.")						
2 Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose						
3 Gross receipts from activities that are not an unrelated trade or business under section 513						
4 Tax revenues levied for the organization's benefit and either paid to or expended on its behalf						
5 The value of services or facilities furnished by a governmental unit to the organization without charge						
6 Total. Add lines 1 through 5						
7a Amounts included on lines 1, 2, and 3 received from disqualified persons						
b Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of \$5,000 or 1% of the amount on line 13 for the year						
c Add lines 7a and 7b						
8 Public support. (Subtract line 7c from line 6.)						

Section B. Total Support

Calendar year (or fiscal year beginning in)	(a) 2020	(b) 2021	(c) 2022	(d) 2023	(e) 2024	(f) Total
9 Amounts from line 6						
10a Gross income from interest, dividends, payments received on securities loans, rents, royalties, and income from similar sources						
b Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975						
c Add lines 10a and 10b						
11 Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on						
12 Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.)						
13 Total support. (Add lines 9, 10c, 11, and 12.)						

14 First 5 years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and **stop here** ☐

Section C. Computation of Public Support Percentage

15 Public support percentage for 2024 (line 8, column (f), divided by line 13, column (f))	15	%
16 Public support percentage from 2023 Schedule A, Part III, line 15	16	%

Section D. Computation of Investment Income Percentage

17 Investment income percentage for 2024 (line 10c, column (f), divided by line 13, column (f))	17	%
18 Investment income percentage from 2023 Schedule A, Part III, line 17	18	%

19a 33 1/3% support tests - 2024. If the organization did not check the box on line 14, and line 15 is more than 33 1/3%, and line 17 is not more than 33 1/3%, check this box and **stop here**. The organization qualifies as a publicly supported organization ☐

b 33 1/3% support tests - 2023. If the organization did not check a box on line 14 or line 19a, and line 16 is more than 33 1/3%, and line 18 is not more than 33 1/3%, check this box and **stop here**. The organization qualifies as a publicly supported organization ☐

20 Private foundation. If the organization did not check a box on line 14, 19a, or 19b, check this box and see instructions ☐

Part IV Supporting Organizations

(Complete only if you checked a box on line 12 of Part I. If you checked box 12a, Part I, complete Sections A and B. If you checked box 12b, Part I, complete Sections A and C. If you checked box 12c, Part I, complete Sections A, D, and E. If you checked box 12d, Part I, complete Sections A and D, and complete Part V.)

Section A. All Supporting Organizations

	Yes	No
1 Are all of the organization's supported organizations listed by name in the organization's governing documents? <i>If "No," describe in Part VI how the supported organizations are designated. If designated by class or purpose, describe the designation. If historic and continuing relationship, explain.</i>		
2 Did the organization have any supported organization that does not have an IRS determination of status under section 509(a)(1) or (2)? <i>If "Yes," explain in Part VI how the organization determined that the supported organization was described in section 509(a)(1) or (2).</i>		
3a Did the organization have a supported organization described in section 501(c)(4), (5), or (6)? <i>If "Yes," answer lines 3b and 3c below.</i>		
b Did the organization confirm that each supported organization qualified under section 501(c)(4), (5), or (6) and satisfied the public support tests under section 509(a)(2)? <i>If "Yes," describe in Part VI when and how the organization made the determination.</i>		
c Did the organization ensure that all support to such organizations was used exclusively for section 170(c)(2)(B) purposes? <i>If "Yes," explain in Part VI what controls the organization put in place to ensure such use.</i>		
4a Was any supported organization not organized in the United States ("foreign supported organization")? <i>If "Yes," and if you checked box 12a or 12b in Part I, answer lines 4b and 4c below.</i>		
b Did the organization have ultimate control and discretion in deciding whether to make grants to the foreign supported organization? <i>If "Yes," describe in Part VI how the organization had such control and discretion despite being controlled or supervised by or in connection with its supported organizations.</i>		
c Did the organization support any foreign supported organization that does not have an IRS determination under sections 501(c)(3) and 509(a)(1) or (2)? <i>If "Yes," explain in Part VI what controls the organization used to ensure that all support to the foreign supported organization was used exclusively for section 170(c)(2)(B) purposes.</i>		
5a Did the organization add, substitute, or remove any supported organizations during the tax year? <i>If "Yes," answer lines 5b and 5c below (if applicable). Also, provide detail in Part VI, including (i) the names and EIN numbers of the supported organizations added, substituted, or removed; (ii) the reasons for each such action; (iii) the authority under the organization's organizing document authorizing such action; and (iv) how the action was accomplished (such as by amendment to the organizing document).</i>		
b Type I or Type II only. Was any added or substituted supported organization part of a class already designated in the organization's organizing document?		
c Substitutions only. Was the substitution the result of an event beyond the organization's control?		
6 Did the organization provide support (whether in the form of grants or the provision of services or facilities) to anyone other than (i) its supported organizations, (ii) individuals that are part of the charitable class benefited by one or more of its supported organizations, or (iii) other supporting organizations that also support or benefit one or more of the filing organization's supported organizations? <i>If "Yes," provide detail in Part VI.</i>		
7 Did the organization provide a grant, loan, compensation, or other similar payment to a substantial contributor (as defined in section 4958(c)(3)(C)), a family member of a substantial contributor, or a 35% controlled entity with regard to a substantial contributor? <i>If "Yes," complete Part I of Schedule L (Form 990).</i>		
8 Did the organization make a loan to a disqualified person (as defined in section 4958) not described on line 7? <i>If "Yes," complete Part I of Schedule L (Form 990).</i>		
9a Was the organization controlled directly or indirectly at any time during the tax year by one or more disqualified persons, as defined in section 4946 (other than foundation managers and organizations described in section 509(a)(1) or (2))? <i>If "Yes," provide detail in Part VI.</i>		
b Did one or more disqualified persons (as defined on line 9a) hold a controlling interest in any entity in which the supporting organization had an interest? <i>If "Yes," provide detail in Part VI.</i>		
c Did a disqualified person (as defined on line 9a) have an ownership interest in, or derive any personal benefit from, assets in which the supporting organization also had an interest? <i>If "Yes," provide detail in Part VI.</i>		
10a Was the organization subject to the excess business holdings rules of section 4943 because of section 4943(f) (regarding certain Type II supporting organizations, and all Type III non-functionally integrated supporting organizations)? <i>If "Yes," answer line 10b below.</i>		
b Did the organization have any excess business holdings in the tax year? <i>(Use Schedule C, Form 4720, to determine whether the organization had excess business holdings.)</i>		

Part IV Supporting Organizations (continued)

	Yes	No
11 Has the organization accepted a gift or contribution from any of the following persons?		
a A person who directly or indirectly controls, either alone or together with persons described on lines 11b and 11c below, the governing body of a supported organization?		
11a		
b A family member of a person described on line 11a above?		
11b		
c A 35% controlled entity of a person described on line 11a or 11b above? If "Yes" to line 11a, 11b, or 11c, provide detail in Part VI .		
11c		

Section B. Type I Supporting Organizations

	Yes	No
1 Did the governing body, members of the governing body, officers acting in their official capacity, or membership of one or more supported organizations have the power to regularly appoint or elect at least a majority of the organization's officers, directors, or trustees at all times during the tax year? If "No," describe in Part VI how the supported organization(s) effectively operated, supervised, or controlled the organization's activities. If the organization had more than one supported organization, describe how the powers to appoint and/or remove officers, directors, or trustees were allocated among the supported organizations and what conditions or restrictions, if any, applied to such powers during the tax year.		
1		
2 Did the organization operate for the benefit of any supported organization other than the supported organization(s) that operated, supervised, or controlled the supporting organization? If "Yes," explain in Part VI how providing such benefit carried out the purposes of the supported organization(s) that operated, supervised, or controlled the supporting organization.		
2		

Section C. Type II Supporting Organizations

	Yes	No
1 Were a majority of the organization's directors or trustees during the tax year also a majority of the directors or trustees of each of the organization's supported organization(s)? If "No," describe in Part VI how control or management of the supporting organization was vested in the same persons that controlled or managed the supported organization(s).		
1		

Section D. All Type III Supporting Organizations

	Yes	No
1 Did the organization provide to each of its supported organizations, by the last day of the fifth month of the organization's tax year, (i) a written notice describing the type and amount of support provided during the prior tax year, (ii) a copy of the Form 990 that was most recently filed as of the date of notification, and (iii) copies of the organization's governing documents in effect on the date of notification, to the extent not previously provided?		
1		
2 Were any of the organization's officers, directors, or trustees either (i) appointed or elected by the supported organization(s) or (ii) serving on the governing body of a supported organization? If "No," explain in Part VI how the organization maintained a close and continuous working relationship with the supported organization(s).		
2		
3 By reason of the relationship described on line 2, above, did the organization's supported organizations have a significant voice in the organization's investment policies and in directing the use of the organization's income or assets at all times during the tax year? If "Yes," describe in Part VI the role the organization's supported organizations played in this regard.		
3		

Section E. Type III Functionally Integrated Supporting Organizations

1 Check the box next to the method that the organization used to satisfy the Integral Part Test during the year (see instructions).			
a <input type="checkbox"/> The organization satisfied the Activities Test. Complete line 2 below.			
b <input type="checkbox"/> The organization is the parent of each of its supported organizations. Complete line 3 below.			
c <input type="checkbox"/> The organization supported a governmental entity. Describe in Part VI how you supported a governmental entity (see instructions).			
2 Activities Test. Answer lines 2a and 2b below.			
a Did substantially all of the organization's activities during the tax year directly further the exempt purposes of the supported organization(s) to which the organization was responsive? If "Yes," then in Part VI identify those supported organizations and explain how these activities directly furthered their exempt purposes, how the organization was responsive to those supported organizations, and how the organization determined that these activities constituted substantially all of its activities.			
2a			
b Did the activities described on line 2a, above, constitute activities that, but for the organization's involvement, one or more of the organization's supported organization(s) would have been engaged in? If "Yes," explain in Part VI the reasons for the organization's position that its supported organization(s) would have engaged in these activities but for the organization's involvement.			
2b			
3 Parent of Supported Organizations. Answer lines 3a and 3b below.			
a Did the organization have the power to regularly appoint or elect a majority of the officers, directors, or trustees of each of the supported organizations? If "Yes" or "No," provide details in Part VI .			
3a			
b Did the organization exercise a substantial degree of direction over the policies, programs, and activities of each of its supported organizations? If "Yes," describe in Part VI the role played by the organization in this regard.			
3b			

Part V Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations

- 1 ☐ Check here if the organization satisfied the Integral Part Test as a qualifying trust on Nov. 20, 1970 (*explain in Part VI*). See instructions.
All other Type III non-functionally integrated supporting organizations must complete Sections A through E.

Section A - Adjusted Net Income		(A) Prior Year	(B) Current Year (optional)
1	Net short-term capital gain	1	
2	Recoveries of prior-year distributions	2	
3	Other gross income (see instructions)	3	
4	Add lines 1 through 3.	4	
5	Depreciation and depletion	5	
6	Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions)	6	
7	Other expenses (see instructions)	7	
8	Adjusted Net Income (subtract lines 5, 6, and 7 from line 4)	8	

Section B - Minimum Asset Amount		(A) Prior Year	(B) Current Year (optional)
1	Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year):		
a	Average monthly value of securities	1a	
b	Average monthly cash balances	1b	
c	Fair market value of other non-exempt-use assets	1c	
d	Total (add lines 1a, 1b, and 1c)	1d	
e	Discount claimed for blockage or other factors (explain in detail in Part VI):		
2	Acquisition indebtedness applicable to non-exempt-use assets	2	
3	Subtract line 2 from line 1d.	3	
4	Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions).	4	
5	Net value of non-exempt-use assets (subtract line 4 from line 3)	5	
6	Multiply line 5 by 0.035.	6	
7	Recoveries of prior-year distributions	7	
8	Minimum Asset Amount (add line 7 to line 6)	8	

Section C - Distributable Amount			Current Year
1	Adjusted net income for prior year (from Section A, line 8, column A)	1	
2	Enter 0.85 of line 1.	2	
3	Minimum asset amount for prior year (from Section B, line 8, column A)	3	
4	Enter greater of line 2 or line 3.	4	
5	Income tax imposed in prior year	5	
6	Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions).	6	
7	<input type="checkbox"/> Check here if the current year is the organization's first as a non-functionally integrated Type III supporting organization (see instructions).		

Schedule A (Form 990) 2024

Part V Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations (continued)**Section D - Distributions**

		Current Year
1	Amounts paid to supported organizations to accomplish exempt purposes	1
2	Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity	2
3	Administrative expenses paid to accomplish exempt purposes of supported organizations	3
4	Amounts paid to acquire exempt-use assets	4
5	Qualified set-aside amounts (prior IRS approval required - <i>provide details in Part VI</i>)	5
6	Other distributions (describe in Part VI). See instructions.	6
7	Total annual distributions. Add lines 1 through 6.	7
8	Distributions to attentive supported organizations to which the organization is responsive (<i>provide details in Part VI</i>). See instructions.	8
9	Distributable amount for 2024 from Section C, line 6	9
10	Line 8 amount divided by line 9 amount	10

Section E - Distribution Allocations (see instructions)	(i) Excess Distributions	(ii) Underdistributions Pre-2024	(iii) Distributable Amount for 2024
1 Distributable amount for 2024 from Section C, line 6			
2 Underdistributions, if any, for years prior to 2024 (reasonable cause required - <i>explain in Part VI</i>). See instructions.			
3 Excess distributions carryover, if any, to 2024			
a From 2019			
b From 2020			
c From 2021			
d From 2022			
e From 2023			
f Total of lines 3a through 3e			
g Applied to under distributions of prior years			
h Applied to 2024 distributable amount			
i Carryover from 2019 not applied (see instructions)			
j Remainder. Subtract lines 3g, 3h, and 3i from line 3f.			
4 Distributions for 2024 from Section D, line 7: \$			
a Applied to underdistributions of prior years			
b Applied to 2024 distributable amount			
c Remainder. Subtract lines 4a and 4b from line 4.			
5 Remaining underdistributions for years prior to 2024, if any. Subtract lines 3g and 4a from line 2. For result greater than zero, <i>explain in Part VI</i> . See instructions.			
6 Remaining underdistributions for 2024. Subtract lines 3h and 4b from line 1. For result greater than zero, <i>explain in Part VI</i> . See instructions.			
7 Excess distributions carryover to 2025. Add lines 3j and 4c.			
8 Breakdown of line 7:			
a Excess from 2020			
b Excess from 2021			
c Excess from 2022			
d Excess from 2023			
e Excess from 2024			

Schedule A (Form 990) 2024

Part VI **Supplemental Information.** Provide the explanations required by Part II, line 10; Part II, line 17a or 17b; Part III, line 12; Part IV, Section A, lines 1, 2, 3b, 3c, 4b, 4c, 5a, 6, 9a, 9b, 9c, 11a, 11b, and 11c; Part IV, Section B, lines 1 and 2; Part IV, Section C, line 1; Part IV, Section D, lines 2 and 3; Part IV, Section E, lines 1c, 2a, 2b, 3a and 3b; Part V, line 1; Part V, Section B, line 1e; Part V, Section D, lines 5, 6, and 8; and Part V, Section E, lines 2, 5, and 6. Also complete this part for any additional information.
(See instructions.)

SCHEDULE A, PART II, LINE 10, EXPLANATION FOR OTHER INCOME:

SAVINGS BOND PAYOUT

2021 AMOUNT: \$ 7,500.

MISCELLANEOUS

2023 AMOUNT: \$ 70.

2024 AMOUNT: \$ 4,126.

**Schedule B
(Form 990)**

(Rev. December 2024)
Department of the Treasury
Internal Revenue Service

Schedule of Contributors

Attach to Form 990, 990-EZ, or 990-PF.
Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Organization type (check one):

Filers of:

Section:

Form 990 or 990-EZ

☒ 501(c)(3) (enter number) organization

☐ 4947(a)(1) nonexempt charitable trust **not** treated as a private foundation

☐ 527 political organization

Form 990-PF

☐ 501(c)(3) exempt private foundation

☐ 4947(a)(1) nonexempt charitable trust treated as a private foundation

☐ 501(c)(3) taxable private foundation

Check if your organization is covered by the **General Rule** or a **Special Rule**.

Note: Only a section 501(c)(7), (8), or (10) organization can check boxes for both the General Rule and a Special Rule. See instructions.

General Rule

☐ For an organization filing Form 990, 990-EZ, or 990-PF that received, during the year, contributions totaling \$5,000 or more (in money or property) from any one contributor. Complete Parts I and II. See instructions for determining a contributor's total contributions.

Special Rules

☒ For an organization described in section 501(c)(3) filing Form 990 or 990-EZ that met the 33 1/3% support test of the regulations under sections 509(a)(1) and 170(b)(1)(A)(vi), that checked Schedule A (Form 990), Part II, line 13, 16a, or 16b, and that received from any one contributor, during the year, total contributions of the greater of **(1)** \$5,000; or **(2)** 2% of the amount on (i) Form 990, Part VIII, line 1h; or (ii) Form 990-EZ, line 1. Complete Parts I and II.

☐ For an organization described in section 501(c)(7), (8), or (10) filing Form 990 or 990-EZ that received from any one contributor, during the year, total contributions of more than \$1,000 *exclusively* for religious, charitable, scientific, literary, or educational purposes, or for the prevention of cruelty to children or animals. Complete Parts I (entering "N/A" in column (b) instead of the contributor name and address), II, and III.

☐ For an organization described in section 501(c)(7), (8), or (10) filing Form 990 or 990-EZ that received from any one contributor, during the year, contributions *exclusively* for religious, charitable, etc., purposes, but no such contributions totaled more than \$1,000. If this box is checked, enter here the total contributions that were received during the year for an *exclusively* religious, charitable, etc., purpose. Don't complete any of the parts unless the **General Rule** applies to this organization because it received *nonexclusively* religious, charitable, etc., contributions totaling \$5,000 or more during the year \$ _____

Caution: An organization that isn't covered by the General Rule and/or the Special Rules doesn't file Schedule B (Form 990), but it **must** answer "No" on Part IV, line 2, of its Form 990; or check the box on line H of its Form 990-EZ or on its Form 990-PF, Part I, line 2, to certify that it doesn't meet the filing requirements of Schedule B (Form 990).

Employer identification number

23-7337229

Part I

[illegible]

Employer identification number

23-7337229

Part II

(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions.)	(d) Date received
	_____ _____ _____	\$ _____	_____
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions.)	(d) Date received
	_____ _____ _____	\$ _____	_____
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions.)	(d) Date received
	_____ _____ _____	\$ _____	_____
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions.)	(d) Date received
	_____ _____ _____	\$ _____	_____
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions.)	(d) Date received
	_____ _____ _____	\$ _____	_____
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions.)	(d) Date received
	_____ _____ _____	\$ _____	_____
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions.)	(d) Date received
	_____ _____ _____	\$ _____	_____
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions.)	(d) Date received
	_____ _____ _____	\$ _____	_____

Name of organization	Employer identification number
BRIGHTFOCUS FOUNDATION	23-7337229

Part III

Exclusively religious, charitable, etc., contributions to organizations described in section 501(c)(7), (8), or (10) that total more than \$1,000 for the year from any one contributor. Complete columns (a) through (e) and the following line entry. For organizations completing Part III, enter the total of exclusively religious, charitable, etc., contributions of \$1,000 or less for the year. (Enter this info. once.) \$

Use duplicate copies of Part III if additional space is needed.

(a) No. from Part I	(b) Purpose of gift	(c) Use of gift	(d) Description of how gift is held
	(e) Transfer of gift		
	Transferee's name, address, and ZIP + 4		Relationship of transferor to transferee
(a) No. from Part I	(b) Purpose of gift	(c) Use of gift	(d) Description of how gift is held
	(e) Transfer of gift		
	Transferee's name, address, and ZIP + 4		Relationship of transferor to transferee
(a) No. from Part I	(b) Purpose of gift	(c) Use of gift	(d) Description of how gift is held
	(e) Transfer of gift		
	Transferee's name, address, and ZIP + 4		Relationship of transferor to transferee
(a) No. from Part I	(b) Purpose of gift	(c) Use of gift	(d) Description of how gift is held
	(e) Transfer of gift		
	Transferee's name, address, and ZIP + 4		Relationship of transferor to transferee

SCHEDULE C
(Form 990)

Department of the Treasury
Internal Revenue Service

Political Campaign and Lobbying Activities

For Organizations Exempt From Income Tax Under Section 501(c) and Section 527
Complete if the organization is described below. Attach to Form 990 or Form 990-EZ.
Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2024

Open to Public
Inspection

If the organization answered "Yes" on Form 990, Part IV, line 3, or Form 990-EZ, Part V, line 46 (Political Campaign Activities), then:

- Section 501(c)(3) organizations: Complete Parts I-A and I-B. Do not complete Part I-C.
- Section 501(c) (other than section 501(c)(3)) organizations: Complete Parts I-A and I-C below. Do not complete Part I-B.
- Section 527 organizations: Complete Part I-A only.

If the organization answered "Yes" on Form 990, Part IV, line 4, or Form 990-EZ, Part VI, line 47 (Lobbying Activities), then:

- Section 501(c)(3) organizations that have filed Form 5768 (election under section 501(h)): Complete Part II-A. Do not complete Part II-B.
- Section 501(c)(3) organizations that have NOT filed Form 5768 (election under section 501(h)): Complete Part II-B. Do not complete Part II-A.

If the organization answered "Yes" on Form 990, Part IV, line 5 (Proxy Tax) (see separate instructions), or Form 990-EZ, Part V, line 35c (Proxy Tax) (see separate instructions), then:

- Section 501(c)(4), (5), or (6) organizations: Complete Part III.

Name of organization

BRIGHTFOCUS FOUNDATION

Employer identification number (EIN)

23-7337229

Part I-A Complete if the organization is exempt under section 501(c) or is a section 527 organization.

1 Provide a description of the organization's direct and indirect political campaign activities in Part IV.

2 Political campaign activity expenditures \$

3 Volunteer hours for political campaign activities

Part I-B Complete if the organization is exempt under section 501(c)(3).

1 Enter the amount of any excise tax incurred by the organization under section 4955 \$

2 Enter the amount of any excise tax incurred by organization managers under section 4955 \$

3 If the organization incurred a section 4955 tax, did it file Form 4720 for this year? ☐ Yes ☐ No

4a Was a correction made? ☐ Yes ☐ No

b If "Yes," describe in Part IV.

Part I-C Complete if the organization is exempt under section 501(c), except section 501(c)(3).

1 Enter the amount directly expended by the filing organization for section 527 exempt function activities \$

2 Enter the amount of the filing organization's funds contributed to other organizations for section 527
exempt function activities \$

3 Total exempt function expenditures. Add lines 1 and 2. Enter here and on Form 1120-POL,
line 17b \$

4 Did the filing organization file Form 1120-POL for this year? ☐ Yes ☐ No

5 Enter the names, addresses, and EINs of all section 527 political organizations to which the filing organization made payments. For each
organization listed, enter the amount paid from the filing organization's funds. Also enter the amount of political contributions received that were
promptly and directly delivered to a separate political organization, such as a separate segregated fund or a political action committee (PAC).
If additional space is needed, provide information in Part IV.

(a) Name	(b) Address	(c) EIN	(d) Amount paid from filing organization's funds. If none, enter -0-.	(e) Amount of political contributions received and promptly and directly delivered to a separate political organization. If none, enter -0-.

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Schedule C (Form 990) 2024

Part II-A Complete if the organization is exempt under section 501(c)(3) and filed Form 5768 (election under section 501(h)).

- A** Check ☐ if the filing organization belongs to an affiliated group (and list in Part IV each affiliated group member's name, address, EIN, expenses, and share of excess lobbying expenditures).
- B** Check ☐ if the filing organization checked box A and "limited control" provisions apply.

Limits on Lobbying Expenditures (The term "expenditures" means amounts paid or incurred.)		(a) Filing organization's totals	(b) Affiliated group totals
1a Total lobbying expenditures to influence public opinion (grassroots lobbying)		0.	
b Total lobbying expenditures to influence a legislative body (direct lobbying)		0.	
c Total lobbying expenditures (add lines 1a and 1b)		0.	
d Other exempt purpose expenditures		52,292,944.	
e Total exempt purpose expenditures (add lines 1c and 1d)		52,292,944.	
f Lobbying nontaxable amount. Enter the amount from the following table in both columns.		1,000,000.	
IF the amount on line 1e, column (a) or (b), is:	THEN the lobbying nontaxable amount is:		
not over \$500,000	20% of the amount on line 1e.		
over \$500,000 but not over \$1,000,000	\$100,000 plus 15% of the excess over \$500,000.		
over \$1,000,000 but not over \$1,500,000	\$175,000 plus 10% of the excess over \$1,000,000.		
over \$1,500,000 but not over \$17,000,000	\$225,000 plus 5% of the excess over \$1,500,000.		
over \$17,000,000	\$1,000,000.		
g Grassroots nontaxable amount (enter 25% of line 1f)		250,000.	
h Subtract line 1g from line 1a. If zero or less, enter -0-		0.	
i Subtract line 1f from line 1c. If zero or less, enter -0-		0.	
j If there is an amount other than zero on either line 1h or line 1i, did the organization file Form 4720 reporting section 4911 tax for this year?			<input type="checkbox"/> Yes <input type="checkbox"/> No

4-Year Averaging Period Under Section 501(h)

(Some organizations that made a section 501(h) election do not have to complete all of the five columns below.
See the separate instructions for lines 2a through 2f.)

Lobbying Expenditures During 4-Year Averaging Period					
Calendar year (or fiscal year beginning in)	(a) 2021	(b) 2022	(c) 2023	(d) 2024	(e) Total
2a Lobbying nontaxable amount	1,000,000.	1,000,000.	1,000,000.	1,000,000.	4,000,000.
b Lobbying ceiling amount (150% of line 2a, column(e))					6,000,000.
c Total lobbying expenditures					
d Grassroots nontaxable amount	250,000.	250,000.	250,000.	250,000.	1,000,000.
e Grassroots ceiling amount (150% of line 2d, column (e))					1,500,000.
f Grassroots lobbying expenditures					

Schedule C (Form 990) 2024

SCHEDULE D
(Form 990)

(Rev. December 2024)

Department of the Treasury
Internal Revenue Service

Supplemental Financial Statements

Complete if the organization answered "Yes" on Form 990,
Part IV, line 6, 7, 8, 9, 10, 11a, 11b, 11c, 11d, 11e, 11f, 12a, or 12b.

Attach to Form 990.

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

Open to Public
Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I

Organizations Maintaining Donor Advised Funds or Other Similar Funds or Accounts. Complete if the organization answered "Yes" on Form 990, Part IV, line 6.

	(a) Donor advised funds	(b) Funds and other accounts
1 Total number at end of year		
2 Aggregate value of contributions to (during year)		
3 Aggregate value of grants from (during year)		
4 Aggregate value at end of year		
5 Did the organization inform all donors and donor advisors in writing that the assets held in donor advised funds are the organization's property, subject to the organization's exclusive legal control?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
6 Did the organization inform all grantees, donors, and donor advisors in writing that grant funds can be used only for charitable purposes and not for the benefit of the donor or donor advisor, or for any other purpose conferring impermissible private benefit?	<input type="checkbox"/> Yes	<input type="checkbox"/> No

Part II

Conservation Easements. Complete if the organization answered "Yes" on Form 990, Part IV, line 7.

1 Purpose(s) of conservation easements held by the organization (check all that apply).
☐ Preservation of land for public use (for example, recreation or education) ☐ Preservation of a historically important land area
☐ Protection of natural habitat ☐ Preservation of a certified historic structure
☐ Preservation of open space

2 Complete lines 2a through 2d if the organization held a qualified conservation contribution in the form of a conservation easement on the last day of the tax year.

	Held at the End of the Tax Year
a Total number of conservation easements	2a
b Total acreage restricted by conservation easements	2b
c Number of conservation easements on a certified historic structure included on line 2a	2c
d Number of conservation easements included on line 2c acquired after July 25, 2006, and not on a historic structure listed in the National Register	2d

3 Number of conservation easements modified, transferred, released, extinguished, or terminated by the organization during the tax year

4 Number of states where property subject to conservation easement is located

5 Does the organization have a written policy regarding the periodic monitoring, inspection, handling of violations, and enforcement of the conservation easements it holds?

☐ Yes ☐ No

6 Staff and volunteer hours devoted to monitoring, inspecting, handling of violations, and enforcing conservation easements during the year

7 Amount of expenses incurred in monitoring, inspecting, handling of violations, and enforcing conservation easements during the year

8 Does each conservation easement reported on line 2d above satisfy the requirements of section 170(h)(4)(B)(i) and section 170(h)(4)(B)(ii)?

☐ Yes ☐ No

9 In Part XIII, describe how the organization reports conservation easements in its revenue and expense statement and balance sheet, and include, if applicable, the text of the footnote to the organization's financial statements that describes the organization's accounting for conservation easements.

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets.

Complete if the organization answered "Yes" on Form 990, Part IV, line 8.

1a If the organization elected, as permitted under FASB ASC 958, not to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide in Part XIII the text of the footnote to its financial statements that describes these items.

b If the organization elected, as permitted under FASB ASC 958, to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide the following amounts relating to these items.

(i) Revenue included on Form 990, Part VIII, line 1 \$

(ii) Assets included in Form 990, Part X \$

2 If the organization received or held works of art, historical treasures, or other similar assets for financial gain, provide the following amounts required to be reported under FASB ASC 958 relating to these items:

a Revenue included on Form 990, Part VIII, line 1 \$

b Assets included in Form 990, Part X \$

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Schedule D (Form 990) (Rev. 12-2024)

Part III Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets (continued)

3 Using the organization's acquisition, accession, and other records, check any of the following that make significant use of its collection items (check all that apply).

a ☐ Public exhibition

d ☐ Loan or exchange program

b ☐ Scholarly research

e ☐ Other _____

c ☐ Preservation for future generations

4 Provide a description of the organization's collections and explain how they further the organization's exempt purpose in Part XIII.

5 During the year, did the organization solicit or receive donations of art, historical treasures, or other similar assets

to be sold to raise funds rather than to be maintained as part of the organization's collection? ☐ Yes ☐ No

Part IV Escrow and Custodial Arrangements Complete if the organization answered "Yes" on Form 990, Part IV, line 9, or reported an amount on Form 990, Part X, line 21.

1a Is the organization an agent, trustee, custodian, or other intermediary for contributions or other assets not included on Form 990, Part X? ☐ Yes ☐ No

b If "Yes," explain the arrangement in Part XIII and complete the following table:

	Amount
c Beginning balance	1c
d Additions during the year	1d
e Distributions during the year	1e
f Ending balance	1f

2a Did the organization include an amount on Form 990, Part X, line 21, for escrow or custodial account liability? ☐ Yes ☐ No

b If "Yes," explain the arrangement in Part XIII. Check here if the explanation has been provided in Part XIII ☐

Part V Endowment Funds Complete if the organization answered "Yes" on Form 990, Part IV, line 10.

	(a) Current year	(b) Prior year	(c) Two years back	(d) Three years back	(e) Four years back
1a Beginning of year balance	286,823.	310,022.	325,000.	302,000.	302,000.
b Contributions	8,079.	23,199.	14,978.	13,634.	14,744.
c Net investment earnings, gains, and losses	-8,079.	-23,199.	-14,978.	23,000.	
d Grants or scholarships					
e Other expenditures for facilities and programs	8,079.	23,199.	14,978.	13,634.	14,744.
f Administrative expenses					
g End of year balance	278,744.	286,823.	310,022.	325,000.	302,000.

2 Provide the estimated percentage of the current year end balance (line 1g, column (a)) held as:

a Board designated or quasi-endowment .0000 %

b Permanent endowment 100 %

c Term endowment .0000 %

The percentages on lines 2a, 2b, and 2c should equal 100%.

3a Are there endowment funds not in the possession of the organization that are held and administered for the organization by:

(i) Unrelated organizations? ☒

(ii) Related organizations? ☒

	Yes	No
3a(i)	X	
3a(ii)		X
3b		

b If "Yes" on line 3a(ii), are the related organizations listed as required on Schedule R? ☐

4 Describe in Part XIII the intended uses of the organization's endowment funds.

Part VI Land, Buildings, and Equipment

Complete if the organization answered "Yes" on Form 990, Part IV, line 11a. See Form 990, Part X, line 10.

Description of property	(a) Cost or other basis (investment)	(b) Cost or other basis (other)	(c) Accumulated depreciation	(d) Book value
1a Land		1,147,363.		1,147,363.
b Buildings		5,465,739.	3,623,837.	1,841,902.
c Leasehold improvements				
d Equipment		2,427,476.	1,462,779.	964,697.
e Other		243,105.	225,416.	17,689.
Total. Add lines 1a through 1e. (Column (d) must equal Form 990, Part X, line 10c, column (B))				3,971,651.

Schedule D (Form 990) (Rev. 12-2024)

Part VII Investments - Other Securities

Complete if the organization answered "Yes" on Form 990, Part IV, line 11b. See Form 990, Part X, line 12.

(a) Description of security or category (including name of security)	(b) Book value	(c) Method of valuation: Cost or end-of-year market value
(1) Financial derivatives		
(2) Closely held equity interests		
(3) Other		
(A) MAKENA PERPETUAL PRIVATE		
(B) EQUITY FUND	3,810,912.	END-OF-YEAR MARKET VALUE
(C) MAKENA PERPETUAL VENTURE		
(D) CAPITAL FUND	4,207,362.	END-OF-YEAR MARKET VALUE
(E)		
(F)		
(G)		
(H)		
Total. (Col. (b) must equal Form 990, Part X, line 12, col. (B))	8,018,274.	

Part VIII Investments - Program Related.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11c. See Form 990, Part X, line 13.

(a) Description of investment	(b) Book value	(c) Method of valuation: Cost or end-of-year market value
(1)		
(2)		
(3)		
(4)		
(5)		
(6)		
(7)		
(8)		
(9)		
Total. (Col. (b) must equal Form 990, Part X, line 13, col. (B))		

Part IX Other Assets

Complete if the organization answered "Yes" on Form 990, Part IV, line 11d. See Form 990, Part X, line 15.

(a) Description	(b) Book value
(1)	
(2)	
(3)	
(4)	
(5)	
(6)	
(7)	
(8)	
(9)	
Total. (Column (b) must equal Form 990, Part X, line 15, col. (B))	

Part X Other Liabilities

Complete if the organization answered "Yes" on Form 990, Part IV, line 11e or 11f. See Form 990, Part X, line 25.

1. (a) Description of liability	(b) Book value
(1) Federal income taxes	
(2) CHARITABLE GIFT ANNUITIES	444,188.
(3) CAPITAL LEASE OBLIGATIONS	108,794.
(4) PNC SAHYUN CRUT RESERVE G++ ST	53,302.
(5) ITB VAUD RESERVE	70,210.
(6)	
(7)	
(8)	
(9)	
Total. (Column (b) must equal Form 990, Part X, line 25, col. (B))	676,494.

2. Liability for uncertain tax positions. In Part XIII, provide the text of the footnote to the organization's financial statements that reports the organization's liability for uncertain tax positions under FASB ASC 740. Check here if the text of the footnote has been provided in Part XIII ... ☒

Schedule D (Form 990) (Rev. 12-2024)

Part XI Reconciliation of Revenue per Audited Financial Statements With Revenue per Return

Complete if the organization answered "Yes" on Form 990, Part IV, line 12a.

1	Total revenue, gains, and other support per audited financial statements	1	73,031,620.
2	Amounts included on line 1 but not on Form 990, Part VIII, line 12:		
a	Net unrealized gains (losses) on investments	2a	502,498.
b	Donated services and use of facilities	2b	9,240,763.
c	Recoveries of prior year grants	2c	105,727.
d	Other (Describe in Part XIII.)	2d	
e	Add lines 2a through 2d	2e	9,848,988.
3	Subtract line 2e from line 1	3	63,182,632.
4	Amounts included on Form 990, Part VIII, line 12, but not on line 1:		
a	Investment expenses not included on Form 990, Part VIII, line 7b	4a	241,292.
b	Other (Describe in Part XIII.)	4b	
c	Add lines 4a and 4b	4c	241,292.
5	Total revenue. Add lines 3 and 4c. (This must equal Form 990, Part I, line 12.)	5	63,423,924.

Part XII Reconciliation of Expenses per Audited Financial Statements With Expenses per Return

Complete if the organization answered "Yes" on Form 990, Part IV, line 12a.

1	Total expenses and losses per audited financial statements	1	62,289,890.
2	Amounts included on line 1 but not on Form 990, Part IX, line 25:		
a	Donated services and use of facilities	2a	9,240,763.
b	Prior year adjustments	2b	
c	Other losses	2c	
d	Other (Describe in Part XIII.)	2d	
e	Add lines 2a through 2d	2e	9,240,763.
3	Subtract line 2e from line 1	3	53,049,127.
4	Amounts included on Form 990, Part IX, line 25, but not on line 1:		
a	Investment expenses not included on Form 990, Part VIII, line 7b	4a	241,292.
b	Other (Describe in Part XIII.)	4b	4,590.
c	Add lines 4a and 4b	4c	245,882.
5	Total expenses. Add lines 3 and 4c. (This must equal Form 990, Part I, line 18.)	5	53,295,009.

Part XIII Supplemental Information

Provide the descriptions required for Part II, lines 3, 5, and 9; Part III, lines 1a and 4; Part IV, lines 1b and 2b; Part V, line 4; Part X, line 2; Part XI, lines 2d and 4b; and Part XII, lines 2d and 4b. Also complete this part to provide any additional information.

PART V, LINE 4:

THE EARNINGS ON THIS ENDOWMENT ARE AVAILABLE FOR THE ALZHEIMER'S DISEASE RESEARCH PROGRAM, ARE RECORDED AS TEMPORARILY RESTRICTED INVESTMENT INCOME, AND ARE RELEASED AS SPENT.

PART X, LINE 2:

BRIGHTFOCUS PERFORMED AN EVALUATION OF UNCERTAINTY IN INCOME TAXES FOR THE YEAR ENDED MARCH 31, 2025, AND DETERMINED THAT THERE WERE NO MATTERS THAT WOULD REQUIRE RECOGNITION IN THE CONSOLIDATED FINANCIAL STATEMENTS OR THAT MAY HAVE ANY EFFECT ON ITS TAX-EXEMPT STATUS.

PART XII, LINE 4B - OTHER ADJUSTMENTS:

CHANGE IN PRESENT VALUE OF GRANTS 4,590.

Part XIII Supplemental Information (continued)

Area for supplemental information with horizontal lines.

**SCHEDULE F
(Form 990)**

(Rev. December 2024)
Department of the Treasury
Internal Revenue Service

Statement of Activities Outside the United States

Complete if the organization answered "Yes" on Form 990, Part IV, line 14b, 15, or 16.

Attach to Form 990.

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

**Open to Public
Inspection**

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I General Information on Activities Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 14b.

1 For grantmakers. Does the organization maintain records to substantiate the amount of its grants and other assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance? ☒ **Yes** ☐ **No**

2 For grantmakers. Describe in Part V the organization's procedures for monitoring the use of its grants and other assistance outside the United States.

3 Activities per Region. (The following Part I, line 3 table can be duplicated if additional space is needed.)

(a) Region	(b) Number of offices in the region	(c) Number of employees, agents, and independent contractors in the region	(d) Activities conducted in the region (by type) (such as, fundraising, program services, investments, grants to recipients located in the region)	(e) If activity listed in (d) is a program service, describe specific type of service(s) in the region	(f) Total expenditures for and investments in the region
EAST ASIA AND THE PACIFIC	0	0	GRANTMAKING		819,000.
EUROPE	0	0	GRANTMAKING		2,125,298.
NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES	0	0	GRANTMAKING		431,595.
SOUTH AMERICA	0	0	GRANTMAKING		300,000.
3 a Subtotal	0	0			3,675,893.
b Total from continuation sheets to Part I	0	0			0.
c Totals (add lines 3a and 3b)	0	0			3,675,893.

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Schedule F (Form 990) (Rev. 12-2024)

Part II **Grants and Other Assistance to Organizations or Entities Outside the United States.** Complete if the organization answered "Yes" on Form 990, Part IV, line 15, for any recipient who received more than \$5,000. Part II can be duplicated if additional space is needed.

1 (a) Name of organization	(b) IRS code section and EIN (if applicable)	(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement	(g) Amount of noncash assistance	(h) Description of noncash assistance	(i) Method of valuation (book, FMV, appraisal, other)
		EAST ASIA & THE PACIFIC	MACULAR DEGENERATION RESEARCH BY DAISY YAO SHU, PHD ENTITLED: M2025005N	409,500.	WIRE TRANSFER	0.		
		EAST ASIA & THE PACIFIC	MACULAR DEGENERATION RESEARCH BY MASAYUKI HATA, PHD ENTITLED: M2025006N	409,500.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY WILLEM ANNAERT, PHD ENTITLED: A2024033S	300,000.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY FRANCES WISEMAN, PHD ENTITLED: A2024040S	300,000.	WIRE TRANSFER	0.		
		NORTH AMERICA (WHICH INCLUDES CANADA AND MEXICO, BUT NOT	ALZHEIMER'S DISEASE RESEARCH BY ISABELLE AUBERT, PHD ENTITLED: A2025018S	300,000.	WIRE TRANSFER	0.		
		SOUTH AMERICA	ALZHEIMER'S DISEASE RESEARCH BY CAROLINA OCHOA-ROSALES, PHD ENTITLED: A2025027S	300,000.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY NADER SAFFARI, PHD ENTITLED: A2025022S	299,217.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY JOHN HARDY, PHD, FRs ENTITLED: A2025012S	231,239.	WIRE TRANSFER	0.		

2 Enter total number of recipient organizations listed above that are recognized as charities by the foreign country, recognized as a tax exempt 501(c)(3) organization by the IRS, or for which the grantee or counsel has provided a section 501(c)(3) equivalency letter

5

3 Enter total number of other organizations or entities

11

Part II Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States. (Schedule F (Form 990), Part II, line 1)

1 (a) Name of organization	(b) IRS code section and EIN (if applicable)	(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement	(g) Amount of non-cash assistance	(h) Description of non-cash assistance	(i) Method of valuation (book, FMV, appraisal, other)
		EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY LAURA FUMAGALLI, PHD ENTITLED: A2025008F	200,000.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY FEDERICA ANASTASI, PHD ENTITLED: A2025004F	199,996.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	MACULAR DEGENERATION RESEARCH BY JOLLE ELISE VERGROESEN, PHD ENTITLED: M2025010F	182,000.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	NATIONAL GLAUCOMA RESEARCH BY PETE WILLIAMS, PHD ENTITLED: G2025006S	181,181.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	BIRAX RESEARCH FUNDING, ENTITLED: CA2023002	146,664.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY OLAV M. ANDERSEN, PHD ENTITLED: CA2025001	85,000.	WIRE TRANSFER	0.		
		NORTH AMERICA (WHICH INCLUDES CANADA AND MEXICO, BUT NOT	ALZHEIMER'S DISEASE RESEARCH BY MALLAR CHAKRAVARTY, PHD ENTITLED: CA2025002	85,000.	WIRE TRANSFER	0.		
		NORTH AMERICA (WHICH INCLUDES CANADA AND MEXICO, BUT NOT	MIND AND SIGHT DISEASES RESEARCH FUNDING, ENTITLED: CA2023003	46,595.	WIRE TRANSFER	0.		

Part III **Grants and Other Assistance to Individuals Outside the United States.** Complete if the organization answered "Yes" on Form 990, Part IV, line 16.

Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance	(b) Region	(c) Number of recipients	(d) Amount of cash grant	(e) Manner of cash disbursement	(f) Amount of noncash assistance	(g) Description of noncash assistance	(h) Method of valuation (book, FMV, appraisal, other)

Part IV Foreign Forms

- 1** Was the organization a U.S. transferor of property to a foreign corporation during the tax year? *If "Yes," the organization may be required to file Form 926, Return by a U.S. Transferor of Property to a Foreign Corporation (see the Instructions for Form 926)* ☐ Yes ☒ No
- 2** Did the organization have an interest in a foreign trust during the tax year? *If "Yes," the organization may be required to separately file Form 3520, Annual Return To Report Transactions With Foreign Trusts and Receipt of Certain Foreign Gifts, and/or Form 3520-A, Annual Information Return of Foreign Trust With a U.S. Owner (see the Instructions for Forms 3520 and 3520-A; don't file with Form 990)* ☐ Yes ☒ No
- 3** Did the organization have an ownership interest in a foreign corporation during the tax year? *If "Yes," the organization may be required to file Form 5471, Information Return of U.S. Persons With Respect to Certain Foreign Corporations (see the Instructions for Form 5471)* ☐ Yes ☒ No
- 4** Was the organization a direct or indirect shareholder of a passive foreign investment company or a qualified electing fund during the tax year? *If "Yes," the organization may be required to file Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund (see the Instructions for Form 8621)* ☐ Yes ☒ No
- 5** Did the organization have an ownership interest in a foreign partnership during the tax year? *If "Yes," the organization may be required to file Form 8865, Return of U.S. Persons With Respect to Certain Foreign Partnerships (see the Instructions for Form 8865)* ☐ Yes ☒ No
- 6** Did the organization have any operations in or related to any boycotting countries during the tax year? *If "Yes," the organization may be required to separately file Form 5713, International Boycott Report (see the Instructions for Form 5713; don't file with Form 990)* ☐ Yes ☒ No

Schedule F (Form 990) (Rev. 12-2024)

Part V Supplemental Information

Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

PART I, LINE 2:

BEFORE AN INTERNATIONAL GRANT IS AWARDED OR PAID, BRIGHTFOCUS CONFIRMS THAT THE RECIPIENT AND/OR INSTITUTION SUPPORTING THE RESEARCH IS NOT INCLUDED ON THE OFAC (OFFICE OF FOREIGN ASSETS CONTROL) SANCTIONS LIST OR THE INTERNATIONAL BOYCOTT LIST ON THE FEDERAL REGISTER.

AFTER AN INTERNATIONAL GRANT IS AWARDED, BRIGHTFOCUS INTERACTS WITH ALL GRANTEEES AT LEAST QUARTERLY BY E-MAIL OR AT SCIENTIFIC MEETINGS. IN ADDITION TO THESE INTERACTIONS, EACH GRANT RECIPIENT IS REQUIRED TO SUBMIT SEPARATE DETAILED ANNUAL SCIENTIFIC PROGRESS AND FINANCIAL REPORTS TO BRIGHTFOCUS. THESE ARE RECEIVED BY THE BRIGHTFOCUS SCIENTIFIC AFFAIRS DEPARTMENT, AND REVIEWED BY SCIENTIFIC STAFF WITH BROAD EXPERTISE, INCLUDING IMAGING, MOLECULAR BIOLOGY AND SIGNALING PATHWAYS, CELL BIOLOGY, ANGIOGENESIS, BIOCHEMISTRY, NEUROSCIENCE, AND GENETICS. SENIOR STAFF REVIEWS EACH PROGRESS REPORT AND EVALUATES THE PROJECT FOR SUFFICIENT PROGRESS TOWARDS THE SPECIFIC AIMS PROPOSED IN THE ORIGINAL APPLICATION OR ANY BUDGETARY CONCERNS. THIS EFFORT IS SUPPORTED BY ADDITIONAL SCIENTIFIC COUNSEL FROM MEMBERS OF THE BRIGHTFOCUS SCIENTIFIC REVIEW COMMITTEES, WHEN REQUIRED. IN ADDITION TO STATEMENTS OF EXPERIMENTAL PROGRESS, ALL GRANTEEES ARE ASKED TO REPORT ANY TECHNICAL PUBLICATIONS, MEDIA REPORTS, OR PATENT APPLICATIONS IN WHICH BRIGHTFOCUS-SPONSORED RESEARCH IS DESCRIBED. IF SIGNIFICANT CONCERNS RELATED TO PROGRESS ON THE AWARDS ARE DISCOVERED, AND NOT RESOLVED AFTER INTERACTION WITH THE AWARD GRANTEE, THE BRIGHTFOCUS STAFF RECOMMENDS APPROPRIATE ACTIONS TO THE CHAIR OF THE SCIENTIFIC AFFAIRS COMMITTEE OF THE BOARD OF DIRECTORS. IN ACCORDANCE WITH THE GRANT AGREEMENT TERMS AND CONDITIONS, BRIGHTFOCUS MAY WITHHOLD FUNDING, OR DISCONTINUE AN AWARD, FOR ANY GRANTEE THAT FAILS TO ACHIEVE SUFFICIENT PROGRESS OR SUBMIT REQUIRED REPORTS.

AT THE CONCLUSION OF THE GRANT AWARD PERIOD, EACH GRANTEE MUST COMPLETE AND SUBMIT A FINAL REPORT THAT IS ALSO REVIEWED BY THE BRIGHTFOCUS SENIOR SCIENTIFIC STAFF. EVALUATION OF THE WORK OF EACH GRANTEE IS QUALITATIVELY AND QUANTITATIVELY ASSESSED THROUGH VARIOUS METRICS RELATED TO THE IMPACT OF THE GRANT ON ITS TARGETED DISEASE FIELD. SUCH IMPACT METRICS HAVE REVEALED THAT 95% OF BRIGHTFOCUS-SUPPORTED RESEARCH RESULTS IN RESEARCH PUBLICATIONS THAT ADVANCE THE FIELDS SERVED BY BRIGHTFOCUS. THIS IMPACT IS FURTHER SUPPORTED BY ANNUAL CATEGORY NORMALIZED CITATION IMPACT ANALYSIS THAT COMPARES BRIGHTFOCUS-SUPPORTED WORKS TO AN UNBIASED COMPARISON OF IMPACT PERFORMANCE VERSUS THE WORLD AVERAGE. BRIGHTFOCUS-SUPPORTED PUBLICATIONS WERE RECENTLY CITED AT 2 TIMES THE FREQUENCY OF THE WORLD AVERAGE. A FINAL EXAMPLE OF IMPACT ASSESSMENT REVEALED THAT THE SUCCESSES OF BRIGHTFOCUS GRANTEEES CONTINUE LONG AFTER THE GRANT EXPIRES. ON AVERAGE, EACH GRANTEE RECEIVES ADDITIONAL GRANTS FOR FOLLOW-ON PROJECTS SPAWNED BY THE BRIGHTFOCUS GRANT, WITH VALUES UP TO 8 TIMES THE LEVEL OF THE INITIAL BRIGHTFOCUS INVESTMENT.

BRIGHTFOCUS SOLICITS FEEDBACK FROM ITS GRANTEEES AND PROVIDES AN ANONYMOUS FORUM FOR COLLECTING SUCH INFORMATION. THROUGH THE BRIGHTFOCUS FOUNDATION WEBSITE AND WITHIN THE SCIENTIFIC PROGRESS REPORTS, THERE ARE DESIGNATED SECTIONS WHERE AWARDEES ARE ASKED TO PROVIDE FEEDBACK TO THE FOUNDATION. THROUGH THIS MECHANISM, THEY ARE GIVEN THE ABILITY TO ANONYMOUSLY PROVIDE FEEDBACK OR COMMUNICATE THEIR CONCERNS TO PROGRAM STAFF OR THE BRIGHTFOCUS' COMPLIANCE OFFICE. ANY SUGGESTIONS, CONCERNS, COMPLAINTS, OR

Part V Supplemental Information

Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

POSITIVE EXPERIENCES CAN BE OUTLINED AND BROUGHT TO THE ATTENTION OF BRIGHTFOCUS IN THIS MANNER, SO THAT BRIGHTFOCUS CAN ADDRESS ANY AREAS NEEDING IMPROVEMENT, REAFFIRM PRAISE-WORTHY POLICIES, OR OTHERWISE ASSESS NEEDS FOR PROGRAMMATIC CHANGE. THE SENIOR LEADERSHIP PRESENTS AND SUMMARIZES THE STATUS AND PROGRESS ON GRANTS TO THE BRIGHTFOCUS BOARD OF DIRECTORS AT EACH OF THEIR QUARTERLY BOARD MEETINGS.

PART I, LINE 3:

BRIGHTFOCUS REPORTED THE EXPENDITURES BASED ON THE ACCOUNTING METHOD USED IN ITS AUDITED FINANCIAL STATEMENTS WHICH IS ON AN ACCRUAL BASIS.

PART II, LINE 1:

BRIGHTFOCUS REPORTED THE EXPENDITURES BASED ON THE ACCOUNTING METHOD USED IN ITS AUDITED FINANCIAL STATEMENTS WHICH IS ON AN ACCRUAL BASIS.

PART II, LINE 1, COLUMN (D)

REGION: EUROPE (INCLUDING ICELAND & GREENLAND) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY WILLEM ANNAERT, PHD ENTITLED: A2024033S DECODING THE ROLE OF AN ALZHEIMER'S CAUSAL GENE IN DISTINCT BRAIN CELL TYPES. INVESTIGATOR'S SUMMARY: MUTATIONS IN THE GENE ENCODING PRESENILIN2 (PSEN2) CAUSE EARLY ONSET FAMILIAL ALZHEIMER'S DISEASE BUT THUS FAR THIS WAS MAINLY STUDIED IN THE CONTEXT OF A BUILD-UP OF TOXIC AMYLOID AGGREGATES. HOWEVER GIVEN ITS RESTRICTED LOCALIZATION IN DEGRADATIVE COMPARTMENTS, WE HYPOTHEZIZE THAT MECHANISMS EXIST LEADING TO DISEASE ONSET THAT MAY DIFFER FROM ITS CLOSE RELATIVE PSEN1. UTILIZING NEW PSEN2 AD MOUSE MODELS AND HUMAN NEURONS/MICROGLIA, WE WILL EMPLOY FUNCTIONAL ASSAYS AND ADVANCED MORPHOLOGICAL STUDIES TO UNRAVEL THE CELL TYPE SPECIFIC CONTRIBUTIONS OF PSEN2 IN AD ETIOPATHOGENESIS. GRANT AWARDED: \$300,000, FLEMISH INSTITUTE FOR BIOTECHNOLOGY, GHENT, BELGIUM.

REGION: EUROPE (INCLUDING ICELAND & GREENLAND) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY FRANCES WISEMAN, PHD ENTITLED: A2024040S THE ROLE OF DYRK1A KINASE IN ALZHEIMER'S DISEASE MICROGLIA DIFFERENCES. INVESTIGATOR'S SUMMARY: DOWN SYNDROME IS A GENETIC CONDITION, CAUSED BY AN EXTRA COPY OF CHROMOSOME 21, AND IS ASSOCIATED WITH A GREATLY INCREASED RISK OF DEVELOPING EARLY-ONSET DEMENTIA CAUSED BY ALZHEIMER'S DISEASE. RECENT RESEARCH HAS DEMONSTRATED THE BRAIN'S IMMUNE RESPONSE TO ALZHEIMER'S DISEASE PATHOLOGY DIFFERS IN PEOPLE WHO HAVE DOWN SYNDROME AND THAT THIS MAY CONTRIBUTE TO THE DEVELOPMENT OF DEMENTIA. OUR DATA INDICATE THAT THE CHROMOSOME 21 GENE, DYRK1A MAY CONTRIBUTE TO THIS; HERE WE PROPOSE TO TEST THIS HYPOTHESIS IN A NEW CELLULAR MODEL OF ALZHEIMER'S DISEASE IN THE CONTEXT OF TRISOMY OF CHROMOSOME 21. GRANT AWARDED: \$300,000, UNIVERSITY COLLEGE LONDON INSTITUTE OF NEUROLOGY, LONDON, UNITED KINGDOM.

REGION: EUROPE (INCLUDING ICELAND & GREENLAND) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY FEDERICA ANASTASI, PHD ENTITLED: A2025004F PERSONALIZED PROTEOMICS TO UNDERSTAND AND PREDICT ALZHEIMER'S PROGRESSION. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) AFFECTS PEOPLE DIFFERENTLY, LEADING TO VARYING RATES OF MEMORY LOSS AND COGNITIVE DECLINE. WHILE BLOOD TESTS CAN HELP DETECT EARLY SIGNS OF AD, THERE'S STILL MUCH TO LEARN ABOUT WHY THESE DIFFERENCES OCCUR. THIS PROJECT FOCUSES ON IDENTIFYING NEW BIOMARKERS TO EXPLAIN WHY

Part V Supplemental Information

Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

INDIVIDUALS EXPERIENCE AD DIFFERENTLY AND PREDICT WHO WILL BE MOST AFFECTED. BY DISCOVERING THESE MARKERS, WE AIM TO DEVELOP PERSONALIZED TOOLS FOR EARLIER INTERVENTION, IMPROVE PREDICTIONS, AND ENHANCE THE RECRUITMENT OF PARTICIPANTS FOR CLINICAL TRIALS. GRANT AWARDED: \$199,996, BARCELONABETA BRAIN RESEARCH CENTER, BARCELONA, SPAIN.

REGION: EUROPE (INCLUDING ICELAND & GREENLAND) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY LAURA FUMAGALLI, PHD ENTITLED: A2025008F LEVERAGING HOW THE BRAIN'S IMMUNE CELLS FUEL FRONTOTEMPORAL DEMENTIA. INVESTIGATOR'S SUMMARY: A MUTATION IN THE C9ORF72 GENE IS THE LEADING GENETIC CAUSE OF FTD AND ALS, BUT ITS ROLE IN BRAIN CELL DAMAGE REMAINS UNCLEAR. THE GENE IS HIGHLY ACTIVE IN MICROGLIA, THE BRAIN'S IMMUNE CELLS, WHICH MAY MALFUNCTION DUE TO THIS MUTATION. SINCE UNHEALTHY MICROGLIA CAN WORSEN BRAIN DISEASES, THIS STUDY WILL EXPLORE HOW THE C9ORF72 MUTATION AFFECTS THEM. USING AN INNOVATIVE MODEL THAT MIMICS A BRAIN-LIKE ENVIRONMENT, I WILL ANALYZE HOW THE MUTATION ALTERS MICROGLIAL ACTIVITY AND FUNCTION. THIS RESEARCH COULD REVEAL NOVEL DRUG TARGETS AND DIAGNOSTICS TOOLS. GRANT AWARDED: \$200,000, FLANDERS INSTITUTE FOR BIOTECHNOLOGY, ANTWERPEN, BELGIUM.

REGION: EUROPE (INCLUDING ICELAND & GREENLAND) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JOHN HARDY, PHD, FRs ENTITLED: A2025012S A NEW LOOK AT GENETICS USING OLD DATA: ALZHEIMER'S PROGRESSION. INVESTIGATOR'S SUMMARY: WE HAVE SPENT BILLIONS OF DOLLARS AND DECADES STUDYING ALZHEIMER'S DISEASE (AD) BUT HAVE NOT YET FOUND AN EFFECTIVE TREATMENT. MOST ARE BASED ON OUR RESEARCH INTO UNDERSTANDING FACTORS INCREASING THE RISK OF GETTING AD. MODIFICATION OF THOSE FACTORS ARE THEN USED TO SEE IF THE SPEED AT WHICH AD PROGRESSES CAN BE SLOWED DOWN. HOWEVER, THERE IS NO EVIDENCE THAT FACTORS THAT DETERMINE RISK OF GETTING AD ARE THE SAME AS THOSE THAT AFFECT PROGRESSION OF AD! GENETICS CAN TELL US ABOUT BIOLOGY. BY REUSING CLINICAL TRIAL DATA AND THEIR GENETICS, WE CAN SEE WHAT THE BIOLOGY OF PROGRESSION IS. GRANT AWARDED: \$231,239, UNIVERSITY COLLEGE LONDON, LONDON, UNITED KINGDOM.

REGION: NORTH AMERICA (WHICH INCLUDES CANADA AND MEXICO, BUT NOT THE U.S.) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ISABELLE AUBERT, PHD ENTITLED: A2025018S USING ULTRASOUND TO HELP THE BRAIN REBUILD MYELIN IN ALZHEIMER'S. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE AFFECTS BOTH WHITE AND GREY MATTER. THE PREDOMINANT CELLS IN WHITE MATTER, OLIGODENDROCYTES, PRODUCE MYELIN, WHICH INSULATES CELLS TO IMPROVE COMMUNICATION. WHITE MATTER DEFICITS CAN RESULT IN CELL LOSS AND COMMUNICATION BREAKDOWN. IN A PRECLINICAL MODEL OF ALZHEIMER'S DISEASE, WE HAVE DISCOVERED THAT NON-INVASIVE ULTRASOUND WAVES CAN GENERATE NEW OLIGODENDROCYTES THAT MAY BOOST MYELIN PRODUCTION. WITH FUNDING, WE AIM TO DEVELOP THIS INNOVATIVE THERAPY, WHICH HAS THE POTENTIAL TO IMPROVE BRAIN FUNCTION AFFECTED BY ALZHEIMER'S DISEASE, INCLUDING LEARNING AND MEMORY. GRANT AWARDED: \$300,000, SUNNYBROOK RESEARCH INSTITUTE, TORONTO, CANADA.

REGION: EUROPE (INCLUDING ICELAND & GREENLAND) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY NADER SAFFARI, PHD ENTITLED: A2025022S CAN ULTRASOUND TRIGGER IMMUNE CELLS TO CLEAR TOXINS IN ALZHEIMER'S DISEASE? INVESTIGATOR'S SUMMARY: AS THE POPULATION AGES, ALZHEIMER'S DISEASE CASES ARE INCREASING AND A BUILD-UP IN THE BRAIN OF A HARMFUL

Part V Supplemental Information

Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

PROTEIN, CALLED AMYLOID BETA (A), IS A KEY FACTOR. CURRENT TREATMENTS TO REDUCE A LEVELS ARE COSTLY AND CAN CAUSE SERIOUS SIDE EFFECTS, INCLUDING BRAIN BLEEDING. THIS STUDY EXPLORES ULTRASOUND AS A SAFE, NON-INVASIVE WAY TO HELP BRAIN IMMUNE CELLS, CALLED MICROGLIA, CLEAR THESE PROTEINS: ULTRASOUND ACTIVATES MICROGLIA, RESTORING THEIR ABILITY TO CLEAN THE BRAIN, AND THIS PROMISING METHOD COULD OFFER A MORE EFFECTIVE AND AFFORDABLE TREATMENT FOR ALZHEIMER'S. GRANT AWARDED: \$299,217, UNIVERSITY COLLEGE LONDON, LONDON, UNITED KINGDOM.

PART II, LINE 1, COLUMN (D) CONTINUED

REGION: SOUTH AMERICA (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY CAROLINA OCHOA-ROSALES, PHD ENTITLED: A2025027S GENETICS AND NEUROIMAGING BIOMARKERS FOR NEURODEGENERATION IN LATIN AMERICA. INVESTIGATOR'S SUMMARY: OUR RESEARCH SEEKS TO UNRAVEL HOW GENETICS SHAPE BRAIN STRUCTURES AND COGNITION, SPECIFIC TO THE LATIN AMERICAN POPULATION. USING NOVEL GENETIC TOOLS AND MULTI-OMICS APPROACHES, WE WILL DIVE INTO THE BIOLOGICAL CONSEQUENCES OF THE GENETIC EFFECTS AND WILL IDENTIFY UNIQUE BIOMARKERS THAT CAN GUIDE PERSONALIZED STRATEGIES IN THE ALZHEIMER'S DISEASE AND RELATED DEMENTIAS HEALTH CARE, TAILORED FOR LATINOS. THE OUTCOMES OF THIS RESEARCH COULD LEAD TO EARLY DETECTION TOOLS AND PERSONALIZED HEALTH INTERVENTIONS TO PROMOTE BETTER BRAIN HEALTH AND REDUCE THE RISK OF NEURODEGENERATIVE DISEASES. GRANT AWARDED: \$300000, ADOLFO IBEZ UNIVERSITY, SANTIAGO, CHILE.

REGION: EUROPE (INCLUDING ICELAND & GREENLAND) (D) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY PETE WILLIAMS, PHD ENTITLED: G2025006S NEW DRUGS FOR GLAUCOMA. INVESTIGATOR'S SUMMARY: CURRENT TREATMENT STRATEGIES FOR GLAUCOMA ONLY FOCUS ON THE MANAGEMENT OF INTRAOCULAR (EYE) PRESSURE. THERE ARE NO AVAILABLE THERAPIES THAT TARGET THE DEGENERATIVE PROCESSES IN THE RETINA AND OPTIC NERVE THEMSELVES. THE WILLIAMS LAB IS DEVELOPING A FIRST-IN-CLASS INJECTABLE FORMULATION FOR GLAUCOMA TO PREVENT BLINDNESS AT ITS ROOT CAUSE - NEURODEGENERATION IN THE RETINA AND OPTIC NERVE. GRANT AWARDED: \$181181, KAROLINSKA INSTITUTET, SOLNA, SWEDEN.

REGION: EAST ASIA & THE PACIFIC (D) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY DAISY YAO SHU, PHD ENTITLED: M2025005N NEW DRUG DELIVERY APPROACH TO TRANSFORM MACULAR DEGENERATION TREATMENT. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR DEGENERATION (AMD) IS A LEADING CAUSE OF BLINDNESS, AFFECTING MILLIONS WORLDWIDE. CURRENT TREATMENTS FOR WET AMD HELP SOME BUT LEAVE MANY WITHOUT EFFECTIVE OPTIONS. THIS PROJECT EXPLORES TWO INNOVATIVE APPROACHES: REPURPOSING FUMARIC ACID ESTERS (FAES), INCLUDING DIMETHYL FUMARATE, AN FDA-APPROVED DRUG, AND TESTING MICROTUBULE INHIBITORS TO TARGET ABNORMAL BLOOD VESSEL GROWTH AND SCARRING. BY DEVELOPING NANOPARTICLE-BASED INJECTABLE THERAPIES, THIS RESEARCH AIMS TO ENHANCE DRUG DELIVERY, REDUCE TREATMENT BURDEN, AND IMPROVE OUTCOMES FOR PATIENTS WITH AMD. GRANT AWARDED: \$409500, UNIVERSITY OF NEW SOUTH WALES, KENSINGTON, AUSTRALIA.

REGION: EAST ASIA & THE PACIFIC (D) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY MASAYUKI HATA, PHD ENTITLED: M2025006N HOW AGING OF THE IMMUNE SYSTEM AFFECTS AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: IMMUNE CELLS, WHICH PLAY A PIVOTAL ROLE IN THE

Part V Supplemental Information

Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

ABERRANT BLOOD VESSEL GROWTH DURING AMD, ARE DYSREGULATED WITH AGING. HOWEVER, LITTLE IS KNOWN ABOUT HOW AGED IMMUNE CELLS IMPACT DISEASE DEVELOPMENT. IN THIS PROPOSAL, WE WILL ASSESS WHICH TYPES OF IMMUNE CELLS ARE MODIFIED IN A WAY THAT INCREASES THE RISK OF AMD DURING AGING. UNDERSTANDING HOW IMMUNE CELLS ARE DYSREGULATED WITH AGING WILL ALLOW US TO GAIN INSIGHT ON MECHANISMS THAT CAUSE AMD AND POTENTIALLY LEAD THE WAY TO DEVELOPING TARGETED INTERVENTIONS. GRANT AWARDED: \$409500, KYOTO UNIVERSITY, KYOTO, JAPAN.

REGION: EUROPE (INCLUDING ICELAND & GREENLAND) (D) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY JOLLE ELISE VERGROESEN, PHD ENTITLED: M2025010F TRACKING BIOLOGICAL RESPONSES TO LIFESTYLE CHANGES IN AMD PATIENTS. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR DEGENERATION (AMD) IS A LEADING CAUSE OF VISION LOSS IN OLDER ADULTS. LIFESTYLE FACTORS LIKE DIET, SMOKING, AND EXERCISE IMPACT AMD RISK, BUT MOTIVATING CHANGE IS CHALLENGING. THIS PROJECT USES BIOMARKERS FROM BLOOD AND STOOL TO SHOW HOW LIFESTYLE CHANGES REDUCE AMD PROGRESSION RISK. WE WILL ANALYZE DATA FROM OVER 13,000 PARTICIPANTS, LINKING BIOMARKERS TO LIFESTYLE AND AMD OUTCOMES. THIS RESEARCH AIMS TO CREATE TOOLS THAT PREDICT RISK, PROVIDE PERSONALIZED FEEDBACK, AND EMPOWER PATIENTS TO MAKE CHANGES, ULTIMATELY PREVENTING VISION LOSS AND REDUCING HEALTHCARE BURDENS. GRANT AWARDED: \$182000, ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM, ROTTERDAM, NETHERLANDS.

REGION: EUROPE (INCLUDING ICELAND AND GREENLAND) (D) PURPOSE OF GRANT: BIRAX RESEARCH FUNDING, ENTITLED: CA2023002 HIGH GRANULARITY IMMUNE PHENOTYPING IN AGEING TOWARDS MOLECULAR MARKERS OF DECLINED IMMUNITY, CHRONIC INFLAMMATION AND NEURODEGENERATIVE DISEASE. GRANT AWARDED: \$146664, THE BRITISH COUNCIL, LONDON, UNITED KINGDOM.

REGION: NORTH AMERICA (D) PURPOSE OF GRANT: MIND AND SIGHT DISEASES RESEARCH FUNDING, ENTITLED: CA2023003 SUPPORT THE CANADIAN INSTITUTES OF HEALTH RESEARCH'S EXCELLENCE, DIVERSITY, AND INDEPENDENCE EARLY CAREER TRANSITION AWARD IN THE CATEGORIES OF BRAIN HEALTH AND VISION DISEASES. THESE AWARDS WILL PROVIDE EARLY-CAREER SUPPORT TO RESEARCHERS FROM SPECIFIC UNDERREPRESENTED GROUPS STUDYING TREATMENTS AND CURES FOR ALZHEIMER'S, AGE-RELATED MACULAR DEGENERATION, AND GLAUCOMA. GRANT AWARDED: \$46595, CANADIAN INSTITUTES OF HEALTH RESEARCH, OTTAWA, CANADA.

REGION: EUROPE (INCLUDING ICELAND & GREENLAND) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY OLAV M. ANDERSEN, PHD ENTITLED: CA2025001 BETTER UNDERSTANDING OF THE ALZHEIMER'S GENE SORL1. INVESTIGATOR'S SUMMARY: THE SORTING OF SORL1 IN COMPARTMENTS OF THE ENDOLYSOSOMAL NETWORK STRONGLY DEPENDS ON BINDING OF ITS SHORT TAIL-DOMAIN TO TRAFFICKING PROTEINS IN THE CYTOSOL. OUR AIM IS TO IDENTIFY NOVEL BINDING PARTNERS AND TO UNCOVER HOW THEIR INTERACTIONS WITH SORL1 ARE REGULATED BY POST-TRANSLATIONAL MODIFICATIONS, INCLUDING KINASE ACTIVITY THAT MODIFY SPECIFIC PARTS OF THE SORL1 TAIL. GRANT AWARDED: \$85000, AARHUS UNIVERSITY, AARHUS, DENMARK.

REGION: NORTH AMERICA (WHICH INCLUDES CANADA AND MEXICO, BUT NOT THE U.S.) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MALLAR CHAKRAVARTY, PHD ENTITLED: CA2025002 THE IMPORTANCE OF SLEEP IN

Part V Supplemental Information

Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

PREVENTING ALZHEIMER'S DISEASE - AN EXAMINATION. INVESTIGATOR'S SUMMARY: IN OUR PROJECT WE WILL BE USING MOUSE MODELS THAT ACCUMULATE ALZHEIMER'S DISEASE PATHOLOGY AND CAN BE USED TO TRACK HOW DISEASE PROCESSES IMPACT THE BRAIN. THE GOAL OF OUR RESEARCH IS TO USE MAGNETIC RESONANCE IMAGING, A NON-INVASIVE TOOL WITH WHOLE BRAIN COVERAGE TO EXAMINE CHANGES IN STRUCTURE AND FUNCTION IN THE BRAINS OF THESE ANIMALS AS THEY UNDERGO SLEEP DEPRIVATION. FURTHER, WE WILL EXAMINE HOW THE MENOPAUSE TRANSITION IN FEMALES (MODELLED BY DEPLETING FEMALES OF ESTROGENS) MAY FURTHER WORSEN THE ACCUMULATED RISK FOR ALZHEIMER'S DISEASE. GRANT AWARDED: \$85000, MCGILL UNIVERSITY, MONTREAL, CANADA.

SCHEDULE G
(Form 990)

(Rev. December 2024)
Department of the Treasury
Internal Revenue Service

Supplemental Information Regarding Fundraising or Gaming Activities
Complete if the organization answered "Yes" on Form 990, Part IV, line 17, 18, or 19, or if the organization entered more than \$15,000 on Form 990-EZ, line 6a.
Attach to Form 990 or Form 990-EZ.
Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

Open to Public Inspection

Name of the organization: BRIGHTFOCUS FOUNDATION
Employer identification number: 23-7337229

Part I Fundraising Activities. Complete if the organization answered "Yes" on Form 990, Part IV, line 17. Form 990-EZ filers are not required to complete this part.

- 1 Indicate whether the organization raised funds through any of the following activities. Check all that apply.
a [X] Mail solicitations
b [X] Internet and email solicitations
c [] Phone solicitations
d [] In-person solicitations
e [X] Solicitation of nongovernment grants
f [] Solicitation of government grants
g [X] Special fundraising events
2 a Did the organization have a written or oral agreement with any individual (including officers, directors, trustees, or key employees listed in Form 990, Part VII) or entity in connection with professional fundraising services? [X] Yes [] No
b If "Yes," list the 10 highest paid individuals or entities (fundraisers) pursuant to agreements under which the fundraiser is to be compensated at least \$5,000 by the organization.

Table with 6 columns: (i) Name and address of individual or entity (fundraiser), (ii) Activity, (iii) Did fundraiser have custody or control of contributions?, (iv) Gross receipts from activity, (v) Amount paid to (or retained by) fundraiser listed in col. (i), (vi) Amount paid to (or retained by) organization. Includes entry for RKD GROUP - 35 PARKWOOD DRIVE, STE. 160, HOPKINTON, and a Total row.

3 List all states in which the organization is registered or licensed to solicit contributions or has been notified it is exempt from registration or licensing.
AK, AL, AR, AZ, CA, CO, CT, DC, FL, GA, HI, IL, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, NC, ND, NH, NJ, NM, NV, OH, OK, OR, PA, RI, SC, TN, UT, VA, WA, WI, WV

Part II Fundraising Events. Complete if the organization answered "Yes" on Form 990, Part IV, line 18, or reported more than \$15,000 of fundraising event contributions and gross income on Form 990-EZ, lines 1 and 6b. List events with gross receipts greater than \$5,000.

		(a) Event #1 CONCERT FOR CURES	(b) Event #2	(c) Other events NONE	(d) Total events (add col. (a) through col. (c))
		(event type)	(event type)	(total number)	
Revenue	1 Gross receipts	253,075.			253,075.
	2 Less: Contributions	222,435.			222,435.
	3 Gross income (line 1 minus line 2)	30,640.			30,640.
Direct Expenses	4 Cash prizes				
	5 Noncash prizes				
	6 Rent/facility costs	12,862.			12,862.
	7 Food and beverages	38,560.			38,560.
	8 Entertainment	13,342.			13,342.
	9 Other direct expenses	22,484.			22,484.
	10 Direct expense summary. Add lines 4 through 9 in column (d)				87,248.
	11 Net income summary. Subtract line 10 from line 3, column (d)				-56,608.

Part III Gaming. Complete if the organization answered "Yes" on Form 990, Part IV, line 19, or reported more than \$15,000 on Form 990-EZ, line 6a.

		(a) Bingo	(b) Pull tabs/instant bingo/progressive bingo	(c) Other gaming	(d) Total gaming (add col. (a) through col. (c))
Revenue	1 Gross revenue				
Direct Expenses	2 Cash prizes				
	3 Noncash prizes				
	4 Rent/facility costs				
	5 Other direct expenses				
	6 Volunteer labor	<input type="checkbox"/> Yes _____ % <input type="checkbox"/> No	<input type="checkbox"/> Yes _____ % <input type="checkbox"/> No	<input type="checkbox"/> Yes _____ % <input type="checkbox"/> No	
	7 Direct expense summary. Add lines 2 through 5 in column (d)				
	8 Net gaming income summary. Subtract line 7 from line 1, column (d)				

9 Enter the state(s) in which the organization conducts gaming activities: _____

a Is the organization licensed to conduct gaming activities in each of these states? ☐ Yes ☐ No

b If "No," explain: _____

10a Were any of the organization's gaming licenses revoked, suspended, or terminated during the tax year? ☐ Yes ☐ No

b If "Yes," explain: _____

- 11 Does the organization conduct gaming activities with nonmembers? ☐ Yes ☐ No
- 12 Is the organization a grantor, beneficiary or trustee of a trust, or a member of a partnership or other entity formed to administer charitable gaming? ☐ Yes ☐ No
- 13 Indicate the percentage of gaming activity conducted in:
- | | | |
|-------------------------------|-----|---|
| a The organization's facility | 13a | % |
| b An outside facility | 13b | % |
- 14 Enter the name and address of the person who prepares the organization's gaming/special events books and records:

Name _____

Address _____

- 15a Does the organization have a contract with a third party from whom the organization receives gaming revenue? ☐ Yes ☐ No

b If "Yes," enter the amount of gaming revenue received by the organization \$ _____ and the amount of gaming revenue retained by the third party \$ _____

c If "Yes," enter the name and address of the third party:

Name _____

Address _____

- 16 Gaming manager information:

Name _____

Gaming manager compensation \$ _____

Description of services provided _____

☐ Director/officer ☐ Employee ☐ Independent contractor

- 17 Mandatory distributions:

a Is the organization required under state law to make charitable distributions from the gaming proceeds to retain the state gaming license? ☐ Yes ☐ No

b Enter the amount of distributions required under state law to be distributed to other exempt organizations or spent in the organization's own exempt activities during the tax year \$ _____

Part IV Supplemental Information. Provide the explanations required by Part I, line 2b, columns (iii) and (v); and Part III, lines 9, 9b, 10b, 15b, 15c, 16, and 17b, as applicable. Also provide any additional information. See instructions.

SCHEDULE G, PART I, LINE 2B, LIST OF TEN HIGHEST PAID FUNDRAISERS:

(I) NAME OF FUNDRAISER: RKD GROUP

(I) ADDRESS OF FUNDRAISER:

35 PARKWOOD DRIVE, STE. 160, HOPKINTON, MA 01748

PART I, LINE 2B, COLUMN (V):

IN THE CONTRACT WITH RKD GROUP, THE MANAGEMENT FEES ARE FIXED AMOUNTS PER MONTH FOR IN-SCOPE SERVICES THAT TOTALS \$1,243,296 PER YEAR OF WHICH \$636,600 HAS BEEN ALLOCATED UNDER PART IX, LINE 11(G) TO PROGRAM AND MANAGEMENT AND ARE NOT CONSIDERED TO BE THE PROFESSIONAL FUNDRAISING CONSULTANT FEE.

Part IV	Supplemental Information <i>(continued)</i>
----------------	--

This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

**SCHEDULE I
(Form 990)**

(Rev. December 2024)

Department of the Treasury
Internal Revenue Service

**Grants and Other Assistance to Organizations,
Governments, and Individuals in the United States**
Complete if the organization answered "Yes" on Form 990, Part IV, line 21 or 22.
Attach to Form 990.
Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

**Open to Public
Inspection**

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number
23-7337229

Part I General Information on Grants and Assistance

- 1** Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance? ☒ **Yes** ☐ **No**
- 2** Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II Grants and Other Assistance to Domestic Organizations and Domestic Governments. Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient that received more than \$5,000. Part II can be duplicated if additional space is needed.

1 (a) Name and address of organization or government	(b) EIN	(c) IRC section (if applicable)	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of noncash assistance	(h) Purpose of grant or assistance
WILLIAM MARSH RICE UNIVERSITY 6100 MAIN ST. BIOSCIENCE RESEARCH C HOUSTON, TX 77030	74-1109620	501(C)(3)	409,500.	0.			MACULAR DEGENERATION RESEARCH BY JERZY SZABLOWSKI, PHD ENTITLED: M2025001N
UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER - 608 STANTON L YOUNG BLVD - OKLAHOMA CITY, OK 73104	73-1563627	501(C)(3)	409,500.	0.			MACULAR DEGENERATION RESEARCH BY ANA J CHUCAIR-ELLIOTT, PHD ENTITLED: M2025002N
LELAND STANFORD JUNIOR UNIVERSITY BYERS EYE INSTITUTE 2452 WATSON COU PALO ALTO, CA 94303	94-1156365	501(C)(3)	409,500.	0.			MACULAR DEGENERATION RESEARCH BY CHARLES DEBOER, MD, PHD ENTITLED: M2025004N
LELAND STANFORD JUNIOR UNIVERSITY 300 CAMPUS DRIVE, GRANT BUILDING, OPHTHALMOLOGY DEPT - STANFORD, CA 94305	94-1156365	501(C)(3)	409,500.	0.			MACULAR DEGENERATION RESEARCH BY MOHAJEET BALVEER BHUCKORY, PHD ENTITLED: M2025007N
NATIONAL EYE INSTITUTE, NIH 10 CENTER DRIVE RM 10N116, FLOOR 10 BETHESDA, MD 20852	52-0858115	501(C)(3)	408,701.	0.			MACULAR DEGENERATION RESEARCH BY RUCHI SHARMA, PHD ENTITLED: M2025003N
BETH ISRAEL DEACONESS MEDICAL CENTER - 330 BROOKLINE AVENUE - BOSTON, MA 02215	04-2103881	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY PETER FRIED, PHD ENTITLED: A2024034S

- 2** Enter total number of section 501(c)(3) and government organizations listed in the line 1 table **57.**
- 3** Enter total number of other organizations listed in the line 1 table **0.**

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Schedule I (Form 990) (Rev. 12-2024)

Part II Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
LELAND STANFORD JUNIOR UNIVERSITY 1201 WELCH RD PALO ALTO, CA 94305	94-1156365	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY AMIRA LATIF HERNANDEZ, PHD ENTITLED: A2024035S
UNIVERSITY OF CALIFORNIA, SAN DIEGO - 9500 GILMAN DRIVE - LA JOLLA, CA 92093	95-6006144	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY JEROME MERTENS, PHD ENTITLED: A2024036S
UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE - 4333 BROOKLYN AVE NE - SEATTLE, WA 98195	91-6001537	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY JUSTIN MILLER, PHD ENTITLED: A2024037S
UNIVERSITY OF CALIFORNIA, SAN DIEGO - 9500 GILMAN DRIVE - LA JOLLA, CA 92093	95-6006144	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY JOHANNES SCHLACHETZKI, MD ENTITLED: A2024038S
UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION - 789 S LIMESTONE, TODD 565 - LEXINGTON, KY 40536	61-6033693	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY LINDA VAN ELDIK, PHD ENTITLED: A2024039S
VANDERBILT UNIVERSITY MEDICAL CENTER - 2213 GARLAND AVE - NASHVILLE, TN 37232	35-2528741	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY MONICA SANTISTEBAN, PHD ENTITLED: A2025011S
THE J. DAVID GLADSTONE INSTITUTES 1650 OWENS ST SAN FRANCISCO, CA 94158	23-7203666	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY KATERINA AKASSOGLOU, PHD ENTITLED: A2025013S
MASSACHUSETTS GENERAL HOSPITAL 114 SIXTEENTH ST CHARLESTOWN, MA 02129	04-2697983	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY KSENIA KASTANENKA, PHD ENTITLED: A2025014S
COLUMBIA UNIVERSITY 622 W 168TH ST NEW YORK, NY 10025	13-5598093	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY JAE-EUN MILLER, PHD ENTITLED: A2025016S

Schedule I (Form 990)

Part II Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
NORTHWESTERN UNIVERSITY - CHICAGO CAMPUS - 300 EAST SUPERIOR STREETTARRY 7-758 - CHICAGO, IL 60611	36-2167817	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY JUSTYNA DOBROWOLSKA ZAKARIA, PHD ENTITLED: A2025019S
WASHINGTON UNIVERSITY IN ST. LOUIS CAMPUS BOX 1054 ONE BROOKINGS DRIVE ST. LOUIS, MO 63130	43-0653611	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY CYRIL POTTIER, PHD ENTITLED: A2025020S
RESEARCH FOUNDATION OF SUNY - UNIVERSITY AT ALBANY - OFFICE FOR SPONSORED PROGRAMS/MSC 312 1400 WASHINGTON AVENUE - ALBANY, NY	14-1368361	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY DAMIAN ZULOAGA, PHD ENTITLED: A2025021S
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI - 3 E 101ST ST - NEW YORK, NY 10029	13-6171197	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY JACK HUMPHREY, PHD ENTITLED: A2025024S
THE OHIO STATE UNIVERSITY 460 W. 12TH AVE COLUMBUS, OH 43210	31-6025986	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY HONGJUN FU, PHD ENTITLED: A2025025S
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL - 115 MASON FARM RD. 6109C NEUROSCIENCE RESEARCH BUILDING, CB 7250 - CHAPEL HILL,	56-6001393	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY TODD J. COHEN, PHD ENTITLED: A2025026S
INDIANA UNIVERSITY 340 WEST 10TH STREET INDIANAPOLIS, IN 46202	35-6001673	501(C)(3)	299,843.	0.			ALZHEIMER'S DISEASE RESEARCH BY MIGUEL MOUTINHO, PHARM D, PHD ENTITLED: A2025015S
BETH ISRAEL DEACONESS MEDICAL CENTER - 330 BROOKLINE AVENUE - BOSTON, MA 02115	04-2103881	501(C)(3)	299,838.	0.			ALZHEIMER'S DISEASE RESEARCH BY FENG TIAN, PHD ENTITLED: A2025017S
INDIANA UNIVERSITY NB BUILDING, 320 W 15TH ST #414 INDIANAPOLIS, IN 46202	35-6001673	501(C)(3)	297,517.	0.			ALZHEIMER'S DISEASE RESEARCH BY REBECCA WALLINGS, DPHIL ENTITLED: A2025023S

Schedule I (Form 990)

Part II Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD JACKSONVILLE, FL 32224	59-3337028	501(C)(3)	235,163.	0.			ALZHEIMER'S DISEASE RESEARCH ENTITLED: CA2021010
EMORY UNIVERSITY 1599 CLIFTON ROAD NE, 4TH FLOOR ATLANTA, GA 30322	58-0566256	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY JOSHNA GADHAVI, PHD ENTITLED: A2024029F
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO - 1550 4TH ST. ROCK HALL 381 - SAN FRANCISCO, CA 94143	94-6036493	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY DONG KYU KIM, PHD ENTITLED: A2024030F
WASHINGTON UNIVERSITY IN ST. LOUIS 4370 DUNCAN AVE ST LOUIS, MO 63110	43-0653611	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY ASHISH SHARMA, PHD ENTITLED: A2024031F
COLUMBIA UNIVERSITY 3227 BROADWAY L-5-055 NEW YORK, NY 10027	13-5598093	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY EMILIANO ZAMPONI, PHD ENTITLED: A2024032F
BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA MS: BCM ROOM: N930 HOUSTON, TX 77030	74-1613878	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY OMAR PEA-RAMOS, PHD ENTITLED: A2025002F
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI - 1425 MADISON AVENUE, FLOOR 9 ROOM 9-02C - NEW YORK, NY 10029	13-6171197	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY MARCOS SCHAAN PROFES, PHD ENTITLED: A2025003F
BRIGHAM AND WOMEN'S HOSPITAL, INC. 60 FENWOOD ROAD BOSTON, MA 02115	04-2312909	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY SARAH ELISE HEUER, PHD ENTITLED: A2025005F
WASHINGTON UNIVERSITY IN ST. LOUIS 4370 DUNCAN AVE SAINT LOUIS, MO 63110	43-0653611	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY JOSHUA EMMERSON, PHD ENTITLED: A2025006F

Schedule I (Form 990)

Part II Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
UNIVERSITY OF CALIFORNIA, IRVINE UNIVERSITY OF CALIFORNIA, IRVINE 30 IRVINE, CA 92697	95-2226406	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY GHAZALEH ESKANDARI-SEDIGHI, PHD ENTITLED: A2025007F
THE SALK INSTITUTE FOR BIOLOGICAL STUDIES - 10010 NORTH TORREY PINES ROAD - LA JOLLA, CA 92037	95-2160097	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY JOSEPH HERDY, PHD ENTITLED: A2025010F
UNIVERSITY OF PITTSBURGH BIOMEDICAL SCIENCE TOWER 3 3501 FIFTH AVENUE - PITTSBURGH, PA 15213	25-0965591	501(C)(3)	199,724.	0.			ALZHEIMER'S DISEASE RESEARCH BY JR-JIUN LIOU, PHD ENTITLED: A2025009F
MAYO CLINC, ROCHESTER 200 FIRST ST. SW ROCHESTER, MN 55905	41-6011702	501(C)(3)	182,000.	0.			NATIONAL GLAUCOMA RESEARCH BY GAVIN RODDY, MD, PHD ENTITLED: G2025001S
UNIVERSITY OF CALIFORNIA, SAN DIEGO - 9452 MEDICAL CENTER DRIVE - LA JOLLA, CA 92037	95-6006144	501(C)(3)	182,000.	0.			NATIONAL GLAUCOMA RESEARCH BY KARL JONAS WAHLIN, PHD ENTITLED: G2025002S
UNIVERSITY OF WISCONSIN-MADISON DEPARTMENT OF OPHTHALMOLOGY MADISON, WI 53706	39-6006492	501(C)(3)	182,000.	0.			NATIONAL GLAUCOMA RESEARCH BY ROB NICKELLS, PHD ENTITLED: G2025003S
DUKE UNIVERSITY SCHOOL OF MEDICINE 2200 W. MAIN STREET, SUITE 710 DURHAM, NC 27705	56-0532129	501(C)(3)	182,000.	0.			NATIONAL GLAUCOMA RESEARCH BY DAN STAMER, PHD ENTITLED: G2025004S
UNIVERSITY OF SOUTHERN CALIFORNIA DEPARTMENT OF OPHTHALMOLOGY 1450 SAN PABLO STREET, 4TH FLOOR - LOS ANGELES,	95-1642394	501(C)(3)	182,000.	0.			NATIONAL GLAUCOMA RESEARCH BY BENJAMIN XU, MD, PHD ENTITLED: G2025005S
THE SCHEPENS EYE RESEARCH INSTITUTE, INC. - 20 STANIFORD STREET - BOSTON, MA 02114	04-2129889	501(C)(3)	182,000.	0.			NATIONAL GLAUCOMA RESEARCH BY TATJANA JAKOBS, MD ENTITLED: G2025008S

Schedule I (Form 990)

Part II Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
UNIVERSITY OF CALIFORNIA, IRVINE 324 ALDRICH HALL IRVINE, CA 92697	95-2226406	501(C)(3)	182,000.	0.			NATIONAL GLAUCOMA RESEARCH BY DOROTA SKOWRONSKA-KRAWCZYK, PHD ENTITLED: G2025009S
UNIVERSITY OF WISCONSIN-MADISON DEPARTMENT OF OPHTHALMOLOGY & VISUAL SCIENCES 3375 MEDICAL SCIENCES CENTER 1	39-6006492	501(C)(3)	182,000.	0.			NATIONAL GLAUCOMA RESEARCH BY COLLEEN MCDOWELL, PHD ENTITLED: G2025010S
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO - 1550 4TH STREET ROOM: 445 - SAN FRANCISCO, CA 94158	94-6036493	501(C)(3)	182,000.	0.			MACULAR DEGENERATION RESEARCH BY VALENCIA FERNANDES, PHD ENTITLED: M2025008F
DUKE UNIVERSITY SCHOOL OF MEDICINE 2351 ERWIN RD, AERI 3000 DURHAM, NC 27705	56-0532129	501(C)(3)	182,000.	0.			MACULAR DEGENERATION RESEARCH BY DR. NOBUHIKO SHIRAKI, PHD ENTITLED: M2025011F
UNIVERSITY OF CALIFORNIA, SAN DIEGO - 9500 GILMAN DRIVE - LA JOLLA, CA 92093	95-6006144	501(C)(3)	182,000.	0.			MACULAR DEGENERATION RESEARCH BY JAESOO JUNG, PHD ENTITLED: M20250013F
GOOD SAMARITAN FOUNDATION 1225 NE 2ND AVENUE, 3RD FLOOR PORTLAND, OR 97232	23-7017276	501(C)(3)	181,798.	0.			NATIONAL GLAUCOMA RESEARCH BY BRAD FORTUNE, OD, PHD ENTITLED: G2025007S
UNIVERSITY OF IDAHO 875 PERIMETER DRIVE, MS 3020 MOSCOW, ID 83844	82-6000945	501(C)(3)	180,864.	0.			MACULAR DEGENERATION RESEARCH BY ASHLEY FARRE, PHD ENTITLED: M2025012F
INDIANA UNIVERSITY 635 BARNHILL DRIVE INDIANAPOLIS, IN 46202	35-6001673	501(C)(3)	180,523.	0.			ALZHEIMER'S DISEASE RESEARCH BY ANLLELY FERNANDEZ, PHD ENTITLED: A2025001F
THE FISHER CENTER FOR ALZHEIMERS DISEASE RESEARCH - FDR STATION, P.O. BOX 220 - NEW YORK, NY 10150	13-3859563	501(C)(3)	133,597.	0.			ALZHEIMER'S DISEASE RESEARCH FUNDING

Schedule I (Form 990)

Part II Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION - 1001 MAYPORT ROAD, PO BOX 331076 - ATLANTIC BEACH, FL 32233	86-2907045	501(C)(3)	115,000.	0.			ALZHEIMER'S DISEASE RESEARCH ENTITLED: CA2021011
MEDICAL TECHNOLOGY ENTERPRISE CONSORTIUM - 315 SIGMA DRIVE - SUMMERVILLE, SC 29486	47-4960128	501(C)(3)	100,000.	0.			ALZHEIMER'S DISEASE RESEARCH ENTITLED: CA2025003
JOHNS HOPKINS UNIVERSITY 3910 KESWICK ROAD N4327B BALTIMORE, MD 21211	52-0595110	501(C)(3)	75,000.	0.			RRESTORE CONSORTIUM RESEARCH FUNDING AND TRAVEL GRANTS FOR CONFERENCE ATTENDEES
HELEN KELLER FOUNDATION FOR RESEARCH & EDUCATION - 1201 11TH AVE. SOUTH, SUITE 300 - BIRMINGHAM, AL 35205	63-0983733	501(C)(3)	75,000.	0.			HELEN KELLER PRIZE FOR VISION RESEARCH FUNDING
INTERNATIONAL SOCIETY FOR EYE RESEARCH - 655 BEACH STREET - SAN FRANCISCO, CA 94109	51-0171667	501(C)(3)	30,000.	0.			TRAVEL GRANTS FOR CONFERENCE ATTENDEES AND RESEARCH SPONSORSHIP
ARVO FOUNDATION FOR EYE RESEARCH 1801 ROCKVILLE PIKE, SUITE 400 ROCKVILLE, MD 20852	52-2322462	501(C)(3)	15,240.	0.			TRAVEL GRANTS FOR CONFERENCE ATTENDEES

Part III **Grants and Other Assistance to Domestic Individuals.** Complete if the organization answered "Yes" on Form 990, Part IV, line 22.
Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance	(b) Number of recipients	(c) Amount of cash grant	(d) Amount of non-cash assistance	(e) Method of valuation (book, FMV, appraisal, other)	(f) Description of noncash assistance

Part IV **Supplemental Information.** Provide the information required in Part I, line 2; Part III, column (b); and any other additional information.**PART I, LINE 2:**

AFTER AN INTERNATIONAL GRANT IS AWARDED, BRIGHTFOCUS INTERACTS WITH ALL GRANTEES AT LEAST QUARTERLY BY E-MAIL OR AT SCIENTIFIC MEETINGS. IN ADDITION TO THESE INTERACTIONS, EACH GRANT RECIPIENT IS REQUIRED TO SUBMIT SEPARATE DETAILED ANNUAL SCIENTIFIC PROGRESS AND FINANCIAL REPORTS TO BRIGHTFOCUS. THESE ARE RECEIVED BY THE BRIGHTFOCUS SCIENTIFIC AFFAIRS DEPARTMENT, AND REVIEWED BY SCIENTIFIC STAFF WITH BROAD EXPERTISE, INCLUDING IMAGING, MOLECULAR BIOLOGY AND SIGNALING PATHWAYS, CELL BIOLOGY, ANGIOGENESIS, BIOCHEMISTRY, NEUROSCIENCE, AND GENETICS. SENIOR STAFF REVIEWS EACH PROGRESS REPORT AND EVALUATES THE PROJECT FOR SUFFICIENT PROGRESS TOWARDS THE SPECIFIC AIMS PROPOSED IN THE ORIGINAL APPLICATION OR ANY BUDGETARY CONCERNS. THIS EFFORT IS SUPPORTED BY ADDITIONAL SCIENTIFIC COUNSEL FROM MEMBERS OF THE BRIGHTFOCUS SCIENTIFIC REVIEW COMMITTEES, WHEN REQUIRED. IN ADDITION TO STATEMENTS OF EXPERIMENTAL PROGRESS, ALL GRANTEES ARE ASKED TO REPORT ANY TECHNICAL PUBLICATIONS, MEDIA REPORTS, OR PATENT APPLICATIONS IN WHICH BRIGHTFOCUS-SPONSORED RESEARCH IS DESCRIBED. IF SIGNIFICANT CONCERNS RELATED TO PROGRESS ON THE AWARDS ARE DISCOVERED, AND NOT RESOLVED AFTER INTERACTION WITH THE AWARD GRANTEE, THE BRIGHTFOCUS

Part IV Supplemental Information

STAFF RECOMMENDS APPROPRIATE ACTIONS TO THE CHAIR OF THE SCIENTIFIC AFFAIRS COMMITTEE OF THE BOARD OF DIRECTORS. IN ACCORDANCE WITH THE GRANT AGREEMENT TERMS AND CONDITIONS, BRIGHTFOCUS MAY WITHHOLD FUNDING, OR DISCONTINUE AN AWARD, FOR ANY GRANTEE THAT FAILS TO ACHIEVE SUFFICIENT PROGRESS OR SUBMIT REQUIRED REPORTS.

AT THE CONCLUSION OF THE GRANT AWARD PERIOD, EACH GRANTEE MUST COMPLETE AND SUBMIT A FINAL REPORT THAT IS ALSO REVIEWED BY THE BRIGHTFOCUS SENIOR SCIENTIFIC STAFF. EVALUATION OF THE WORK OF EACH GRANTEE IS QUALITATIVELY AND QUANTITATIVELY ASSESSED THROUGH VARIOUS METRICS RELATED TO THE IMPACT OF THE GRANT ON ITS TARGETED DISEASE FIELD. SUCH IMPACT METRICS HAVE REVEALED THAT 95% OF BRIGHTFOCUS-SUPPORTED RESEARCH RESULTS IN RESEARCH PUBLICATIONS THAT ADVANCE THE FIELDS SERVED BY BRIGHTFOCUS. THIS IMPACT IS FURTHER SUPPORTED BY ANNUAL CATEGORY NORMALIZED CITATION IMPACT ANALYSIS THAT COMPARES BRIGHTFOCUS-SUPPORTED WORKS TO AN UNBIASED COMPARISON OF IMPACT PERFORMANCE VERSUS THE WORLD AVERAGE. BRIGHTFOCUS-SUPPORTED PUBLICATIONS WERE RECENTLY CITED AT 2 TIMES THE FREQUENCY OF THE WORLD AVERAGE. A FINAL EXAMPLE OF IMPACT ASSESSMENT REVEALED THAT THE SUCCESSES OF BRIGHTFOCUS GRANTEES CONTINUE LONG AFTER THE GRANT EXPIRES. ON AVERAGE, EACH GRANTEE RECEIVES ADDITIONAL GRANTS FOR FOLLOW-ON PROJECTS SPAWNED BY THE BRIGHTFOCUS GRANT, WITH VALUES UP TO 8 TIMES THE LEVEL OF THE INITIAL BRIGHTFOCUS INVESTMENT.

BRIGHTFOCUS SOLICITS FEEDBACK FROM ITS GRANTEES AND PROVIDES AN ANONYMOUS FORUM FOR COLLECTING SUCH INFORMATION. THROUGH THE BRIGHTFOCUS FOUNDATION WEBSITE AND WITHIN THE SCIENTIFIC PROGRESS REPORTS, THERE ARE DESIGNATED SECTIONS WHERE AWARDEES ARE ASKED TO PROVIDE FEEDBACK TO THE FOUNDATION. THROUGH THIS MECHANISM, THEY ARE GIVEN THE ABILITY TO ANONYMOUSLY PROVIDE FEEDBACK OR COMMUNICATE THEIR CONCERNS TO PROGRAM STAFF OR THE BRIGHTFOCUS' COMPLIANCE OFFICE. ANY SUGGESTIONS, CONCERNS, COMPLAINTS, OR POSITIVE EXPERIENCES CAN BE OUTLINED AND BROUGHT TO THE ATTENTION OF BRIGHTFOCUS IN THIS MANNER, SO THAT BRIGHTFOCUS CAN ADDRESS ANY AREAS NEEDING IMPROVEMENT, REAFFIRM PRAISE-WORTHY POLICIES, OR OTHERWISE ASSESS NEEDS FOR PROGRAMMATIC CHANGE. THE SENIOR LEADERSHIP PRESENTS AND SUMMARIZES THE STATUS AND PROGRESS ON GRANTS TO THE BRIGHTFOCUS BOARD OF DIRECTORS AT EACH OF THEIR QUARTERLY BOARD MEETINGS.

PART II, LINE 1(H)

NAME OF ORGANIZATION OR GOVERNMENT: EMORY UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JOSHNA GADHAVI, PHD ENTITLED: A2024029F ASSESSING THE IMPACT OF BLOOD-BRAIN BARRIER DYSFUNCTION IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: BLOOD-BRAIN BARRIER (BBB) BREAKDOWN HAS BEEN OBSERVED IN VARIOUS NEURODEGENERATIVE DISEASES INCLUDING ALZHEIMER'S DISEASE. IN A HEALTHY BRAIN, THE BBB DOES NOT ALLOW TRANSPORTATION OF PROTEINS OR LARGE MOLECULES INTO THE BRAIN. HOWEVER, DUE TO BBB DYSFUNCTION, ENHANCED PERMEABILITY OF PLASMA-DERIVED PROTEINS CAN BE OBSERVED IN DIFFERENT PARTS OF BRAIN REGIONS, AND MAY LEAD TO NEUROTOXICITY, NEUROINFLAMMATION, AND OXIDATIVE STRESS. THIS PROJECT WILL IDENTIFY NOVEL BIOMARKERS AND KEY TARGETS FOR BBB BREAKDOWN AND EXPLORE HOW IT MAY CONTRIBUTE TO ALZHEIMER'S DIAGNOSIS AND PROGRESSION.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY DONG KYU KIM, PHD ENTITLED: A2024030F DEFINING THE IMPACT OF CYTOKINE

Part IV Supplemental Information

SIGNALING IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: IMMUNE SIGNALS REGULATE BRAIN HOMEOSTASIS AND ARE ALSO A MAJOR DRIVER OF ALZHEIMER'S DISEASE PATHOLOGY. THIS STUDY WILL INVESTIGATE HOW ASTROCYTE-MICROGLIA CROSSTALK VIA IL-33 CYTOKINE IMPACTS ALZHEIMER'S DISEASE PATHOLOGY AND BEHAVIOR. THIS WORK WILL DETERMINE THE MECHANISTIC IMPACT OF A KEY IMMUNE PATHWAY IN AD PATHOLOGY AND SUGGEST THE NOVEL HYPOTHESIS THAT ECM DISRUPTION IS LINKED TO AD PATHOLOGY.

NAME OF ORGANIZATION OR GOVERNMENT: WASHINGTON UNIVERSITY IN ST. LOUIS (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ASHISH SHARMA, PHD ENTITLED: A2024031F CIRCADIAN RHYTHM DISRUPTION AND ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THIS STUDY INVESTIGATES HOW DISRUPTIONS TO CIRCADIAN RHYTHMS, COMMON IN AGING AND ALZHEIMER'S DISEASE, IMPACT DISEASE PROGRESSION USING A MOUSE MODEL OF CHRONIC JETLAG (CJL). RESEARCHERS AIM TO UNDERSTAND HOW CJL AFFECTS ALZHEIMER'S MARKERSAMYLOID PLAQUES AND TAU PROTEIN ACCUMULATION. INVESTIGATING THE CONNECTION BETWEEN CIRCADIAN DISRUPTION, GLIAL FUNCTION, AND ALZHEIMER'S-RELATED CHANGES MAY REVEAL THERAPEUTIC STRATEGIES, OFFERING NOVEL APPROACHES TO DISEASE PREVENTION.

NAME OF ORGANIZATION OR GOVERNMENT: COLUMBIA UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY EMILIANO ZAMPONI, PHD ENTITLED: A2024032F MECHANISMS OF INHIBITORY NEURON VULNERABILITY TO ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: INHIBITORY INTERNEURONS, ONE OF THE KEY PLAYERS IN HUMAN COGNITIVE PROCESSES, ARE AMONG THE FIRST NEURONAL POPULATIONS AFFECTED BY AD ONSET. I PROPOSE THEIR ELEVATED ENERGY CONSUMPTION RATES MAKE THESE INTERNEURONS MORE VULNERABLE TO AD. USING MULTIPLE INNOVATIVE APPROACHES, I WILL INVESTIGATE THREE FUNDAMENTAL ASPECTS UNDERLYING INHIBITORY INTERNEURON VULNERABILITY TO AD. BY COMPLETING THE AIMS OF MY PROPOSAL, I EXPECT TO GAIN NEW INSIGHTS INTO THE PATHOLOGICAL BASIS OF THIS SOCIALLY DEVASTATING NEUROLOGICAL CONDITION AND TO DEVELOP NOVEL THERAPEUTIC APPROACHES.

NAME OF ORGANIZATION OR GOVERNMENT: BETH ISRAEL DEACONESS MEDICAL CENTER (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY PETER FRIED, PHD ENTITLED: A2024034S TREATING INSOMNIA IN MILD COGNITIVE IMPAIRMENT. INVESTIGATOR'S SUMMARY: MANY PEOPLE WITH MILD COGNITIVE IMPAIRMENT (MCI) EXPERIENCE SYMPTOMS OF INSOMNIA, SUCH AS DIFFICULTY FALLING OR STAYING ASLEEP, WHICH CAN SPEED COGNITIVE DECLINE AND WORSEN QUALITY OF LIFE. WE PROPOSE TO TEST A NOVEL INTERVENTION TO IMPROVE SLEEP AND COGNITION IN PERSONS WITH MCI THAT COMBINES NONINVASIVE NEUROMODULATION WITH TRANSCRANIAL MAGNETIC STIMULATION WITH AN INTERNET-DELIVERED COGNITIVE BEHAVIORAL THERAPY FOR INSOMNIA PROGRAM. IF SUCCESSFUL, THIS APPROACH WILL MEET THE NEED FOR AN EFFICACIOUS, NON-PHARMACOLOGIC, AND ACCESSIBLE THERAPY FOR PERSONS WITH MCI AND INSOMNIA.

NAME OF ORGANIZATION OR GOVERNMENT: LELAND STANFORD JUNIOR UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY AMIRA LATIF HERNANDEZ, PHD ENTITLED: A2024035S TARGETING BRAIN CELL MISCOMMUNICATION TO RESTORE MEMORY IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THE BRAIN'S ABILITY TO ADAPT AND CHANGE, KNOWN AS SYNAPTIC PLASTICITY, REQUIRES THE EXPRESSION OF SPECIFIC GENES AND PROTEINS IN DIFFERENT BRAIN CELLS, NEURONS AND ASTROCYTES, WHICH IS AFFECTED IN BRAIN DISORDERS LIKE ALZHEIMER'S. IN ORDER TO FIND POTENTIAL THERAPEUTIC STRATEGIES TO RECOVER SYNAPTIC PLASTICITY, CELL COMMUNICATION, AND TO IMPROVE MEMORY IN ALZHEIMER'S, WE WILL USE

Part IV Supplemental Information

ADVANCED TECHNIQUES IN MOUSE MODELS AND LAB-GROWN HUMAN CELLS WITH ALZHEIMER'S-LIKE PATHOLOGY. OUR RESULTS WILL CONTRIBUTE TO THE DEVELOPMENT OF IMPROVED TREATMENTS FOR PATIENTS WITH SYNAPTIC PLASTICITY DISORDERS.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN DIEGO (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JEROME MERTENS, PHD ENTITLED: A2024036S CANCER-LIKE METABOLIC CHANGES IN ALZHEIMER'S DISEASE NEURONS. INVESTIGATOR'S SUMMARY: THIS RESEARCH FOCUSES ON HOW METABOLIC CHANGES IMPACT GENE EXPRESSION AND PROTEIN MODIFICATIONS IN ALZHEIMER'S DISEASE (AD). USING NEURONS FROM AD PATIENTS, WE'VE IDENTIFIED DISRUPTIONS IN METABOLIC PATHWAYS LEADING TO ABNORMAL GENE PROCESSING. OUR STUDY AIMS TO UNDERSTAND HOW THESE CHANGES CONTRIBUTE TO KEY AD FEATURES, SUCH AS TAU TANGLE FORMATION. BY UNDERSTANDING UPSTREAM METABOLIC PATHWAYS OF AD PATHOLOGY, WE AIM TO IDENTIFY POTENTIAL INTERVENTION TARGETS TO RESCUE THE LOSS OF SYNAPTIC FUNCTION AND PREVENT NEURONAL CELL DEATH.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JUSTIN MILLER, PHD ENTITLED: A2024037S EXPLORING RURAL HEALTH DISPARITIES IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THERE IS EMERGING EVIDENCE THAT OLDER ADULTS LIVING IN RURAL COMMUNITIES ARE AT INCREASED RISK FOR ALZHEIMER'S DISEASE (AD); HOWEVER, RURAL COMMUNITIES HAVE BEEN SEVERELY UNDERREPRESENTED IN AD RESEARCH, AND THE FACTORS THAT MAY BE CONTRIBUTING TO THESE URBAN-RURAL DISPARITIES ARE UNCLEAR. OUR LONG-TERM GOAL IS TO FULLY CHARACTERIZE COGNITIVE AGING AND VALIDATE AD-SPECIFIC BIOMARKERS AMONG RURAL-DWELLING OLDER ADULTS. THIS PROJECT WILL ENRICH THE BIOMARKER CHARACTERIZATION OF OUR RURAL COHORT AND FACILITATE IDENTIFICATION OF THE MOST VIABLE BLOOD MARKERS FOR USE IN RURAL-DWELLING OLDER ADULTS.

PART II, LINE 1(H) CONTINUED

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN DIEGO (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JOHANNES SCHLACHETZKI, MD ENTITLED: A2024038S REGULATION OF MICROGLIA PHENOTYPES IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE IS DEFINED BY THE ACCUMULATION OF HARMFUL PROTEINS IN THE BRAIN. MICROGLIA, THE IMMUNE CELLS OF THE BRAIN, PLAY A KEY ROLE IN THIS PROCESS, BUT THE MOLECULAR MECHANISMS THAT LEAD TO DISTINCT PHENOTYPES ARE UNCLEAR. THIS STUDY WILL USE ADVANCED TECHNIQUES TO ISOLATE AND ANALYZE MICROGLIA, REVEALING HOW THEY CONTRIBUTE TO DISEASE AND IDENTIFYING NEW TARGETS FOR DEVELOPING EFFECTIVE TREATMENTS. WE WILL TEST THE HYPOTHESIS THAT SPECIFIC GROUPS OF PROTEIN FAMILIES (MIT/TFE AND AP-1), ARE RESPONSIBLE FOR CONTROLLING THE GENES THAT MICROGLIA TURN ON OR OFF IN ALZHEIMER'S DISEASE.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY LINDA VAN ELDIK, PHD ENTITLED: A2024039S DYSREGULATED ASTROCYTE P38, BRAIN INFLAMMATION, AND ALZHEIMER'S PATHOLOGY. INVESTIGATOR'S SUMMARY: ASTROCYTES, THE MOST ABUNDANT GLIAL CELL TYPE IN THE BRAIN, BECOME ABNORMALLY ACTIVATED EARLY IN ALZHEIMER'S DISEASE (AD) AND CAN LEAD TO DETRIMENTAL BRAIN INFLAMMATION AND NERVE CELL DAMAGE. THE P38 MAPK DRIVES INFLAMMATION IN MICROGLIA BUT ITS ROLE IN ASTROCYTES IS

Part IV Supplemental Information

UNDERSTUDIED. OUR PROJECT WILL USE NOVEL MOUSE MODELS AND WELL-CHARACTERIZED HUMAN BIOSPECIMENS TO DEFINE THE POTENTIAL LINKAGE BETWEEN ASTROCYTE P38, NEUROINFLAMMATION, AND AD NEUROPATHOLOGIC CHANGE, THUS PROVIDING NEW INSIGHT INTO MECHANISMS BY WHICH ABNORMAL ASTROCYTE ACTIVATION IN AD CONTRIBUTES TO DISEASE PROGRESSION.

NAME OF ORGANIZATION OR GOVERNMENT: INDIANA UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ANLLEY FERNANDEZ, PHD ENTITLED: A2025001F LINKING PLAQUE SHAPES TO AMYLOID STRUCTURES IN ALZHEIMER DISEASE. INVESTIGATOR'S SUMMARY: ALZHEIMER DISEASE (AD) IS MARKED BY ABNORMAL DEPOSITS OF AMYLOID- (A) AND TAU PROTEINS IN THE BRAIN, LEADING TO MEMORY LOSS AND COGNITIVE DECLINE. USING CUTTING-EDGE CRYO-ELECTRON MICROSCOPY, WE AIM TO STUDY THE STRUCTURES OF A IN DIFFERENT PLAQUE TYPES AND BRAIN REGIONS. OUR RESEARCH FOCUSES ON UNDERSTANDING HOW THESE STRUCTURAL VARIATIONS CONTRIBUTE TO DISEASE PROGRESSION, ESPECIALLY IN CASES LINKED TO GENETIC RISK FACTORS LIKE APOE4. THIS WORK COULD UNCOVER NEW DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS, ADVANCING EFFORTS TO COMBAT AD AND RELATED DISORDERS.

NAME OF ORGANIZATION OR GOVERNMENT: BAYLOR COLLEGE OF MEDICINE (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY OMAR PEA-RAMOS, PHD ENTITLED: A2025002F THE ASTROCYTE CELL SURFACE PROTEOME IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: CELL SURFACE PROTEINS (CSPS) HELP CELLS COMMUNICATE AND RESPOND TO THEIR ENVIRONMENT, MAKING THEM KEY DRUG TARGETS. WE PERFORMED CSP PROFILING OF MOUSE ASTROCYTES DURING A-AMYLOID PLAQUE BUILDUP AND IDENTIFIED CD44 AS A TOP CANDIDATE. WE FOUND THAT WHEN CD44 BINDS TO ITS LIGAND OPN, ASTROCYTES TRIGGER LIPID ACCUMULATION WHILE MICE LACKING CD44 SHOW REDUCED INFLAMMATION. BY STUDYING CD44 IN LIVE MICE AND CULTURED ASTROCYTES, WE AIM TO UNCOVER ITS ROLE IN AD AND EXPLORE ITS POTENTIAL AS A THERAPEUTIC TARGET.

NAME OF ORGANIZATION OR GOVERNMENT: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MARCOS SCHAAN PROFES, PHD ENTITLED: A2025003F THE ROLE OF JADE1 IN TAUOPATHY. INVESTIGATOR'S SUMMARY: TAUOPATHIES, SUCH AS ALZHEIMER'S DISEASE, RESULT FROM THE TOXIC AGGREGATION OF TAU PROTEINS, BUT THE EXACT PROCESS REMAINS UNCLEAR. WE ARE INVESTIGATING JADE1, A PROTEIN THAT SPECIFICALLY BINDS TOXIC TAU, TO DETERMINE IF IT PREVENTS AGGREGATION OR PROMOTES CLEARANCE VIA CELLULAR PATHWAYS LIKE AUTOPHAGY. USING ADVANCED CELLULAR MODELS, INCLUDING ONE THAT USES LIGHT TO CONTROL TAU BEHAVIOR, OUR RESEARCH AIMS TO UNCOVER HOW JADE1 WORKS AND EXPLORE ITS POTENTIAL AS A TARGET FOR FUTURE TREATMENTS.

NAME OF ORGANIZATION OR GOVERNMENT: BRIGHAM AND WOMEN'S HOSPITAL, INC. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SARAH ELISE HEUER, PHD ENTITLED: A2025005F DETERMINING THE CELLULAR IMPACTS OF ABCA7 MUTATIONS IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: GENETICS PLAYS A KEY ROLE IN GOVERNING ALZHEIMER'S DISEASE (AD) RISK, WITH MANY MUTATIONS LINKED TO LIPID BIOLOGY PROTEINS. ABCA7 IS A LIPID TRANSPORTER AND HAS SEVERAL AD RISK MUTATIONS, SOME FOUND EXCLUSIVELY IN INDIVIDUALS OF AFRICAN ANCESTRY. HOWEVER, THE EFFECTS OF THESE MUTATIONS REMAIN UNCLEAR DUE TO THE HISTORICAL LACK OF DIVERSE REPRESENTATION IN RESEARCH STUDIES. USING MODELS OF LIVING BRAIN CELLS DERIVED FROM HUMANS THAT HARBOR THESE MUTATIONS, I WILL STUDY HOW MODIFYING ABCA7 ALTERS PROTEINS, LIPIDS, AND CELL FUNCTION, PAVING THE WAY FOR INCLUSIVE, PERSONALIZED AD THERAPIES.

Part IV Supplemental Information

NAME OF ORGANIZATION OR GOVERNMENT: WASHINGTON UNIVERSITY IN ST. LOUIS
 (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JOSHUA EMMERSON,
 PHD ENTITLED: A2025006F TARGETING THE ADAPTIVE IMMUNITY TO PREVENT
 ALZHEIMER'S BRAIN DEGENERATION. INVESTIGATOR'S SUMMARY:
 NEURODEGENERATIVE DISEASES SUCH AS ALZHEIMER'S DISEASE (AD) INVOLVE THE
 BUILDUP OF TAU PROTEINS AND SIGNIFICANT BRAIN DEGENERATION. THIS
 TAU-MEDIATED DAMAGE IS MAINLY DRIVEN BY INFLAMMATION IN THE BRAIN, WITH
 RECENT EVIDENCE OF INFILTRATING T-LYMPHOCYTES (T-CELLS) BEING ESSENTIAL
 TO THIS PROCESS. THIS PROJECT WILL APPLY MULTIDISCIPLINARY APPROACHES
 TO DETERMINE THE CANDIDATE SIGNALING PATHWAY(S) RESPONSIBLE FOR
 ATTRACTING T-CELLS TO THE BRAIN IN DISEASE, AND TO BLOCK T-CELL
 INFILTRATION AS TO PREVENT SUBSEQUENT TAU-MEDIATED BRAIN DEGENERATION
 IN A GENETICALLY MODIFIED MOUSE MODEL.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, IRVINE
 (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY GHAZALEH
 ESKANDARI-SEDIGHI, PHD ENTITLED: A2025007F UNDERSTANDING THE ROLE OF
 BRAIN IMMUNE CELLS IN PROTECTION AGAINST ALZHEIMER'S. INVESTIGATOR'S
 SUMMARY: UNDERSTANDING HOW ALZHEIMER'S DISEASE (AD) IS FORMED IS
 CHALLENGING DUE TO THE COMPLEX, MULTIFACETED NATURE OF THE DISEASE. IT
 IS KNOWN NOW THAT THE HERITABILITY OF AD IS OVER 60%. SO, UNDERSTANDING
 THE DISEASE MECHANISM, CAN BE ACHIEVED BY EXPLORING THESE HEREDITARY
 ELEMENTS IN PATIENTS VS. HEALTHY INDIVIDUALS. OF NOTE, SOME RARE
 HEREDITARY FACTORS TURN OUT TO BE PROTECTIVE AND CAN PROVIDE PROTECTION
 AGAINST AD. TAKING ADVANTAGE OF NOVEL, MULTI-FACETED STEM CELL MODELS,
 WE WILL STUDY APOE3 CHRISTCHURCH AS ONE OF SUCH RARE, RESILIENT
 FACTORS, WITH SPECIFIC FOCUS ON BRAIN RESIDENT IMMUNE CELLS.

PART II, LINE 1(H) CONTINUED

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF PITTSBURGH (H)
 PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JR-JIUN LIOU, PHD
 ENTITLED: A2025009F NEUROIMAGING AND NEUROPATHOLOGY OF ALZHEIMER'S
 DISEASE IN DOWN SYNDROME. INVESTIGATOR'S SUMMARY: WHY DO INDIVIDUALS
 WITH DOWN SYNDROME DEVELOP ALZHEIMER'S DISEASE DECADES EARLIER THAN THE
 GENERAL POPULATION? THIS PROPOSAL WILL USE HIGH-RESOLUTION IMAGING AND
 POSTMORTEM BRAIN SAMPLES FROM WELL-CHARACTERIZED COHORTS OF ADULTS WITH
 DOWN SYNDROME AND LATE-ONSET ALZHEIMER'S DISEASE. BY IDENTIFYING
 IMAGING BIOMARKERS AND CLARIFYING EARLY DISEASE MECHANISMS, WE AIM TO
 ADVANCE UNDERSTANDING OF ALZHEIMER'S IN DOWN SYNDROME, PROMOTE
 INCLUSIVE RESEARCH, AND GUIDE EFFECTIVE INTERVENTIONS TO IMPROVE
 DIAGNOSTICS AND TREATMENT STRATEGIES.

NAME OF ORGANIZATION OR GOVERNMENT: THE SALK INSTITUTE FOR BIOLOGICAL
 STUDIES (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JOSEPH
 HERDY, PHD ENTITLED: A2025010F BLOCKING JUMPING GENES TO STOP BRAIN
 INFLAMMATION IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY:
 ALZHEIMER'S DISEASE (AD) IS A FATAL NEURODEGENERATIVE DISEASE WITH NO
 AVAILABLE CURES. BY GENERATING PATIENT SPECIFIC INDUCED NEURONS (INS),
 WE FOUND THAT THERE IS A SMALL POPULATION OF INFLAMMATORY NEURONS THAT
 COULD BE TARGETED TO TREAT AD INSTEAD OF STRATEGIES THAT AFFECT THE
 ENTIRE BRAIN. HOWEVER, HOW THESE NEURONS BECOME INFLAMMATORY, AND
 THEREFORE WAYS TO INTERVENE ARE CURRENTLY UNKNOWN. IN THIS PROJECT, WE
 DEEPLY CHARACTERIZE A PROMISING GENETIC TARGET DRIVING INFLAMMATION,
 AND ASSESS IF BLOCKING ITS ACTIVITY IS A CANDIDATE FOR REVERSING

Part IV Supplemental Information

HALLMARKS OF AD.

NAME OF ORGANIZATION OR GOVERNMENT: VANDERBILT UNIVERSITY MEDICAL CENTER (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MONICA SANTISTEBAN, PHD ENTITLED: A2025011S UNDERSTANDING THE CHOROID PLEXUS IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THE RENIN ANGIOTENSIN SYSTEM MAY PLAY AN IMPORTANT ROLE IN THE PROGRESSION OF PATHOLOGY IN ALZHEIMER'S DISEASE. IN THIS PROPOSAL, WE WILL LOOK AT THE CHOROID PLEXUS, A SMALL TISSUE WITHIN THE BRAIN THAT MAKES THE CEREBROSPINAL FLUID, AS A NOVEL SOURCE CONTRIBUTING TO THE LOCAL BRAIN RENIN ANGIOTENSIN SYSTEM AND COGNITIVE DECLINE IN AD. SINCE THERE ARE LIKELY A LOT MORE CHANGES HAPPENING IN THE CHOROID PLEXUS OTHER THAN THE RENIN ANGIOTENSIN SYSTEM, WE WILL ALSO ESTABLISH A COMPREHENSIVE DATABASE OF THE TRANSCRIPTIONAL CHANGES IN THE CHOROID PLEXUS IN AD TO SERVE AS A TOOL FOR FUTURE DISCOVERY.

NAME OF ORGANIZATION OR GOVERNMENT: THE J. DAVID GLADSTONE INSTITUTES (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY KATERINA AKASSOGLOU, PHD ENTITLED: A2025013S UNRAVELING THE TRIGGERS TO MYELIN DAMAGE IN IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: MYELIN DAMAGE HAS EMERGED AS A KEY PLAYER TO ALZHEIMER'S DISEASE (AD). HOWEVER, THE TRIGGERS OF MYELIN PATHOLOGY IN AD REMAIN LARGELY UNKNOWN. FIBRINOGEN, A BLOOD CLOTTING PROTEIN DEPOSITED IN AD BRAIN IS A POTENT INDUCER OF NEUROTOXIC INFLAMMATION AND INHIBITOR OF MYELIN REPAIR. WE WILL DETERMINE THE ROLE OF FIBRINOGEN ON MYELIN-FORMING CELLS IN AD MICE WITH STATE-OF-THE-ART IMAGING, MULTIOMIC TECHNOLOGIES, AND BEHAVIORAL ANALYSIS OF LEARNING AND MEMORY IN AD MICE, AS WELL AS TESTING PHARMACOLOGIC TREATMENTS PROMOTING REMYELINATION.

NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY KSENIA KASTANENKA, PHD ENTITLED: A2025014S A SLEEPING PILL FOR ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE IS A MEMORY DISORDER WITHOUT AN EFFECTIVE CURE. DISRUPTIONS IN BRAIN ACTIVITY ASSOCIATED WITH SLEEP AND MEMORY IMPAIRMENTS ALZHEIMER'S PATIENTS EXPERIENCE COULD HOLD THE KEY TO DEVELOPMENT OF EFFECTIVE THERAPEUTIC STRATEGIES. SINCE ALZHEIMER'S PATIENTS SUFFER FROM SLEEP DISTURBANCES, ADMINISTRATION OF FDA-APPROVED SLEEPING PILLS COULD RESTORE THEIR SLEEP AND SLOW DISEASE PROGRESSION. THUS, WE WILL ADMINISTER PROVEN AND SAFE SLEEPING PILLS IN A MOUSE MODEL. THE RESULTS WILL INDICATE WHETHER SLEEPING PILLS COULD BE EFFECTIVE AT SLOWING ALZHEIMER'S DISEASE.

NAME OF ORGANIZATION OR GOVERNMENT: INDIANA UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MIGUEL MOUTINHO, PHARM D, PHD ENTITLED: A2025015S HOW DOES NIACIN PRODUCTION IN THE GUT ASSOCIATED TO ALZHEIMER'S DISEASE? INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE HAS BEEN CORRELATED WITH IMBALANCES IN GUT BACTERIA, HOWEVER, THE MECHANISTIC LINK BETWEEN DISEASE PROGRESSION AND GUT DYSBIOSIS HAVE NOT BEEN FULLY ELUCIDATED. IN THIS PROJECT, WE WILL TEST THE HYPOTHESIS THAT THE SYNTHESIS OF NIACIN IN THE GUT IS DYSREGULATED IN ALZHEIMER'S DISEASE, WHICH LEADS TO A REDUCED SUPPLY OF NIACIN TO BRAIN AND EXACERBATES THE DISEASE. CONVERSELY, WE WILL ASSESS IF INCREASING NIACIN SYNTHESIS IN THE GUT AND SUPPLY TO THE BRAIN CAN MITIGATE DISEASE PROGRESSION, WHICH COULD PAVE THE WAY FOR NOVEL THERAPEUTIC STRATEGIES AIMING AT GUT MICROBIOME.

Part IV Supplemental Information

NAME OF ORGANIZATION OR GOVERNMENT: COLUMBIA UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JAE-EUN MILLER, PHD ENTITLED: A2025016S REPAIRING THE BODY CLOCK TO DELAY ALZHEIMER'S DISEASE.

INVESTIGATOR'S SUMMARY: BREAKDOWN IN CIRCADIAN RHYTHM IS BOTH A RISK FACTOR AND A SYMPTOM OF ALZHEIMER'S. THIS SUGGESTS A VICIOUS CYCLE OF CIRCADIAN DISRUPTION DRIVING DISEASE, AND DISEASE DRIVING CIRCADIAN DISRUPTION. IF WE COULD PREVENT CIRCADIAN DISRUPTION, WE MAY BE ABLE TO PREVENT DISEASE. THE ROOT CAUSE OF CIRCADIAN DYSFUNCTION IN ALZHEIMER'S IS UNCLEAR. TO ADDRESS THIS, WE WILL DETERMINE HOW TAUOPATHY, A KEY COMPONENT OF ALZHEIMER'S DISEASE, DISRUPTS THE FUNCTION OF THE MASTER CIRCADIAN CLOCK. WE WILL ALSO DEVELOP AN APPROACH RESTORE CIRCADIAN RHYTHM IN A DISEASE MODEL AND DETERMINE IF THIS PREVENTS DISEASE.

PART II, LINE 1(H) CONTINUED

NAME OF ORGANIZATION OR GOVERNMENT: BETH ISRAEL DEACONESS MEDICAL CENTER (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY FENG TIAN, PHD ENTITLED: A2025017S MONITORING NEURAL ACTIVITY AND NEUROINFLAMMATION IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: NEUROINFLAMMATION IS ONE KEY HALLMARK OF ALZHEIMER'S DISEASE (AD) AND ONE OF THE MOST ATTRACTIVE DIRECTIONS FOR NOVEL AD DRUG DEVELOPMENT. HOWEVER, IT IS STILL UNCLEAR HOW NEUROINFLAMMATION CONTRIBUTES TO MEMORY LOSS AND COGNITIVE DEFICITS. WE WILL INNOVATIVELY LEVERAGE ADVANCED BRAIN MACHINE INTERFACE AND GENETIC TOOLS TO STUDY THE ROLE BETWEEN NEUROINFLAMMATION AND NEURAL ACTIVITY CHANGES DURING AD PROGRESSION.

NAME OF ORGANIZATION OR GOVERNMENT: NORTHWESTERN UNIVERSITY - CHICAGO CAMPUS (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JUSTYNA DOBROWOLSKA ZAKARIA, PHD ENTITLED: A2025019S AMYLOID PRECURSOR PROTEIN PROCESSING THROUGH A NOVEL PATHWAY IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: ALTHOUGH APP, THE PARENT PROTEIN OF ABETA, WAS DISCOVERED 40 YEARS AGO, IT WASN'T UNTIL RECENTLY THAT A NEW CLEAVAGE PRODUCT OF APP WAS DETECTED IN HUMAN BIOFLUIDS. ETA-SECRETASE WAS FOUND TO CUT APP TO GENERATE AETA. AETA HAS BEEN SHOWN TO BE VERY IMPORTANT IN PROCESSES THAT PLAY A ROLE IN MEMORY FORMATION AND ITS LEVELS CHANGE IN MOUSE MODELS WHEN PROSPECTIVE AD THERAPIES ARE ADMINISTERED. NOT MUCH IS KNOWN ABOUT AETA IN HUMANS, AND THUS WE WANT TO DEVELOP A METHOD TO MEASURE HOW QUICKLY AETA IS PRODUCED AND CLEARED IN A HEALTHY OLDER HUMAN AND THEN COMPARE THIS TO AETA METABOLISM IN AD.

NAME OF ORGANIZATION OR GOVERNMENT: WASHINGTON UNIVERSITY IN ST. LOUIS (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY CYRIL POTTIER, PHD ENTITLED: A2025020S EXPLORING THE ORIGIN AND COMPOSITION OF A UNIQUE PATHOLOGY IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: SOME PEOPLE WITH EARLY-ONSET ALZHEIMER'S HAVE A RARE TYPE OF PATHOLOGY IN THE BRAIN CALLED "COTTON WOOL PLAQUES" (CWPS), BUT THEIR CAUSE IS STILL A MYSTERY. OUR RESEARCH WILL EXPLORE WHAT MAKES THESE PLAQUES UNIQUE, WHAT PROTEINS THEY CONTAIN COMPARED TO TYPICAL ALZHEIMER'S PLAQUES, AND WHETHER SPECIFIC GENES ARE INVOLVED. BY STUDYING CWPS, WE HOPE TO UNCOVER NEW INSIGHTS INTO HOW ALZHEIMER'S DEVELOPS AND WHY THE DISEASE VARIES BETWEEN PATIENTS.

NAME OF ORGANIZATION OR GOVERNMENT: RESEARCH FOUNDATION OF SUNY - UNIVERSITY AT ALBANY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY DAMIAN ZULOAGA, PHD ENTITLED: A2025021S INTERACTIONS OF PREGNANCY

Part IV Supplemental Information

AND MENOPAUSE ON ALZHEIMER'S DISEASE OUTCOMES. INVESTIGATOR'S SUMMARY: WOMEN ARE DISPROPORTIONATELY AFFECTED BY ALZHEIMER'S DISEASE (AD) RELATIVE TO MEN. LIFE COURSE FACTORS UNIQUE TO WOMEN, INCLUDING PREGNANCY AND MENOPAUSE, LIKELY CONTRIBUTE TO FEMALE VULNERABILITY ALTHOUGH HOW THESE TWO FACTORS INTERACT TO AFFECT AD RELATED OUTCOMES IS UNKNOWN. WE PROPOSE TO USE A MOUSE MODEL OF AD TO DETERMINE HOW THE COMBINATION OF PREGNANCY AND MENOPAUSE IMPACT COGNITIVE/BEHAVIORAL FUNCTIONS AND AD ASSOCIATED NEUROPATHOLOGY.

NAME OF ORGANIZATION OR GOVERNMENT: INDIANA UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY REBECCA WALLINGS, DPHIL ENTITLED: A2025023S UNDERSTANDING THE ROLE OF A SUPPRESSED IMMUNE SYSTEM IN FRONTOTEMPORAL DEMENTIA. INVESTIGATOR'S SUMMARY: I PREVIOUSLY PUBLISHED FINDINGS THAT SHOWED IMMUNE CELLS OUTSIDE OF THE BRAIN WHICH CARRY FTD-ASSOCIATED MUTATIONS HAVE A DAMPENED IMMUNE RESPONSE. A DAMPENED IMMUNE RESPONSE IS OFTEN ASSOCIATED WITH IMMUNE CELL EXHAUSTION (ICE); WHEN IMMUNE CELLS LOSE THE ABILITY TO RESPOND TO INFECTIONS AND INFLAMMATION. HERE WE WILL INVESTIGATE 1. THE DOWNSTREAM EFFECTS OF ICE ON OTHER IMMUNE CELLS, AND 2. HOW ICE IN THE PERIPHERY CONTRIBUTES TO DEGENERATION AND INFLAMMATION IN THE BRAIN. THE COMPLETION OF THIS PROPOSAL WILL INFORM US OF THE ROLE OF ICE IN FTD AND IF THIS IS A POTENTIAL THERAPEUTIC TARGET.

NAME OF ORGANIZATION OR GOVERNMENT: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JACK HUMPHREY, PHD ENTITLED: A2025024S TDP-43 IN THE AGING BRAIN: WHEN AND WHERE? INVESTIGATOR'S SUMMARY: DISEASES OF THE AGING BRAIN SUCH AS ALZHEIMER'S ARE CAUSED BY MULTIPLE FACTORS, INCLUDING THE PROTEINS AMYLOID AND TAU, BUT RECENTLY, AN ADDITIONAL PROTEIN TDP-43 HAS BEEN LINKED TO A FASTER DECLINE IN SOME PATIENTS. WE WILL INVESTIGATE TDP-43 IN A SET OF AUTOPSIED BRAINS FROM MULTIPLE DISEASES AND ASSOCIATE ITS PRESENCE TO THE PRESENCE OF AMYLOID AND TAU. WE WILL THEN STUDY WHICH SPECIFIC BRAIN CELLS CONTAIN CHANGES IN TDP-43 LEVELS AND WHAT THAT DOES TO THEM, WHICH COULD HELP TO UNDERSTAND HOW TDP-43 RELATES TO AGING AND DEMENTIA.

NAME OF ORGANIZATION OR GOVERNMENT: THE OHIO STATE UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY HONGJUN FU, PHD ENTITLED: A2025025S PLCG2 VARIANTS AND THEIR IMPLICATIONS IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: PLCG2, AN ENZYME THAT IS IMPORTANT IN CELL-TO-CELL COMMUNICATION, ALSO PLAYS A ROLE IN THE RISK OF DEVELOPING LATE ONSET ALZHEIMER'S DISEASE (AD). THE GENE THAT ENCODES FOR THIS ENZYME HAS AD-ASSOCIATED VARIANTS: ONE OF WHICH PROTECTS AGAINST AD, AND ONE OF WHICH PROMOTES AD. WE AIM TO IDENTIFY THE ROLE THAT THESE TWO AD-ASSOCIATED PLCG2 VARIANTS PLAY IN THE DEVELOPMENT AND PROGRESSION OF MICROTUBULE-ASSOCIATED PROTEIN TAU AGGREGATES, CELL DEATH, AND MEMORY LOSS.

NAME OF ORGANIZATION OR GOVERNMENT: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY TODD J. COHEN, PHD ENTITLED: A2025026S HARNESSING THE PROTEIN CHIP/STUB1 TO REDUCE ALZHEIMER'S BRAIN PATHOLOGY. INVESTIGATOR'S SUMMARY: THE RESEARCH FOCUSES ON THE ROLE OF THE PROTEIN CHIP/STUB1 IN ALZHEIMER'S DISEASE, PARTICULARLY ITS ABILITY TO PREVENT THE AGGREGATION OF TAU PROTEINS LINKED TO THE DISEASE'S PROGRESSION. BY ENGINEERING CHIP VARIANTS THAT ENHANCE ITS CHAPERONE FUNCTION, THE STUDY AIMS TO REDUCE

Part IV Supplemental Information

TAU PATHOLOGY AND IMPROVE COGNITIVE FUNCTION IN ALZHEIMER'S PATIENTS. THIS INNOVATIVE APPROACH COULD LEAD TO NEW GENE THERAPIES FOR ALZHEIMER'S AND OTHER TAU-RELATED DISEASES.

NAME OF ORGANIZATION OR GOVERNMENT: MAYO CLINIC, ROCHESTER (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY GAVIN RODDY, MD, PHD ENTITLED: G2025001S DEVELOPING A NEW TREATMENT FOR GLAUCOMA THAT AVOIDS THE USE OF DAILY DROPS. INVESTIGATOR'S SUMMARY: GLAUCOMA IS THE LEADING CASE OF IRREVERSIBLE BLINDNESS WORLDWIDE. CURRENT TREATMENTS THAT REQUIRE DAILY INSTILLATION OF EYEDROPS TO LOWER PRESSURE CAUSE SIDE EFFECTS AND FAIL TO ADEQUATELY TREAT MANY PATIENTS. MY LAB DEVELOPED A PRESSURE-LOWERING DRUG THAT ACTS FOR 6 MONTHS WITH A SINGLE INJECTION. WE NOW SEEK TO TEST THIS DRUG IN A LARGE ANIMAL IN HOPES OF BRINGING A NEW THERAPY TO PATIENTS.

PART II, LINE 1(H) CONTINUED

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN DIEGO (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY KARL JONAS WAHLIN, PHD ENTITLED: G2025002S REPAIRING THE HUMAN RETINA BY CELL REPROGRAMMING. INVESTIGATOR'S SUMMARY: RETINAL GANGLION CELL NEURONS CONNECT THE EYE TO THE BRAIN AND WHEN THEY DIE, WHETHER THROUGH GLAUCOMA OR THROUGH ACUTE TRAUMA, THIS LEADS TO PERMANENT VISION LOSS AND BLINDNESS. SIMILAR TO HOW THIS OCCURS THROUGHOUT THE ANIMAL KINGDOM, WE PROPOSE TO DEVELOP THE CAPABILITY TO DO THIS IN HUMAN RETINAL TISSUES THROUGH THE CONVERSION OF EXISTING MLLER CELLS IN THE EYE.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF WISCONSIN-MADISON (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY ROB NICKELLS, PHD ENTITLED: G2025003S MITOCHONDRIA IN RETINAL GANGLION CELLS. INVESTIGATOR'S SUMMARY: RETINAL GANGLION CELLS RECEIVE INPUT FROM A TREE-LIKE DENDRITIC ARBOR THAT EXHIBITS PATHOLOGY AFTER OPTIC NERVE DAMAGE. THIS STUDY EXAMINES THE BIOLOGY OF ENERGY PRODUCING ORGANELLES CALLED MITOCHONDRIA IN ARBOR PATHOLOGY INCLUDING HOW SPECIALIZED CELLS CALLED MICROGLIA PARTICIPATE IN THIS PROCESS.

NAME OF ORGANIZATION OR GOVERNMENT: DUKE UNIVERSITY SCHOOL OF MEDICINE (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY DAN STAMER, PHD ENTITLED: G2025004S ROLE OF A KEY GENE, ANGPTL7 IN STEROID-INDUCED GLAUCOMA. INVESTIGATOR'S SUMMARY: GLUCOCORTICOIDS ARE WIDELY USED ANTI-INFLAMMATORY DRUGS THAT TREAT A VARIETY OF DISEASES, BUT LONG-TERM USE OFTEN RESULTS IN ELEVATED EYE PRESSURE THAT CAN LEAD TO GLAUCOMA. USING THE MOST ADVANCED RESEARCH TECHNOLOGIES, THE PRESENT PROJECT IS DESIGNED TO UNDERSTAND HOW ANGPTL7, A GLAUCOMA RISK GENE, IS INVOLVED IN ELEVATING EYE PRESSURE AFTER GLUCOCORTICOID TREATMENT.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF SOUTHERN CALIFORNIA (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY BENJAMIN XU, MD, PHD ENTITLED: G2025005S ENHANCING ACCESS TO GLAUCOMA CARE USING ARTIFICIAL INTELLIGENCE. INVESTIGATOR'S SUMMARY: GLAUCOMA IS THE MOST COMMON CAUSE OF IRREVERSIBLE VISION LOSS WORLDWIDE. A PUBLIC HEALTH CRISIS IS EMERGING DUE TO THE RAPID RISE IN GLAUCOMA PREVALENCE, SHORTAGE OF EYECARE PROVIDERS, AND GLARING ACCESS AND EQUITY ISSUES. WE PROPOSE TO INTEGRATE TELEOPHTHALMOLOGY AND ARTIFICIAL INTELLIGENCE (AI) TO ENHANCE THE DELIVERY OF HIGH-QUALITY, REPRODUCIBLE, EQUITABLE,

Part IV Supplemental Information**RESOURCE-EFFICIENT GLAUCOMA CARE.**

NAME OF ORGANIZATION OR GOVERNMENT: GOOD SAMARITAN FOUNDATION (H)
PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY BRAD FORTUNE, OD, PHD
ENTITLED: G2025007S ASSESSMENT OF VASCULAR RESISTANCE IN GLAUCOMA.
INVESTIGATOR'S SUMMARY: ABNORMAL BLOOD FLOW WITHIN THE EYE IS THOUGHT TO BE ONE FACTOR CONTRIBUTING TO THE DEVELOPMENT AND PROGRESSION OF GLAUCOMA. HOWEVER, QUESTIONS REMAIN ABOUT HOW AND WHEN THIS OCCURS. OUR PROPOSAL AIMS TO DETERMINE WHETHER VASCULAR RESISTANCE IS ELEVATED DURING EARLY STAGES OF GLAUCOMA. OUR RESULTS WILL CONTRIBUTE IMPORTANT KNOWLEDGE AND USEFUL DIAGNOSTIC TOOLS TO THE GLAUCOMA RESEARCH COMMUNITY.

NAME OF ORGANIZATION OR GOVERNMENT: THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY TATJANA JAKOBS, MD ENTITLED: G2025008S INTERLEUKIN-10 AS A NEUROPROTECTIVE FACTOR IN GLAUCOMA. INVESTIGATOR'S SUMMARY: VISUAL IMPAIRMENT IN GLAUCOMA IS CAUSED BY THE DEGENERATION AND EVENTUAL DEATH OF RETINAL GANGLION CELLS THROUGH MECHANISMS THAT ARE NOT FULLY UNDERSTOOD. RETINAL MICROGLIA CAN PLAY NEUROPROTECTIVE AND NEUROTOXIC ROLES IN GLAUCOMA. WE IDENTIFIED IL10 AS A CANDIDATE FOR A MICROGLIA-DERIVED FACTOR THAT MAY SELECTIVELY BOOST THE NEUROPROTECTIVE EFFECTS.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, IRVINE (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY DOROTA SKOWRONSKA-KRAWCZYK, PHD ENTITLED: G2025009S ROLE OF IOP ELEVATION IN INCREASING VULNERABILITY OF RETINA TO STRESS. INVESTIGATOR'S SUMMARY: AGING, A PROCESS WHERE DAMAGE ACCUMULATES IN OUR CELLS OVER TIME, MAKES TISSUES MORE SENSITIVE TO ELEVATED INTRAOCULAR PRESSURE (IOP). HOWEVER, IT IS UNKNOWN HOW CELLS BECOME MORE VULNERABLE AS THEY AGE. OUR EXPERIMENTS WILL EXPLORE HOW RETINAS RESPOND TO IOP-RELATED STRESS AND THE MECHANISMS BEHIND THIS VULNERABILITY, AIMING TO FIND NEW WAYS TO PROTECT RETINAL NEURONS FROM GLAUCOMATOUS CHANGES.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF WISCONSIN-MADISON (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY COLLEEN MCDOWELL, PHD ENTITLED: G2025010S NOVEL MECHANISMS REGULATING PRESSURE IN THE EYE. INVESTIGATOR'S SUMMARY: ELEVATED PRESSURE IN THE EYE IS A MAJOR RISK FACTOR FOR GLAUCOMA AND IS DUE TO FLUID BUILDUP AND IMPROPER DRAINAGE IN THE EYE. IT IS KNOWN THAT FLUID DRAINAGE FROM THE EYE IS NOT UNIFORM CIRCUMFERENTIALLY, AND THIS STUDY AIMS TO STUDY HOW THESE SEGMENTAL DIFFERENCES IN FLUID FLOW ARE DEVELOPED AND REGULATED. THESE DATA WILL HELP IDENTIFY NOVEL MECHANISMS TO LOWER PRESSURE IN THE EYE.

NAME OF ORGANIZATION OR GOVERNMENT: WILLIAM MARSH RICE UNIVERSITY (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY JERZY SZABLOWSKI, PHD ENTITLED: M2025001N A BLOOD TEST TO MEASURE GENES ASSOCIATED WITH MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: ONE CAN GAIN A LOT OF INFORMATION FROM EXCISING A TISSUE AND ANALYZING ITS BIOCHEMICAL BEHAVIOR, SUCH AS EXPRESSION OF GENES UNDERLYING DISEASE. HOWEVER, FOR THE RETINA SUCH EXCISION IS IMPOSSIBLE AS IT WOULD RESULT IN VISION LOSS. WE ARE USING A CUTTING-EDGE TECHNOLOGY TO MEASURE ACTIVITY OF GENES WITHIN THE RETINA WITH A BLOOD TEST. SPECIFICALLY, WE ARE FOCUSING ON TWO GENES THAT ARE SUSPECTED OF INCREASING THE RISK OF DEVELOPING A VISION DISORDER CALLED AGE-RELATED MACULAR DEGENERATION.

Part IV Supplemental Information

IF WE ARE SUCCESSFUL, DOCTORS COULD MEASURE EXPRESSION OF PATIENTS GENES IN RETINA WITHOUT DAMAGING IT.

PART II, LINE 1(H) CONTINUED

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY ANA J CHUCAIR-ELLIOTT, PHD ENTITLED: M2025002N THE ROLE OF AGING, DIET, AND INFLAMMATION IN RPE DEGENERATIVE PROCESSES. INVESTIGATOR'S SUMMARY: AMD IS A BLINDING DISEASE IN WHICH THE CELLS THAT PROCESS VISUAL INFORMATION, PHOTORECEPTORS, DEGENERATE AND DIE. THIS NEURODEGENERATION IS PARTLY DUE TO FAILURE OF THE RETINAL PIGMENTED EPITHELIUM (RPE), THE TISSUE THAT LIES BENEATH THE RETINA, TO SUPPORT NORMAL TISSUE STRUCTURE AND VISUAL FUNCTION. AGING IS THE MAIN RISK FACTOR FOR AMD, BUT DIET AND INFLAMMATION ALSO INCREASE AMD RISK. OUR PROPOSED RESEARCH AIMS TO STUDY HOW AGING AND DIET INTERACT WITH IMMUNE CELLS, MICROGLIA AND MACROPHAGES, TO AFFECT THE RPE GENETIC PROGRAMS AND FUNCTION FOR DISCOVERY OF CANDIDATE TARGETS TO TREAT AMD.

NAME OF ORGANIZATION OR GOVERNMENT: NATIONAL EYE INSTITUTE, NIH (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY RUCHI SHARMA, PHD ENTITLED: M2025003N STUDYING THE ROLE OF GENES & THE TONE OF OUR EYE PIGMENT IN AMD. INVESTIGATOR'S SUMMARY: AMD IS A COMMON EYE DISEASE AFFECTING MANY PEOPLE WORLDWIDE. CAUCASIANS ARE MORE LIKELY TO DEVELOP AMD THAN BLACK INDIVIDUALS. WE WILL USE MODELS CREATED FROM PATIENT STEM CELL-DERIVED RETINAL PIGMENT EPITHELIUM AND CHOROID TO EXPLORE THE CELLULAR PROCESSES THAT MAKE SOME PEOPLE MORE VULNERABLE TO AMD WHILE OTHERS RESIST IT. OUR GOAL IS TO UNDERSTAND HOW PIGMENTATION, CERTAIN GENETIC FACTORS, AND CELLULAR PROCESSES CONTRIBUTE TO THE RISK OF AMD. THIS RESEARCH WILL HELP US UNCOVER HOW SOME PEOPLE RESIST AMD, WHICH MAY LEAD TO NEW DRUGS TO TREAT OR PREVENT THE DISEASE.

NAME OF ORGANIZATION OR GOVERNMENT: LELAND STANFORD JUNIOR UNIVERSITY (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY CHARLES DEBOER, MD, PHD ENTITLED: M2025004N MICROFABRICATED IMPLANT TO TREAT AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: THERAPEUTICS TO TREAT AGE-RELATED MACULAR DEGENERATION (AMD) ARE INJECTED INTO THE VITREOUS, WHILE THE ACTUAL SITE OF PATHOLOGY OCCURS DEEPER IN THE EYE, AT THE LEVEL OF THE CHOROID AND RETINA. THE SUPRACHOROIDAL SPACE IS IN DIRECT CONTACT WITH PATHOLOGIC VESSELS IN WET AMD AND DIRECT TARGETING COULD INCREASE LOCAL DRUG CONCENTRATIONS AND POSSIBLY IMPROVE EFFICACY. WE PROPOSE USING A NOVEL DEVICE CONSISTING OF A REFILLABLE DRUG RESERVOIR AND A TINY TUBE INSERTED INTO THE SUPRACHOROIDAL SPACE FOR EXTENDED LOCALIZED DRUG DELIVERY, PROVIDING A NEW WAY TO TREAT AMD.

NAME OF ORGANIZATION OR GOVERNMENT: LELAND STANFORD JUNIOR UNIVERSITY (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY MOHAJEET BALVEER BHUCKORY, PHD ENTITLED: M2025007N ELECTRONIC IMPLANTS FOR RESTORING SHARP VISION IN MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: IN ADVANCED AMD, THE LOSS OF THE LIGHT-SENSITIVE CELLS IN THE CENTRAL RETINA, PHOTORECEPTORS (PR), LEAD TO BLINDNESS. HOWEVER, THE REMAINING CONNECTING NEURONS THAT RELAY VISUAL SIGNALS TO THE BRAIN STAY MOSTLY INTACT. OUR CURRENT ELECTRONIC PHOTORECEPTORS (EPR) CAN STIMULATE THESE NEURONS, RESTORING THE FLOW OF VISUAL INFORMATION TO THE BRAIN. THIS PROJECT AIMS TO SIGNIFICANTLY ENHANCE THE RESOLUTION BY DEVELOPING CUTTING-EDGE, CELL-SIZED EPR IMPLANTS, OFFERING THE POTENTIAL TO IMPROVE PROSTHETIC VISION BEYOND LEGAL BLINDNESS AND APPROACH NATURAL

Part IV Supplemental Information

VISION.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY VALENCIA FERNANDES, PHD ENTITLED: M2025008F HOW METABOLIC STRESS CAN DRIVE MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR DEGENERATION (AMD) IS CAUSED BY DAMAGE TO THE RETINAL PIGMENT EPITHELIUM (RPE), WHICH NOURISHES AND SUPPORTS THE RETINA. CHRONIC INFLAMMATION, LIPID ACCUMULATION, AND MITOCHONDRIAL INJURY ACT TOGETHER TO COMPROMISE RPE HEALTH, BUT EXACTLY HOW THIS OCCURS IS NOT WELL UNDERSTOOD. THIS RESEARCH PROPOSES TO IDENTIFY THE KEY PLAYERS IN THIS PROCESS BY FOCUSING ON A PROTEIN CALLED STAT3, WHICH IS A MASTER REGULATOR OF CELL HEALTH, AND INVESTIGATE WHETHER IT CAN BE A DRUG TARGET IN AMD.

NAME OF ORGANIZATION OR GOVERNMENT: DUKE UNIVERSITY SCHOOL OF MEDICINE (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY DR. NOBUHIKO SHIRAKI, PHD ENTITLED: M2025011F MICROGLIA'S ROLES IN AMD TO INFORM THERAPIES FOR VISION LOSS PREVENTION. INVESTIGATOR'S SUMMARY: OUTER RETINAL DISEASES, LIKE AMD, CAUSE PERMANENT VISION LOSS DUE TO DAMAGE TO LIGHT-SENSITIVE CELLS. WHILE SOME IMMUNE CELLS HELP CLEAR HARMFUL DEBRIS, RECENT FINDINGS SUGGEST DISTINCT SUBTYPES WITH DIFFERENT FUNCTIONS. GENETIC ANALYSIS IDENTIFIED TWO SUBTYPES IN A CERTAIN IMMUNE CELL, ONE OF WHICH MAY WORSEN INFLAMMATION. STUDIES WITH GENETICALLY MODIFIED MICE SHOWED THAT REDUCING CERTAIN MOLECULES IN THESE CELLS REDUCED RETINAL DAMAGE AFTER LIGHT EXPOSURE. THIS RESEARCH AIMS TO CLARIFY THE IMMUNE CELL ROLES IN AMD, AIMING TO INFORM THERAPIES FOR PREVENTION OF VISION LOSS IN AMD PATIENTS.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF IDAHO (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY ASHLEY FARRE, PHD ENTITLED: M2025012F SHAPING OF NEURONAL CONNECTIONS BY RESIDENT IMMUNE CELLS. INVESTIGATOR'S SUMMARY: IN LATE STAGES OF AGE-RELATED MACULAR DEGENERATION (AMD), LIGHT SENSING CELLS (PHOTORECEPTORS) IN THE EYE DIE, LEADING TO VISION LOSS. TO TREAT THIS WITH FUTURE APPROACHES, WE CAN POTENTIALLY REPLACE PHOTORECEPTORS, BUT IN ORDER TO WORK PROPERLY, THESE CELLS NEED TO BE ABLE TO COMMUNICATE WITH OTHER NEURONS IN THE EYE THAT PROCESS LIGHT INFORMATION AND PASS IT TO THE BRAIN. WITH THIS PROJECT, WE WILL DETERMINE HOW MICROGLIA (IMMUNE CELLS OF THE EYE) COULD HELP NEW PHOTORECEPTORS ESTABLISH CONNECTIONS WITH OTHER NEURONS, POTENTIALLY MAKING FUTURE AMD TREATMENTS MORE EFFECTIVE.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN DIEGO (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY JAESOO JUNG, PHD ENTITLED: M20250013F HEPARAN SULFATE REGULATION OF HTRA1-MEDIATED PROTEOSTASIS IN BRUCH'S MEMBRANE IN AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: HTRA1 IS A STRONG GENETIC RISK FACTOR FOR AGE-RELATED MACULAR DEGENERATION (AMD), BUT ITS NATURAL SUBSTRATES IN BRUCH'S MEMBRANE (BRM) REMAIN UNKNOWN. TO UNCOVER HOW ALTERED HTRA1 PROTEOLYSIS CONTRIBUTES TO DRUSEN FORMATION, WE WILL USE ISOTOPE-LABELING DEGRADOMICS TO IDENTIFY ITS ENDOGENOUS SUBSTRATES. WE WILL THEN DEVELOP A HIGH-TIME-RESOLVING HOMOGENEOUS TIME-RESOLVED FLUORESCENCE (HTRF) ASSAY TO EVALUATE HOW HEPARAN SULFATES MODULATE HTRA1-MEDIATED HYDROLYSIS OF THESE CANDIDATE SUBSTRATES, PROVIDING INSIGHT INTO MECHANISMS DRIVING EARLY AMD PATHOLOGY.

Part IV Supplemental Information

PART II, LINE 1(H) CONTINUED

NAME OF ORGANIZATION OR GOVERNMENT: MAYO CLINIC, JACKSONVILLE (H)

PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH ENTITLED: CA2021010

MOLECULAR NEURODEGENERATION JOURNAL. INVESTIGATOR'S SUMMARY: THE AIM OF MOLECULAR NEURODEGENERATION (MN) JOURNAL

([HTTPS://MOLECULARNEURODEGENERATION.BIOMEDCENTRAL.COM/](https://molecularneurodegeneration.biomedcentral.com/)) IS TO SERVE THE SCIENTIFIC COMMUNITY BY PUBLISHING HIGH-IMPACT, HIGH-QUALITY, AND FRONT-LINE RESEARCH DISCOVERIES IN DIVERSE AREAS OF NEURODEGENERATIVE DISEASES INCLUDING ALZHEIMER'S DISEASE AND EYE-RELATED DEGENERATIVE CONDITIONS. MN IS THE OFFICIAL JOURNAL OF THE BRIGHTFOCUS FOUNDATION. THE OPEN ACCESS PUBLISHING MODEL PROVIDES FREE ARTICLES TO THE GENERAL PUBLIC, AS WELL AS SCIENTISTS, CLINICIANS, AND OTHER HEALTHCARE. THE JOURNAL HAS SEEN FURTHER GROWTH IN RECENT YEARS IN PARTICULAR IN THE AREA OF SCIENTIFIC IMPACT AND REPUTATION. SOME OF THESE ARE REFLECTED IN THE FOLLOWING METRICS: 1) 1,877,858 DOWNLOADS IN 2024; 2) JOURNAL CITATION REPORTS (JCR) TRACKED CITATIONS: 9,015 IN 2022; 9,806 IN 2023; AND 11,362 IN 2024; 3) JOURNAL IMPACT FACTOR: 15.1 IN 2022; 15.1 IN 2023; 17.5 IN 2024; 4) 2024 JCR RANKING: MOLECULAR NEURODEGENERATION RANKED NO. 4 AMONG 314 NEUROSCIENCE JOURNALS (WITHIN THE TOP 1.1%).

NAME OF ORGANIZATION OR GOVERNMENT: INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH ENTITLED: CA2021011 INTERNATIONAL SOCIETY FOR MOLECULAR

NEURODEGENERATION. INVESTIGATOR'S SUMMARY: THIS AWARD IS FOR THE CREATION, AND GROWTH OF, THE "INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION" (ISMND) AND SUPPORT OF ITS BI-ANNUAL MEETINGS AND EDUCATIONAL AND SCIENTIFIC PURPOSES. ISMND'S MISSION IS TO SERVE AS AN ACCELERATOR FOR THE CONTINUOUS IMPROVEMENT OF BRAIN AND EYE HEALTH AND WELL-BEING BY CREATING A MULTIDISCIPLINARY GLOBAL PLATFORM FOR SCIENTISTS, PHYSICIANS, AND THE PUBLIC FROM DIFFERENT FACETS AND SCIENTIFIC DISCIPLINES TO MORE READILY CONNECT, SHARE AND COMMUNICATE SCIENTIFIC DISCOVERIES, AND DEVELOP CURES FOR NEURODEGENERATIVE DISEASES, IN THE HOPES OF A WORLD FREE OF BRAIN AND EYE DISEASES.

NAME OF ORGANIZATION OR GOVERNMENT: MEDICAL TECHNOLOGY ENTERPRISE

CONSORTIUM (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH ENTITLED: CA2025003 THE CONCUSSION ASSESSMENT, RESEARCH, & EDUCATION (CARE)

CONSORTIUM BIOBANK. INVESTIGATOR'S SUMMARY: THE OVERARCHING GOAL IS TO LEVERAGE THE DEEPLY ENRICHED CARE COHORT OF MALE AND FEMALE COLLEGIATE ATHLETES AND MILITARY PERSONNEL WITH AND WITHOUT MILD TBI

(MTBI)/CONCUSSION AND/OR REPETITIVE HEAD IMPACT EXPOSURE, TO DETERMINE IF A PANEL OF ADRD GENOMIC FACTORS CAN IDENTIFY YOUNG ADULTS (3RD AND 4TH DECADE OF LIFE) WITH VERY EARLY INDICATORS CONSISTENT WITH PRECLINICAL ADRD, WHO MIGHT BENEFIT FROM PRIMARY PREVENTIVE STRATEGIES (ELIMINATION OF HEAD IMPACT EXPOSURE), OR EARLY CONSIDERATION OF RECENTLY APPROVED DISEASE MODIFYING THERAPIES (DMTS).

SCHEDULE J
(Form 990)

(Rev. December 2024)
Department of the Treasury
Internal Revenue Service

Compensation Information

For certain Officers, Directors, Trustees, Key Employees, and Highest
Compensated Employees
Complete if the organization answered "Yes" on Form 990, Part IV, line 23.
Attach to Form 990.
Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

Open to Public
Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I Questions Regarding Compensation

1a Check the appropriate box(es) if the organization provided any of the following to or for a person listed on Form 990, Part VII, Section A, line 1a. Complete Part III to provide any relevant information regarding these items.

- | | |
|--|--|
| <input type="checkbox"/> First-class or charter travel | <input type="checkbox"/> Housing allowance or residence for personal use |
| <input type="checkbox"/> Travel for companions | <input type="checkbox"/> Payments for business use of personal residence |
| <input type="checkbox"/> Tax indemnification and gross-up payments | <input type="checkbox"/> Health or social club dues or initiation fees |
| <input type="checkbox"/> Discretionary spending account | <input type="checkbox"/> Personal services (such as maid, chauffeur, chef) |

b If any of the boxes on line 1a are checked, did the organization follow a written policy regarding payment or reimbursement or provision of all of the expenses described above? If "No," complete Part III to explain

2 Did the organization require substantiation prior to reimbursing or allowing expenses incurred by all directors, trustees, and officers, including the CEO/Executive Director, regarding the items checked on line 1a?

3 Indicate which, if any, of the following the organization used to establish the compensation of the organization's CEO/Executive Director. Check all that apply. Do not check any boxes for methods used by a related organization to establish compensation of the CEO/Executive Director, but explain in Part III.

- | | |
|---|---|
| <input checked="" type="checkbox"/> Compensation committee | <input type="checkbox"/> Written employment contract |
| <input checked="" type="checkbox"/> Independent compensation consultant | <input checked="" type="checkbox"/> Compensation survey or study |
| <input checked="" type="checkbox"/> Form 990 of other organizations | <input checked="" type="checkbox"/> Approval by the board or compensation committee |

4 During the year, did any person listed on Form 990, Part VII, Section A, line 1a, with respect to the filing organization or a related organization:

- a Receive a severance payment or change-of-control payment?
- b Participate in or receive payment from a supplemental nonqualified retirement plan?
- c Participate in or receive payment from an equity-based compensation arrangement?
- If "Yes" to any of lines 4a-c, list the persons and provide the applicable amounts for each item in Part III.

Only section 501(c)(3), 501(c)(4), and 501(c)(29) organizations must complete lines 5-9.

5 For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any compensation contingent on the revenues of:

- a The organization?
- b Any related organization?
- If "Yes" on line 5a or 5b, describe in Part III.

6 For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any compensation contingent on the net earnings of:

- a The organization?
- b Any related organization?
- If "Yes" on line 6a or 6b, describe in Part III.

7 For persons listed on Form 990, Part VII, Section A, line 1a, did the organization provide any nonfixed payments not described on lines 5 and 6? If "Yes," describe in Part III

8 Were any amounts reported on Form 990, Part VII, paid or accrued pursuant to a contract that was subject to the initial contract exception described in Regulations section 53.4958-4(a)(3)? If "Yes," describe in Part III

9 If "Yes" on line 8, did the organization also follow the rebuttable presumption procedure described in Regulations section 53.4958-6(c)?

Yes No

1b

2

4a

4b

4c

5a

5b

6a

6b

7

8

9

X

X

X

X

X

X

X

X

X

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Schedule J (Form 990) (Rev. 12-2024)

Part II Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees. Use duplicate copies if additional space is needed.

For each individual whose compensation must be reported on Schedule J, report compensation from the organization on row (i) and from related organizations, described in the instructions, on row (ii). Do not list any individuals that aren't listed on Form 990, Part VII.

Note: The sum of columns (B)(i)-(iii) for each listed individual must equal the total amount of Form 990, Part VII, Section A, line 1a, applicable column (D) and (E) amounts for that individual.

(A) Name and Title		(B) Breakdown of W-2 and/or 1099-MISC and/or 1099-NEC compensation			(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation in column (B) reported as deferred on prior Form 990
		(i) Base compensation	(ii) Bonus & incentive compensation	(iii) Other reportable compensation				
(1) STACY PAGOS HALLER PRESIDENT/CEO	(i)	423,113.	0.	1,715.	0.	46,677.	471,505.	0.
	(ii)	0.	0.	0.	0.	0.	0.	0.
(2) NANCY KEACH SR. VP, STRATEGIC PARTNERSHIPS	(i)	268,573.	0.	1,584.	0.	51,713.	321,870.	0.
	(ii)	0.	0.	0.	0.	0.	0.	0.
(3) R. BRIAN ELDERTON SR. VP, DEVELOPMENT	(i)	259,608.	0.	1,715.	0.	40,046.	301,369.	0.
	(ii)	0.	0.	0.	0.	0.	0.	0.
(4) JONATHAN WALSH SVP, FINANCE & ADMINISTRATION	(i)	226,326.	0.	460.	0.	4,251.	231,037.	0.
	(ii)	0.	0.	0.	0.	0.	0.	0.
(5) DIANE BOVENKAMP, PHD VP, SCIENTIFIC AFFAIRS	(i)	195,690.	0.	552.	0.	24,358.	220,600.	0.
	(ii)	0.	0.	0.	0.	0.	0.	0.
(6) SHARYN ROSSI - PHD, DIR. OF SCIENT. PROGRAMS, NEUROSCIENCE	(i)	125,492.	0.	240.	0.	42,143.	167,875.	0.
	(ii)	0.	0.	0.	0.	0.	0.	0.
(7) LISA MORGAN SENIOR DIRECTOR, ANNUAL GIVING	(i)	134,563.	0.	552.	0.	22,867.	157,982.	0.
	(ii)	0.	0.	0.	0.	0.	0.	0.
(8) PREETI SUBRAMANIAN - PHD, DIR. OF SCIENT. PROGRAMS, VISION SCIENCE	(i)	139,571.	0.	360.	0.	16,400.	156,331.	0.
	(ii)	0.	0.	0.	0.	0.	0.	0.
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							

Part III Supplemental Information

Provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 3, 4a, 4b, 4c, 5a, 5b, 6a, 6b, 7, and 8, and for Part II. Also complete this part for any additional information.

PART I, LINE 3:
THE LAST COMPENSATION SURVEY WAS COMPLETED ON 3/9/2022.

SCHEDULE M
(Form 990)

Department of the Treasury
Internal Revenue Service

Noncash Contributions

Complete if the organizations answered "Yes" on Form 990, Part IV, line 29 or 30.
Attach to Form 990.

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2024

Open to Public
Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I Types of Property

	(a) Check if applicable	(b) Number of contributions or items contributed	(c) Noncash contribution amounts reported on Form 990, Part VIII, line 1g	(d) Method of determining noncash contribution amounts
1 Art - Works of art				
2 Art - Historical treasures				
3 Art - Fractional interests				
4 Books and publications				
5 Clothing and household goods				
6 Cars and other vehicles				
7 Boats and planes				
8 Intellectual property				
9 Securities - Publicly traded	X	45	394,954.	FMV
10 Securities - Closely held stock				
11 Securities - Partnership, LLC, or trust interests				
12 Securities - Miscellaneous				
13 Qualified conservation contribution - Historic structures				
14 Qualified conservation contribution - Other ...				
15 Real estate - Residential				
16 Real estate - Commercial				
17 Real estate - Other				
18 Collectibles				
19 Food inventory				
20 Drugs and medical supplies				
21 Taxidermy				
22 Historical artifacts				
23 Scientific specimens				
24 Archeological artifacts				
25 Other (.....)				
26 Other (.....)				
27 Other (.....)				
28 Other (.....)				

29 Number of Forms 8283 received by the organization during the tax year for contributions
for which the organization completed Form 8283, Part V, Donee Acknowledgement

29

30a During the year, did the organization receive by contribution any property reported on Part I, lines 1 through 28, that it
must hold for at least 3 years from the date of the initial contribution, and which isn't required to be used for
exempt purposes for the entire holding period?

b If "Yes," describe the arrangement in Part II.

31 Does the organization have a gift acceptance policy that requires the review of any nonstandard contributions?

32a Does the organization hire or use third parties or related organizations to solicit, process, or sell noncash
contributions?

b If "Yes," describe in Part II.

33 If the organization didn't report an amount in column (c) for a type of property for which column (a) is checked,
describe in Part II.

Yes No

30a		X
31	X	
32a	X	

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Schedule M (Form 990) 2024

Part II **Supplemental Information.** Provide the information required by Part I, lines 30b, 32b, and 33, and whether the organization is reporting in Part I, column (b), the number of contributions, the number of items received, or a combination of both. Also complete this part for any additional information.

SCHEDULE M, PART I, COLUMN (B):

BRIGHTFOCUS REPORTS THE NUMBER OF CONTRIBUTIONS IN PART I, COLUMN B.

SCHEDULE M, PART I, LINE 32B:

BRIGHTFOCUS ENGAGED THE SERVICES OF A COMMERCIAL REAL ESTATE BROKER TO SOLICIT AND SELL THE COMMERCIAL REAL ESTATE DONATED TO THE ORGANIZATION 25 YEARS AGO.

**SCHEDULE O
(Form 990)**

(Rev. December 2024)

Department of the Treasury
Internal Revenue Service

Supplemental Information to Form 990 or 990-EZ

Complete to provide information for responses to specific questions on
Form 990 or 990-EZ or to provide any additional information.

Attach to Form 990 or Form 990-EZ.

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

**Open to Public
Inspection**

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

FORM 990, PART III, LINE 1, DESCRIPTION OF ORGANIZATION MISSION:
BRIGHTFOCUS FOUNDATION FUNDS EXCEPTIONAL RESEARCH WORLDWIDE TO DEFEAT
ALZHEIMER'S DISEASE, MACULAR DEGENERATION, AND GLAUCOMA AND PROVIDES
EXPERT INFORMATION ON THESE HEARTBREAKING DISEASES.

OUR VISION IS: A WORLD FREE FROM DISEASES OF MIND AND SIGHT.
COLLECTIVELY, MORE THAN 300 MILLION PEOPLE WORLDWIDE SUFFER FROM THESE
DISEASES.

BRIGHTFOCUS HAS A PROVEN TRACK RECORD OF SUPPORTING THE MOST
INNOVATIVE, EARLY-STAGE RESEARCH SEEKING TO FOSTER A BETTER
UNDERSTANDING OF, TREATMENTS FOR, AND ULTIMATELY, A CURE FOR, THESE
AGE-RELATED DISEASES WITH NO CURE. SINCE 1973, BRIGHTFOCUS HAS AWARDED
MORE THAN \$310 MILLION IN RESEARCH GRANTS TO THOUSANDS OF SCIENTISTS IN
28 COUNTRIES THROUGH ITS THREE PROGRAMS: ALZHEIMER'S DISEASE RESEARCH,
MACULAR DEGENERATION RESEARCH, AND NATIONAL GLAUCOMA RESEARCH. THE
RESEARCH WE SUPPORT IS CAREFULLY CHOSEN BY OUR SCIENTIFIC REVIEW
COMMITTEES, COMPRISING WORLD-RENOWNED RESEARCHERS AND LEADERS IN THEIR
FIELDS. OUR RESEARCH FUNDING HAS LED TO MAJOR CONTRIBUTIONS TO
UNDERSTANDING, DIAGNOSING, PREVENTING, AND TREATING THESE DISEASES AND
PROVIDES SUPPORT FOR SCIENTISTS WHO HAVE RECEIVED PRESTIGIOUS AWARDS,
INCLUDING TWO NOBEL PRIZES. AN INDICATOR OF OUR ABILITY TO PUSH NEW
BOUNDARIES OF KNOWLEDGE IS THAT BRIGHTFOCUS FUNDED GRANTEEES WERE ABLE
TO OBTAIN 8 TIMES THE ORIGINAL FUNDING AMOUNT PROVIDED BY BRIGHTFOCUS,
TO CONTINUE TO DEVELOP THEIR INNOVATIONS.

THE WORLD-CLASS RESEARCH IDENTIFIED AND SUPPORTED BY BRIGHTFOCUS IS ON
THE CUTTING EDGE OF THE FIGHT TO SAVE MIND AND SIGHT. OUR FUNDING ACTS
AS A CATALYST IN EARLY-STAGE RESEARCH, AND BRIGHTFOCUS RESEARCH
PROGRAMS ARE DESIGNED TO PROVIDE INITIAL FUNDING FOR HIGHLY INNOVATIVE
EXPERIMENTAL IDEAS. DUE TO THE STRUCTURED GRANT REVIEW AND APPROVAL
PROCESS, THE RESEARCH IMPACT OF BRIGHTFOCUS IS VERY HIGH. MOST
RECIPIENTS OF BRIGHTFOCUS FUNDING GO ON TO RECEIVE FUTURE GRANTS FROM
OTHER SOURCES THAT ARE UP TO 8 TIMES LARGER THAN THE ORIGINAL
BRIGHTFOCUS AWARD. THIS HIGH RETURN ON BRIGHTFOCUS INVESTMENT SPEAKS TO
OUR ABILITY TO IDENTIFY PROMISING RESEARCH IN ITS EARLIEST STAGES AND
SPAWN FUTURE SCIENTIFIC DISCOVERIES. IT IS OUR FIRM BELIEF THAT HAVING
THE COURAGE TO INVEST IN INNOVATIVE IDEAS WILL LEAD TO REVOLUTIONARY
APPROACHES AND LIFE-SAVING BREAKTHROUGHS.

ALONG WITH FUNDING CUTTING-EDGE RESEARCH TO FIND CURES FOR SOME OF THE
WORLD'S COSTLIEST DISEASES, BRIGHTFOCUS ALSO PROVIDES FREE,
EXPERT-VETTED EDUCATIONAL MATERIALS TO HUNDREDS OF THOUSANDS OF PEOPLE
IMPACTED BY THESE DISEASES NATIONWIDE. WE GROUND THESE EDUCATIONAL
MATERIALS IN THE LATEST RESEARCH FINDINGS AND BREAKTHROUGHS.

BRIGHTFOCUS ALSO INCREASES PUBLIC AWARENESS OF ALZHEIMER'S, MACULAR
DEGENERATION, AND GLAUCOMA, AND COMMUNICATES WITH THOUGHT LEADERS AND
ELECTED OFFICIALS ABOUT THE IMPORTANCE OF SCIENTIFIC RESEARCH IN THESE
AREAS.

BRIGHTFOCUS' AWARD-WINNING PUBLIC SERVICE ANNOUNCEMENTS (PSAS) HAVE

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Schedule O (Form 990) (Rev. 12-2024)

LHA 432211 01-15-25

Name of the organization	Employer identification number
BRIGHTFOCUS FOUNDATION	23-7337229

APPEARED ON TELEVISION, RADIO, AND IN PRINT THROUGHOUT THE NATION. THE IMPACT OF ALZHEIMER'S, MAKE A PLAN TODAY: GET YOUR EYES CHECKED, AND FINDING ANSWERS IN THE FIGHT AGAINST ALZHEIMER'S SEEK TO RAISE AWARENESS ABOUT THESE DISEASES AND THE IMPORTANCE OF EARLY DETECTION. SIMILAR MESSAGES HAVE BEEN DELIVERED THROUGH DONATED PRINT PSA SPACE IN AIRPORTS AND TRAIN STATIONS, AS WELL AS AT PHARMACIES, SUPERMARKETS AND DIGITALLY. IN FISCAL YEAR 2025, THESE PSA MESSAGES GENERATED \$9,240,763 IN DONATED MEDIA SERVICES AND GARNERED OVER 425 MILLION IMPRESSIONS.

WE CONTINUE TO INCREASE OUR PRINT PUBLICATIONS, MANY IN SPANISH, THAT PROVIDE HELPFUL INFORMATION TO PATIENTS AND CAREGIVERS, AND REGULARLY PRODUCE NEW VIDEO AND AUDIO RESOURCES IN CONJUNCTION WITH ALLIES IN THE MEDICAL AND SCIENTIFIC COMMUNITIES.

PARTNERING WITH SEVERAL HIGH-PROFILE PUBLIC AND PRIVATE ORGANIZATIONS, BRIGHTFOCUS IS HELPING TO BETTER EDUCATE THE PUBLIC ON THE LATEST RESEARCH DEVELOPMENTS PERTAINING TO ALZHEIMER'S, MACULAR DEGENERATION, AND GLAUCOMA, AS WELL AS THE IMPORTANCE OF EQUITABLE PARTICIPATION IN CLINICAL RESEARCH TO ACCELERATE THE PATH TO CURES FOR NEURODEGENERATIVE DISEASES.

SPECIFICALLY, BRIGHTFOCUS PRODUCES AND DISSEMINATES FREE PROGRAMS INCLUDING:

BRIGHTFOCUS VISION CHATS. SINCE 2014, THESE AUDIO DISCUSSIONS HAVE BROUGHT TOGETHER PATIENTS AND CAREGIVERS FOR INTERACTIVE MONTHLY TELEPHONE FORUMS TO LEARN FROM AND ASK QUESTIONS OF LEADING VISION DISEASE EXPERTS. THE CHATS ARE ARCHIVED ON OUR WEBSITE, WITH AUDIO AND PRINT TRANSCRIPTS AVAILABLE IN SEVERAL ACCESSIBLE FORMATS ONLINE, INCLUDING AS PODCASTS ON SPOTIFY AND APPLE ITUNES.

ZOOM IN ON DEMENTIA AND ALZHEIMER'S, A MONTHLY VIRTUAL DISCUSSION OPEN TO THE PUBLIC FEATURING WORLD-RENOWNED RESEARCH SCIENTISTS WHO SHARE THE LATEST BREAKTHROUGHS AND FINDINGS IN THE FIELD. ALL EPISODES ARE RECORDED AND AVAILABLE TO WATCH ON DEMAND ON OUR WEBSITE AND YOUTUBE.

WE REGULARLY PUBLISH ARTICLES AND RESOURCES PROVIDING LAY-PERSON INFORMATION ABOUT COMMONLY ASKED DISEASE QUESTIONS. TWO MILLION VISITORS EACH YEAR TO OUR WEBSITE, WWW.BRIGHTFOCUS.ORG, FIND A WEALTH OF INFORMATION ON RESEARCH, SYMPTOMS, TREATMENTS, AND CAREGIVER SUPPORT.

BRIGHTFOCUS IS A PRESENTING PARTNER OF SEVERAL DOCUMENTARY FILMS, INCLUDING TAKING CARE, REMEMBERING GENE WILDER, AND GLEN CAMPBELL: I'LL BE ME, AND EXECUTES ASSOCIATED EDUCATIONAL IMPACT CAMPAIGNS. THESE FILMS ARE SHOWN IN COMMUNITY SETTINGS ACROSS THE COUNTRY TO INCREASE AWARENESS OF, AND PARTICIPATION IN, ALZHEIMER'S CLINICAL RESEARCH.

BRIGHTFOCUS HAS A LONG-RUNNING AND ROBUST DIRECT MAIL PROGRAM ACROSS THE THREE RESEARCH AREAS IT SUPPORTS. BRIGHTFOCUS MAELS AWARENESS-RAISING MATERIALS ACROSS ITS THREE PROGRAM AREAS TO OVER 600,000 NATIONAL HOUSEHOLDS, WITH MESSAGES FOCUSING ON:

RISK FACTORS AND SYMPTOM RECOGNITION THROUGH PUBLIC AWARENESS AND STEPS THE PUBLIC SHOULD TAKE THAT MAY HELP REDUCE THEIR RISK.

LIFESTYLE CHOICES THAT PROMOTE GOOD HEALTH, ENCOURAGING READERS TO TAKE ACTION TO REDUCE THE LIKELIHOOD OF THE ONSET OF THE DISEASE.

RESEARCH RESULTS AND TREATMENTS AVAILABLE TO ADDRESS THE DISEASE.

BRIGHTFOCUS REGULARLY INTERACTS WITH ADVOCACY ORGANIZATIONS,

Name of the organization	Employer identification number
BRIGHTFOCUS FOUNDATION	23-7337229

GOVERNMENTS AT ALL LEVELS, AND MEMBERS OF THE MEDIA, TO CALL GREATER ATTENTION TO DISEASES OF MIND AND SIGHT AND SHARE THE LATEST RESEARCH AND BEST PRACTICES WITH PUBLIC FIGURES AND KEY STAKEHOLDERS. THROUGH OUR OWN OUTREACH EFFORTS, AS WELL AS VIA ACTIVE ROLES IN ADVOCACY COALITIONS, WE HELP ADVANCE THE CAUSE OF PIONEERING SCIENCE AND BETTER POSITION BRIGHTFOCUS AS A RESOURCE FOR THOSE STRUGGLING WITH AND SEARCHING FOR CURES FOR THESE TERRIBLE DISEASES.

BRIGHTFOCUS IS THE PRESENTING SPONSOR OF THE HELEN KELLER PRIZE FOR VISION RESEARCH, ONE OF THE MOST PRESTIGIOUS RECOGNITIONS IN THE FIELD. SELECTED BY A PANEL OF THE WORLD'S FOREMOST VISION SCIENTISTS, EACH YEAR'S LAUREATE IS HONORED FOR A GROUNDBREAKING CONTRIBUTION OR DISCOVERY TO SAVE SIGHT. BRIGHTFOCUS BEGAN ITS SPONSORSHIP IN 2015 TO CALL GREATER ATTENTION TO VISION RESEARCH ACROSS THE PRIVATE AND PUBLIC SECTORS. BRIGHTFOCUS WAS HONORED IN 2023 FOR ITS CONTRIBUTIONS TO ADVANCING GLOBAL VISION RESEARCH BY THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY (ARVO) FOUNDATION.

FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE:
ALZHEIMER'S DISEASE RESEARCH (ADR)

ALZHEIMER'S DISEASE IS THE ONLY CAUSE OF DEATH AMONG THE TOP 10 IN AMERICA WITHOUT A WAY TO PREVENT, CURE, OR EVEN SLOW ITS PROGRESSION. IT IS AN IRREVERSIBLE DEGENERATION OF THE BRAIN THAT CAUSES DISRUPTIONS IN MEMORY, COGNITION, PERSONALITY, AND OTHER FUNCTIONS AND INEVITABLY LEADS TO DEATH. AN ESTIMATED 55 MILLION PEOPLE WORLDWIDE HAVE ALZHEIMER'S DISEASE OR OTHER DEMENTIAS, WITH WOMEN AND BLACK AND HISPANIC ADULTS MOST AT RISK.

ALZHEIMER'S DISEASE RESEARCH (ADR), A BRIGHTFOCUS FOUNDATION PROGRAM, FUNDS RESEARCH FOCUSED ON UNDERSTANDING THE CAUSES OF ALZHEIMER'S DISEASE, EARLY DETECTION, TREATMENTS TO HELP SLOW OR STOP ITS PROGRESSION, AND ULTIMATELY TO PREVENT THE DISEASE ALTOGETHER. ADR ANNUALLY AWARDS PEER-REVIEWED GRANTS TO SCIENTISTS FROM INSTITUTIONS WORLDWIDE WHO ARE CONDUCTING BIOMEDICAL AND CLINICAL RESEARCH ON ALZHEIMER'S DISEASE.

SINCE INCEPTION, ADR HAS INVESTED NEARLY \$190 MILLION IN RESEARCH GRANTS TO DEFEAT ALZHEIMER'S DISEASE. DURING THE FISCAL YEAR ENDING MARCH 31, 2025, ADR AWARDED \$10,207,897 IN PEER-REVIEWED GRANT AWARDS TO 40 NEW RESEARCH PROJECTS.

NOTABLE PROJECTS INCLUDE: INFLAMMATORY FACTORS DRIVING MYELIN DYSFUNCTION, NOVEL INTERVENTIONS USING FOCUSED ULTRASOUND TECHNOLOGY, HARNESSING DISEASE DIFFERENCES TO GENERATE PERSONALIZED PROTEIN SIGNATURES, THE ROLE OF MULTIPLE PREGNANCIES AND MENOPAUSE ON DEMENTIA RISK, AND DIFFERENCES IN GENETICS AND DISEASE RISK FOR UNDERREPRESENTED POPULATIONS. ADDITIONAL INFORMATION ABOUT SPECIFIC PROJECTS IS INCLUDED IN SCHEDULES F & I.

BRIGHTFOCUS IS HONORED TO HAVE SUPPORTED THE EARLY RESEARCH OF TWO NOBEL PRIZE WINNERS. DR. STANLEY PRUSINER AND DR. PAUL GREENGARD, WHOSE WORK HAS BEEN INSTRUMENTAL IN OUR CURRENT UNDERSTANDING OF ALZHEIMER'S DISEASE.

Name of the organization	Employer identification number
BRIGHTFOCUS FOUNDATION	23-7337229

BRIGHTFOCUS CONTINUES ITS PARTNERSHIP WITH THE ACADEMIC JOURNAL MOLECULAR NEURODEGENERATION AS THE OFFICIAL JOURNAL OF BRIGHTFOCUS FOUNDATION. THE JOURNAL PUBLISHES TECHNICAL PAPERS RELATED TO NEURODEGENERATION IN THE THREE DISEASE AREAS. TO ACCELERATE SCIENTIFIC PROGRESS, IT IS AN OPEN-ACCESS JOURNAL, AND ALL CONTENT IS FREE OF CHARGE. THIS OPEN ACCESS ENSURES MAXIMAL REACH OF JOURNAL CONTENTS TO SCIENTISTS AND CARE PROVIDERS WORLDWIDE. MOLECULAR NEURODEGENERATION IS CURRENTLY THE HIGHEST IMPACT OPEN ACCESS JOURNAL IN THE NEUROSCIENCES.

IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, ALZHEIMER'S DISEASE RESEARCH PROVIDES EXPERT-VETTED RESOURCES ON DETECTING, TREATING, AND LIVING WITH THE DISEASE. THESE ARE AVAILABLE ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG/ADR.

FORM 990, PART III, LINE 4B, DESCRIPTION OF PROGRAM SERVICE:
MACULAR DEGENERATION RESEARCH (MDR)

AGE-RELATED MACULAR DEGENERATION IS A LEADING CAUSE OF VISION LOSS IN THE UNITED STATES. IT DESTROYS THE MACULA, THE PART OF THE EYE THAT PROVIDES SHARP, CENTRAL VISION NEEDED FOR SEEING OBJECTS CLEARLY. THE MOST COMMON EYE CONDITION IN PEOPLE AGE 60 AND OLDER, IT CAN LEAD TO VISION LOSS IN ONE OR BOTH EYES, MAKING IT DIFFICULT TO RECOGNIZE FACES, DRIVE A CAR, OR READ. AT LEAST 20 MILLION AMERICANS HAVE SOME TYPE OF MACULAR DEGENERATION, INCLUDING BOTH THE EARLY AND LATER STAGES OF THE WET AND DRY TYPES.

MACULAR DEGENERATION RESEARCH (MDR), A BRIGHTFOCUS FOUNDATION PROGRAM, HAS AWARDED NEARLY \$57 MILLION TO SCIENTISTS STUDYING THE DISEASE. THE LATEST RESEARCH IS FOCUSED ON NOVEL TREATMENTS, UNDERSTANDING THE CAUSES AND DISEASE PROGRESSION, PREDICTION METHODS AND DISEASE MODELING, DRUG THERAPIES, THE ROLE OF METABOLISM AND IMMUNE RESPONSE IN DISEASE RISK, GENES, AND NEW IMAGING, MACHINE LEARNING, AND SCREENING TECHNIQUES.

MDR GRANTS ARE AVAILABLE TO MACULAR DEGENERATION RESEARCHERS WORLDWIDE. MDR PLACES SPECIAL EMPHASIS ON ENCOURAGING APPLICATIONS FROM YOUNG SCIENTISTS AND THOSE WITH CUTTING-EDGE IDEAS. ANNUAL GRANT APPLICATIONS ARE PEER-REVIEWED, AND RECIPIENT SELECTIONS ARE BASED ON SCIENTIFIC MERIT.

DURING THE FISCAL YEAR ENDING MARCH 31, 2025, MDR AWARDED \$3,774,565 IN PEER-REVIEWED GRANT AWARDS TO 12 NEW RESEARCH PROJECTS. DETAILS ABOUT SPECIFIC PROJECTS ARE INCLUDED IN SCHEDULES F & I.

IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, MACULAR DEGENERATION RESEARCH PROVIDES EXPERT-VETTED RESOURCES ON DETECTING, TREATING, AND LIVING WITH THIS DISEASE. THESE ARE AVAILABLE ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG/MDR.

FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICE:
NATIONAL GLAUCOMA RESEARCH (NGR)

GLAUCOMA IS THE SECOND LEADING CAUSE OF BLINDNESS WORLDWIDE ACCORDING TO A RECENT REPORT FROM THE WORLD HEALTH ORGANIZATION, APPROXIMATELY 80

Name of the organization	Employer identification number
BRIGHTFOCUS FOUNDATION	23-7337229

MILLION PEOPLE AROUND THE WORLD HAVE GLAUCOMA. MORE THAN FOUR MILLION AMERICANS ARE LIVING WITH GLAUCOMA. IN THE UNITED STATES, GLAUCOMA IS A LEADING CAUSE OF BLINDNESS AMONG BLACK AND HISPANIC AMERICANS. WITH EARLY DETECTION AND TREATMENT, GLAUCOMA OFTEN CAN BE MANAGED TO PROTECT EYES FROM MORE SERIOUS VISION LOSS. IT IS ESTIMATED THAT ONLY HALF OF THE PEOPLE LIVING WITH GLAUCOMA ARE AWARE THAT THEY HAVE THE DISEASE.

NATIONAL GLAUCOMA RESEARCH (NGR), A BRIGHTFOCUS FOUNDATION PROGRAM, HAS AWARDED NEARLY \$53 MILLION WORLDWIDE IN RESEARCH GRANTS TOWARD THE STUDY OF GLAUCOMA. NGR-SUPPORTED RESEARCH HAS FOCUSED ON THE EYE-BRAIN CONNECTION, HOW PRESSURE BUILDUP IN THE EYE CAN AFFECT SYNAPTIC NERVE COMMUNICATIONS, NEUROPROTECTION AND OPTIC NERVE REGENERATION, DISCOVERING GLAUCOMA RISK GENES, AI/DEEP LEARNING AND ADAPTIVE OPTICS, SLEEP DISTURBANCE AND GLAUCOMA RISK, DEVELOPING EARLY GLAUCOMA SCREENING, AND PURSUING NOVEL GENETIC COUNSELING AND COMMUNICATION STRATEGIES, AMONGST OTHER INNOVATIVE PURSUITS.

NGR GRANTS ARE AVAILABLE TO GLAUCOMA RESEARCHERS WORLDWIDE. NGR PLACES SPECIAL EMPHASIS ON ENCOURAGING APPLICATIONS FROM YOUNG SCIENTISTS AND THOSE WITH CUTTING-EDGE IDEAS. ANNUAL GRANT APPLICATIONS ARE PEER-REVIEWED, AND RECIPIENT SELECTIONS ARE BASED ON SCIENTIFIC MERIT.

DURING THE FISCAL YEAR ENDING MARCH 31, 2025, NGR AWARDED \$1,818,979 IN PEER-REVIEWED GRANT AWARDS FOR 10 NEW PROJECTS. DETAILS ABOUT SPECIFIC PROJECTS ARE INCLUDED IN SCHEDULES F & I.

IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, NATIONAL GLAUCOMA RESEARCH PROVIDES EXPERT-VETTED RESOURCES ON DETECTING, TREATING, AND LIVING WITH THE DISEASE. THESE ARE AVAILABLE ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG/NGR.

FORM 990, PART VI, SECTION B, LINE 11B:

A DRAFT OF THE FEDERAL FORM 990 IS DISTRIBUTED TO THE AUDIT COMMITTEE FOR REVIEW PRIOR TO BEING SUBMITTED TO THE INTERNAL REVENUE SERVICE. THE DRAFT FEDERAL FORM 990 IS DISTRIBUTED EARLY ENOUGH TO PROVIDE EACH COMMITTEE MEMBER WITH A REASONABLE AMOUNT OF TIME FOR REVIEW AND SUBMISSION OF QUESTIONS OR COMMENTS PRIOR TO THE FILING DEADLINE. THE FINAL FEDERAL FORM 990 IS DISTRIBUTED TO EACH MEMBER OF THE FULL BOARD OF DIRECTORS PRIOR TO BEING FILED WITH THE INTERNAL REVENUE SERVICE. THE DRAFT OR FINAL FEDERAL FORM 990 MAY BE DISTRIBUTED IN PERSON, BY REGULAR MAIL, E-MAIL, OR FAX.

FORM 990, PART VI, SECTION B, LINE 12C:

BRIGHTFOCUS HAS ALL EMPLOYEES, OFFICERS, AND DIRECTORS AGREE TO THE CODE OF CONDUCT THAT INCLUDES ADHERENCE TO THE CONFLICT OF INTEREST AND IMPLEMENTATION POLICY. EACH BOARD DIRECTOR, OFFICER, AND EMPLOYEE IS REQUIRED TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE STATEMENT ANNUALLY.

EMPLOYEES MEET ANNUALLY WITH THE BRIGHTFOCUS' CHIEF COMPLIANCE OFFICER TO REVIEW THEIR CONFLICT OF INTEREST STATEMENTS, AND GIVE AN ANNUAL CONFLICT OF INTEREST COMPLIANCE REPORT TO THE BOARD CHAIR AND VICE CHAIR. IF A CONFLICT IS REPORTED, IT IS THEN REFERRED TO THE PRESIDENT/CEO AND/OR BRIGHTFOCUS' LEGAL COUNSEL AND, IF APPROPRIATE AND NECESSARY, THEN TO THE BOARD OF DIRECTORS OR ITS APPOINTED COMMITTEE FOR FURTHER ACTION.

THE DIRECTOR'S AND OFFICER'S STATEMENTS ARE REVIEWED BY THE BRIGHTFOCUS

Name of the organization	Employer identification number
BRIGHTFOCUS FOUNDATION	23-7337229

LEGAL COUNSEL. IF A CONFLICT IS REPORTED, IT IS THEN REFERRED TO THE BOARD OF DIRECTORS OR ITS APPOINTED COMMITTEE FOR FURTHER ACTION.

AT THE TIME OF THE BRIGHTFOCUS DISCUSSION AND DECISION CONCERNING A CONFLICT OF INTEREST, THE CONFLICTED PARTY IS NOT PRESENT IN THE MEETING.

FORM 990, PART VI, SECTION B, LINE 15:

BRIGHTFOCUS' BOARD OF DIRECTORS HAS OVERALL AUTHORITY AND RESPONSIBILITY FOR APPROVING THE ANNUAL BUDGET WHICH INCLUDES SALARY AND BENEFITS FOR ALL EMPLOYEES AT EVERY LEVEL INCLUDING NON-DIRECTOR OFFICERS AND KEY EMPLOYEES. ALL PAY ADJUSTMENTS ARE MADE ON A YEARLY BASIS EFFECTIVE APRIL 1ST, THE BEGINNING OF THE BRIGHTFOCUS FISCAL YEAR.

BEFORE APPROVING THE COMPENSATION OF THE PRESIDENT/CEO, THE BOARD DETERMINES THE TOTAL COMPENSATION TO BE PROVIDED BY BRIGHTFOCUS TO THE PRESIDENT/CEO IS REASONABLE CONSIDERING THE POSITION, RESPONSIBILITY AND QUALIFICATION OF THE POSITION HELD, INCLUDING THE RESULT OF AN EVALUATION OF PRIOR PERFORMANCE FOR BRIGHTFOCUS, IF APPLICABLE. THE PRESIDENT/CEO IS EVALUATED YEARLY BY THE BOARD OF DIRECTORS USING AN IN-DEPTH GOAL ATTAINMENT STRUCTURE, THAT INCLUDES A SELF-ASSESSMENT AND A BOARD OF DIRECTOR'S ASSESSMENT AND EVALUATION AGAINST SET GOALS, OUTCOMES, AND DELIVERABLES. IN ADDITION, THE BOARD OF DIRECTORS PERIODICALLY ENGAGES AN OUTSIDE CONSULTANT TO OBTAIN AND CONSIDER APPROPRIATE DATA, INCLUDING A SALARY SURVEY, WHICH INCLUDES INFORMATION COMPILED FROM THE FEDERAL FORM 990 OF OTHER ORGANIZATIONS, CONCERNING COMPENSATION PAID TO CEOS IN SIMILAR CIRCUMSTANCES. IN MAKING THE DETERMINATION, THE BOARD OF DIRECTORS CONSIDERS TOTAL COMPENSATION TO INCLUDE THE SALARY AND VALUE OF ALL BENEFITS PROVIDED BY BRIGHTFOCUS TO THE INDIVIDUAL IN PAYMENT FOR SERVICES. AT THE TIME OF THE BRIGHTFOCUS BOARD DISCUSSION AND DECISION CONCERNING THE PRESIDENT/CEO'S COMPENSATION, THE PRESIDENT/CEO IS NOT PRESENT IN THE MEETING.

THE BOARD OF DIRECTORS SHALL SET FORTH THE BASIS FOR ITS DECISIONS WITH RESPECT TO COMPENSATION IN THE MINUTES OF THE MEETING AT WHICH THE DECISIONS ARE MADE, INCLUDING THE CONCLUSIONS OF THE EVALUATION AND THE BASIS FOR DETERMINING THAT THE INDIVIDUAL'S COMPENSATION WAS REASONABLE CONSIDERING THE EVALUATION AND COMPARABILITY DATA.

THE PRESIDENT/CEO IS CHARGED WITH SETTING THE SALARIES OF ALL OTHER EMPLOYEES IN ACCORDANCE WITH A COMPENSATION STRUCTURE AND BUDGET APPROVED BY THE BOARD OF DIRECTORS. THE PRESIDENT/CEO AND HUMAN RESOURCES REVIEW EMPLOYEE COMPENSATION AND BENEFITS THAT INCLUDE KEY EMPLOYEES, BY PERIODICALLY ENGAGING AN OUTSIDE CONSULTANT TO CONDUCT COMPENSATION AND BENEFIT BENCHMARKING STUDIES THAT INCLUDE VARIOUS REGIONAL AND NATIONAL NON-PROFIT COMPENSATION REPORTS AND SURVEYS. COMPENSATION DELIBERATIONS AND DECISIONS INCLUDE THE REVIEW OF SELF AND SUPERVISORY EVALUATIONS OF EMPLOYEE PERFORMANCE COMPARED TO SET INDIVIDUAL AND ORGANIZATIONAL GOALS.

FORM 990, PART VI, LINE 17, LIST OF STATES RECEIVING COPY OF FORM 990:

AK,AL,AR,CA,CT,FL,GA,HI,IL,KS,KY,ME,MD,MA,MI,MN,MO,MS,NC,ND,NH,NJ,NM,NY,OH,OK,OR,PA,RI,SC,TN,UT,VA,WA,WI,WV

FORM 990, PART VI, SECTION C, LINE 19:

BRIGHTFOCUS MAKES ITS GOVERNING DOCUMENTS INCLUDING ITS ARTICLES OF INCORPORATION AND BYLAWS, THE FEDERAL FORM 1023, THE 501(C)(3) LETTER OF DETERMINATION FROM THE INTERNAL REVENUE SERVICE, CONFLICT OF INTEREST

Name of the organization	Employer identification number
BRIGHTFOCUS FOUNDATION	23-7337229

POLICY, AUDITED FINANCIAL STATEMENTS AND FEDERAL FORM 990 AVAILABLE TO THE PUBLIC UPON REQUEST. IN ADDITION, THE PUBLIC ALSO HAS ACCESS TO THE ANNUAL REPORT, AUDITED FINANCIAL STATEMENTS, THE 501(C)(3) LETTER OF DETERMINATION FROM THE INTERNAL REVENUE SERVICE, AND FEDERAL FORM 990 ON ITS WEBSITE AT WWW.BRIGHTFOCUS.ORG.

FORM 990, PART XI, LINE 9, CHANGES IN NET ASSETS:	
RECOVERIES OF PRIOR YEAR GRANTS	105,727.
CHANGE IN PRESENT VALUE OF GRANTS	4,590.
TOTAL TO FORM 990, PART XI, LINE 9	110,317.

FORM 990, PART XII, LINE 2C:
THE PROCESS HAS NOT CHANGED FROM PRIOR YEAR.

**SCHEDULE R
(Form 990)**

(Rev. January 2025)

Department of the Treasury
Internal Revenue Service

Related Organizations and Unrelated Partnerships
Complete if the organization answered "Yes" on Form 990, Part IV, line 33, 34, 35b, 36, or 37.
Attach to Form 990.

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

**Open to Public
Inspection**

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number
23-7337229

Part I Identification of Disregarded Entities. Complete if the organization answered "Yes" on Form 990, Part IV, line 33.

(a) Name, address, and EIN (if applicable) of disregarded entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Total income	(e) End-of-year assets	(f) Direct controlling entity
NATIONAL DEVELOPMENT, LLC - 23-7337229 22512 GATEWAY CENTER DRIVE CLARKSBURG, MD 20871	PROPERTY RENTAL AND MANAGEMENT	MARYLAND	8,684,432.	24,681.	BRIGHTFOCUS FOUNDATION
AMERICAN HEALTH ASSISTANCE, LLC - 23-7337229 22512 GATEWAY CENTER DRIVE CLARKSBURG, MD 20871	OWNER OF BRIGHTFOCUS HEADQUARTERS	MARYLAND	0.	2,981,266.	BRIGHTFOCUS FOUNDATION

Part II Identification of Related Tax-Exempt Organizations. Complete if the organization answered "Yes" on Form 990, Part IV, line 34, because it had one or more related tax-exempt organizations during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	(g) Section 512(b)(13) controlled entity?	
						Yes	No

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Schedule R (Form 990) (Rev. 1-2025)

Part V Transactions With Related Organizations. Complete if the organization answered "Yes" on Form 990, Part IV, line 34, 35b, or 36.**Note:** Complete line 1 if any entity is listed in Parts II, III, or IV of this schedule.

	Yes	No
1 During the tax year, did the organization engage in any of the following transactions with one or more related organizations listed in Parts II-IV?		
a Receipt of (i) interest, (ii) annuities, (iii) royalties, or (iv) rent from a controlled entity	1a	
b Gift, grant, or capital contribution to related organization(s)	1b	
c Gift, grant, or capital contribution from related organization(s)	1c	
d Loans or loan guarantees to or for related organization(s)	1d	
e Loans or loan guarantees by related organization(s)	1e	
f Dividends from related organization(s)	1f	
g Sale of assets to related organization(s)	1g	
h Purchase of assets from related organization(s)	1h	
i Exchange of assets with related organization(s)	1i	
j Lease of facilities, equipment, or other assets to related organization(s)	1j	
k Lease of facilities, equipment, or other assets from related organization(s)	1k	
l Performance of services or membership or fundraising solicitations for related organization(s)	1l	
m Performance of services or membership or fundraising solicitations by related organization(s)	1m	
n Sharing of facilities, equipment, mailing lists, or other assets with related organization(s)	1n	
o Sharing of paid employees with related organization(s)	1o	
p Reimbursement paid to related organization(s) for expenses	1p	
q Reimbursement paid by related organization(s) for expenses	1q	
r Other transfer of cash or property to related organization(s)	1r	
s Other transfer of cash or property from related organization(s)	1s	
2 If the answer to any of the above is "Yes," see the instructions for information on who must complete this line, including covered relationships and transaction thresholds.		

(a) Name of related organization	(b) Transaction type (a-s)	(c) Amount involved	(d) Method of determining amount involved
(1)			
(2)			
(3)			
(4)			
(5)			
(6)			

Provide the following information for each entity taxed as a partnership through which the organization conducted more than five percent of its activities (measured by total assets or gross revenue) that was not a related organization. See instructions regarding exclusion for certain investment partnerships.

[illegible]

Provide additional information for responses to questions on Schedule R. See instructions.